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Abstract
Metastases, the leading cause of death from all types of cancer, first appears in tumour–
draining lymph nodes. Due to their small size and low vascularisation, metastases are
very diﬃcult to detect and treat with conventional imaging and therapeutic modalities.
Hence, the aim of this project was to develop and evaluate a theranostic nano-platform
to enable Radionuclide Therapy (RNT) and multimodal imaging to improve the therapy
and diagnosis of lymph node metastases. The nano-platform used in this thesis consists
of a superparamagnetic iron-oxide nanoparticle (SPION) called Feraheme R (FH). The
work presented in this thesis consists of four main studies.
First, FH and two other SPIONs were radiolabelled with radioisotopes commonly
used in the clinic (89Zr, 177Lu and 90Y) for imaging and therapy. The SPIONs were
radiolabelled using a novel chelate-free technique, which produced a high radiochem-
ical yield and purity (up to 98%) while nanoparticle characterisation revealed that the
radioisotopes bind to the surface of the FH core.
In the second study, a series of phantom experiments were performed as a proof of
concept of the FH nanoparticle platform for multimodality imaging. These studies con-
firmed that 89Zr-FH nanoparticles can be detected in suﬃciently low concentration for
clinical applications using Positron Emission Tomography (PET) and can provide en-
hanced contrast for diagnostic Magnetic Resonance Imaging (MRI). Furthermore, anal-
ysis of relative image contrast showed that PET and MR images can be combined in a
complementary manner using either sequential or simultaneous PET/MR imaging. An
additional phantom study demonstrated the ability to image 177Lu-FH using with Single
Photon Emission Computed Tomography (SPECT).
The third study was a proof of concept for 90YRNT. An in vitro study was performed
whereby the radiobiological parameters of 90Y were derived for three diﬀerent human
colorectal cancer cell lines and benchmarked with external beam radiotherapy (EBRT).
Results demonstrated that the eﬃcacy of RNT is highly dependent on the initial dose-
rate at which the total dose is delivered. Therefore, the kinetics of DNA double strand
break (DSB) induction, repair and misrepair must be considered when deriving radio-
biological parameters of 90Y. This study predicts that for longer half-life radionuclides
such as 90Y, a higher initial activity and a larger total dose is required to achieve a clinical
outcome that is as eﬀective as EBRT.
The fourth study, a Monte Carlo simulation study, was performed to investigate the
subcellular mechanisms of dose delivery of the radionuclide 223Ra when treating metas-
tases. These simulations showed that the eﬃcacy of cell kill in alpha particle therapy
need not rely solely on ionisation clustering around DNA but may also depend on indi-
v
rect DNA damage through the production of free radicals and the ensuing intracellular
signaling. These results open a pathway towards radio–nanoplatform delivery of 223Ra
as nanoparticles do not tend to localise to the nucleus.
In summary, the main findings of this thesis are: FH nanoparticles were successfully
radiolabelled with 90Y and 177Lu which was the first experimental demonstration that
the HIR technique can be extended to radiolabel FH with these isotopes; the 89Zr-FH
is a novel nanotechnology for simultaneous PET/MR imaging providing the capability
of integrating the spatial resolution and tissue contrast provided by MR imaging with
the high sensitivity of PET; in RNT with low LET emitters such as 90Y, the therapeutic
outcome can be highly aﬀected by initial dose–rate; the indirect cell damage may play
an important role in RNT with alpha emitting isotopes due to the stochastic nature of
alpha particle energy deposition.
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Introduction
Cancer nanomedicine is a rapidly developing interdisciplinary research field. The last
few decades, has seen a rapid growth of interest in utilising nanoparticles and nanotech-
nology in cancer medicine1. This is mainly due to the suitable physical and chemical
properties of nanoparticles for in vivo applications. Nanoparticles (NPs) can be designed
with diﬀerent size, shape, material and surface chemistry for medical applications. Can-
cer nanomedicine for targeted drug delivery and imaging is widely investigated pre-
clinically and clinically. The first clinical nanoparticle platform was liposomal based
agents2. Recently, new types of nanoparticle such as polymer- based, peptide-based,
nanoshells, carbon nanotubes and magnetic nanoparticles have been translated into clin-
ical practice. Among these nanoparticles, Superparamagnetic Iron Oxide Nanoparti-
cles (SPIONs) have attracted a great deal of attention in clinical medicine2. The chemi-
cally active surface and paramagnetic property of SPIONs in a magnetic field potentially
makes them useful as multifunctional agent in medicine.
Additionally, recent investigations and developments in radiochemistry and radio-
pharmacy have provided a platform for developing radiolabelled SPIONs (radio-SPIONs)
for cancer therapy and diagnosis (thus theranostic)3,4. Therapeutic, diagnostic or ther-
anostic radio-SPION (or other NP carriers) have been developed in the past decade by
utilising a variety ofmedical radioisotopes. Radiolabelling technique is the predominant
method for designing a radio-SPIONs and assessing its stability in vivo (e.g. biodistri-
bution, pharmacokinetic behaviour). Radio-SPIONs have great potential for translating
into clinical practice for more accurate diagnosis and targeted therapy. Current conven-
tional imaging modalities have been shown to be limited in detecting and characterising
small cancer metastases in the lymph nodes5. However, a diagnostic radio-SPION can
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potentially act as a dual contrast agent in multimodal imaging to enhance the cancer di-
agnosis. For example, SPION labelled with a positron emitting isotope could simultane-
ously act as a Positron Emission Tomography (PET) and Magnetic Resonance Imaging
(MRI) contrast agent to combine the high sensitivity of PET imaging with high contrast
MRI in a complementary manner using either sequential or simultaneous PET/MRI to
enhance the diagnostic imaging. Moreover, in developing a therapeutic radio-SPION
for radionuclide therapy (RNT), fundamental investigations in radiobiology and assess-
ment with personalised dosimetry are required. In summary, the adaptation of nuclear
imaging and therapy to nanomedicine (nuclear nanomedicine) could potentially lead to
the development of clinical applications for cancer theranostics which is the core aim of
this thesis.
Chapter 2 of this thesis reviews the current literature in the field of nanomedicine,
nuclear medicine and Monte Carlo (MC) simulation with a particular reference to devel-
oping radio-SPIONs for cancer therapy (RNT radiobiology and dosimetry) and multi-
modal imaging (e.g. PET/MRI). In this chapter the current NP radiolabelling techniques
are reviewed, including Heat Induced Radiolabelling (HIR) which is used in the studies
presented in Chapter 3 and Chapter 4. Chapter 3 includes the experimental procedure
for chelate-free radiolabelling of three common medical radioisotopes 89Zr, 90Y and
177Lu with the SPION called Feraheme R (FH) and two other SPIONs (provided by the
School of Chemistry at the University of Sydney). These SPIONs were radiolabelled
with 89Zr using the HIR technique. Next, the HIR experimental protocol (including ra-
diochemical analysis) was modified and optimised for labelling 90Y and 177Lu with FH.
This was the first experimental attempt at radiolabelling FH with these two therapeutic
(i.e. 90Y) and theranostic (i.e. 177Lu) isotopes. The capability of these radio-SPIONs
as a multimodal agent for PET/MRI, PET/CT (computed tomography), SPECT (Single
Positron Emission Computed Tomography)/CT was evaluated by performing a series
of phantom studies. Furthermore non-radioactive 90Zr was labelled with SPIONs for
Transmission Electron Microscopy (TEM) characterisation. Phantom images and TEM
results are presented in Chapter 3. The work presented in Chapter 3 and 4 for FH radio-
SPION (for radiolabelling 90Y and 177Lu and 89Zr) development will be submitted to
the the Commercialisation, Development & IP unit (CDIP) at the University of Sydney
for patent protection.
Radio-SPION hybrid MR-PET imaging presents an exciting opportunity to simulta-
neously detect and accurately diagnose lymph node metastases by combining the high
spatial resolution and tissue contrast of MRI with the high sensitivity of PET. Chapter 4
presents phantom studies confirmed that 89Zr-FH SPION can be detected in suﬃciently
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low concentration for clinical applications using PET and can provide enhanced contrast
for diagnostic MRI. Results presented in Chapter 4 will be submitted to International
Journal of Nanomedicine upon completion of the invention disclosure.
In developing a radio-SPION (90Y-FH, 177Lu-FH) for RNT, the radionuclide selec-
tion, geometry (large or micro target), radiobiological parameters, physical properties of
radiation such as linear energy transfer (LET) and dose–rate are among the main factors
to consider. Thus two diﬀerent studies were performed to investigate potential radioiso-
topes for a therapeutic radio-SPION. Chapter 5 presents a proof of concept for 90Y-FH
RNT. An in vitro study was performed whereby the radiobiological parameters of 90Y
were derived for three diﬀerent human colorectal cancer cell lines and benchmarkedwith
external beam radiotherapy (EBRT). Results showed that for low dose—rate radioiso-
topes such as 90Y, the kinetics of DNA double strand break (DSB) induction, repair and
misrepair can highly impact the cellular dose response. Chapter 6 presents results from
a Monte Carlo simulation study for an alpha emitter, 223Ra, was performed to investi-
gate the subcellular mechanisms of dose delivery of high LET particles when treating
metastases. Simulation results demonstrated the dose deposition from alpha particles
is highly localised (within a cell or few cell diameters) and due to its ability to produce
dense ionisation along its track, it can induce both direct DNA and indirect DNAdamage
through the production of free radicals and the ensuing intracellular signaling. These
results also suggested that 223Ra could open a pathway towards radio–nanoplatform de-
livery of 223Ra for metastatic cancer.
The findings of this thesis and future work are summarised in Chapter 7.
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I would like to describe a field, in which little has been
done, but in which an enormous amount can be done
in principle.
Richard Feynman
2
Literature Survey
This literature survey provides an overview of the development of nuclear nanomedicine
as a platform for simultaneous cancer therapy and diagnosis (and thus theranostics)
which is the basis of this thesis. After providing a brief history of nanoscience devel-
opment and its translation to medicine within the context of cancer theranostics, Sec-
tion 2.2 reviews diﬀerent types of nanoparticle (NP) and their applications in cancer
medicine. Next, the development of multifunctional Superparamagnetic Iron Oxide
Nanoparticle (SPION) as a platform for multimodal imaging and therapy is presented in
Section 2.3. The following Section 2.4 reviews the common medical isotopes and radio-
labelling techniques in nuclear medicine. Section 2.4.4 discusses the current molecular
imaging modalities and following Section 2.5 and Section 2.6 review and discuss the
current RNT radiobiology theory and available Radionuclide Therapy (RNT) modali-
ties. Finally Section 2.7 reviews and discuses the most common and known RNT com-
putational dosimetry.
2.1 Introduction to Nanomedicine
The legendary physicist, Albert Einstein believed that imagination is the generator of
knowledge and Richard Feynman was one of the best examples in the history of science
to demonstrate this philosophy. On 29 December 1959, Feyman delivered his histori-
cal lecture titled "There’s Plenty of Room at the Bottom: An Invitation to Enter a New
Field of Physics"6. He was fascinated by how biological systems such as cells at very
small scale can do all kinds of marvelous things: "Consider the possibility that we too
can make a thing very small which does what we want that we can manufacture an
object that maneuvers at that level!"6. Next Feynman for the first time opened a new
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problem of manipulating things on an atomic and molecular scale: "Now comes the
interesting question: How do we make such a tiny mechanism? I leave that to you."
This problem was the inspiration that led to today’s development of nanoscience and
technology. The ability to explore the material structure and their characteristics at the
Figure 2.1: Illustration of relative sizes of bojects.
nanoscale has made a great change in many fields of science such as medicine. In the
comparison of NPs to their bulk systems, the main property of NPs which make them
fundamentally diﬀerent in their behaviour is the surface related and quantum character-
istics. Eﬃcient drug and medical radioisotopes loading (due to highly reactive surface
of NPs) and some of the unique physical properties (e.g. magnetic properties) of NPs
led to rapidly growing interest in NPs for medical applications such as drug delivery
and imaging. Particles or molecules with 10-100 atoms (at least in one dimension) are
normally regarded as nanoparticles7 (see Figure 2.1). Generally, NPs are sized between
1-100 nanometers. NPs compared to their bulk system (e.g. microparticles) have high
surface area–to–volume ratio (see Figure 2.2). Therefore in a NP, the number of atoms
at the surface is greater than those within their internal core and consequently they have
a high number of interaction sites available at the surface which makes them chemically
more reactive8. Moreover, at nano scale where the size of particles (e.g nanocrystal) is
comparable to the de Broglie wavelength of an electron, the change in electronic energy
levels become discretely discrete, a condition known as the quantum confinement of the
electron wavefunction9. This eﬀect is responsible for some of the unique behaviour (e.g.
optical) of NPs such as quantum dots. These unique properties (e.g. optical, magnetic,
active surface) give NPs potential to be used as a diagnostic agent or carrier for deliver-
ing therapy and thus to be an ideal platform for developing theranostic nano-agents in
medicine.
SPIONs are among many types of developed NPs which have become the centre of
attention in nanomedicine research since 198010. Later SPIONs with a biocompatible
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Figure 2.2: Illustration of the diﬀerence in surface area-to-volume ratio between a nanoparticle
and a microparticle.
polymer coating and core surfacemodification were developed for nanomedicine and nu-
clear medicine applications. The key features of SPIONs are; exhibiting magnetisation
only in an applied magnetic field and the ability to load drugs and medical radioiso-
Figure 2.3: Demonstration of MR imaging principle.
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topes (due to highly active surface). During the past few decades, further developments
in radiochemistry and radiation sciences have led to applying the field of nanomedicine
to nuclear medicine for enabling multimodal medical imaging (radiolabelled NPs with
imaging isotopes) and RNT (radiolabelled NPs with therapeutic isotopes) of diﬀerent
types of cancer. This has significantly improved the cancer diagnosis and therapy11.
Currently magnetic NP-based MR imaging is utilised in cancer medicine for enhancing
the MR image contrast.
MRI is a non-invasive imaging modality which works based on the electromagnetic
response of tissues (e.g. water). MRI relies on the magnetic properties of certain atomic
nuclei such as 1H, 11B, 13C, 19F, or 31P as a source of signal for imaging12. However,
among these nuclei, water protons (1H, which is in all human tissue) are utilised as the
most common source of signal in clinical MRI. Under the magnetic field of the MRI
scanner (B0), the proton (from water molecules or tissue) spins will be aligned parallel
with B0 which creates a longitudinal magnetisation. When a radiofrequency (RF) pulse
similar to the frequency that proton spins precess at (i.e. Larmor frequency) is applied,
the water protons can be rotated antiparallel with B0 and subsequently oscillate in the
magnetic field. After the removal of the RF, while they are returning to their ground state
they emit signals with an energy that was gained from the RF (see Figure 2.3). These
signals are then detected using RF coils (which act like antenne) to make the detailed
images of tissues in the body. The relaxation of water protons can occur via longitudi-
nal (T1) and transverse (T2) relaxation processes. The recorded relaxation processes are
then reconstructed into gray–scale images. Paramagnetic NPs such as SPIONs create
local magnetic inhomogeneities in the environment (due to interactions with surround-
ing water molecules) that they interact with. They can perturb the relaxation processes
(e.g. T2) and thus result in darker images (in contrast to a region where SPIONs are not
presented). SPIONs have been used clinically to enhance the contrast of MR images by
aﬀecting the relaxation processes13.
SPION-based MR imaging has emerged as a common approach in medical imaging
specifically in imaging lymph nodes associated with cancer metastasis. This is due to
its natural uptake in lymph node as well as its ability to produce high contrast between
the cancerous and healthy tissues14. Although the current clinical MRI technology has
inadequate sensitivity for detecting micro-metastases15,16 (see Figure 2.4), the devel-
opment of combing the two imaging modalities, positron emission tomography (PET)
andMRI has the capability to enhance the sensitivity in cancer diagnosis. Nanomaterial-
based PET agents are generally NPs which are positron–emitter–labelled utilising chela-
tors or polymers17. With current radiolabelling techniques a range of positron–emitter–
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labelled SPIONs have been developed. Most of these techniques utilise chelators for
labelling NPs or SPIONs with positron emitters or even therapeutic radioisotopes18.
Despite all the advantages of chelation methods, recent studies have shown the chelate-
based NPs are not fully stable in vivo as the chemical bond between the labelled isotope
and NPs can be broken by physical and chemical processes and cause toxicity (e.g. free
isotope accumulation in the bone19). However, recently a chelate-free radiolabelling
technique was developed for labelling SPIONs with a range of medical radioisotopes
which promises a more stable radiolabelled SPION (radio-SPION) in vivo20. In this
technique, the radioisotope is directly (i.e. without chelator) bonded with the negatively
charged surface of the SPIONs via heat.
Figure 2.4: Demonstration of a radio-SPION as a theranostic applications agent for multimodal
imaging and RNT.
Additionally, multifunctional NPs have opened up a new avenue in RNT. The ability
to eﬀectively deliver internal radiation to a tumour or metastasis with minimal lateral
damage has attracted tremendous interest in cancer therapy. Peptide Receptor Radionu-
clide Therapy (PRRT) and Radioimmunotherapy (RIT) have shown great promise in
treating cancer metastases. In PRRT a molecule which targets a specific receptor on the
cell surface is labelled with a radionuclide such as 177Lu, 90Y or 213Bi to target primary
tumours and tumour metastases21. The eﬃcacy of PRRT and other similar radionu-
clide therapies such as 223RaCl2 relies on selectively delivering high localised dose for
killing the tumour cells. The localisation of energy deposition from the therapeutic ra-
dionuclide is dependent upon the nature of the emitted radiation. Each radionuclide
can decay via diﬀerent nuclear de-excitation processes which result in emitting diﬀer-
ent types of radiation. The emitted radiation from therapeutic radionuclides originate
from nuclear and atomic de-excitation. In nuclear de-excitation, the emitted radiation is
categorised into three main types of radiation; energetic alpha particles, energetic and
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relatively low energy beta particles, gamma and X-rays. During an Electron Capture
(EC) process a proton–rich nucleus can interact with an inner shell electron (i.e K or L)
and convert a proton to a neutron and neutrino. This process generally leads to an excited
daughter nuclide (with characteristic momentum and energy) which further de-excites
via nuclear gamma emission. Both the initial EC process as well as the nuclear gamma
emission (also known as Internal conversion, IC) result in releasing a cluster of low en-
ergy electrons called Auger and conversion electrons. Additionally, after both nuclear
and atomic de-excitation, the daughter atom becomes highly charged and chemically
reactive due to self-ionisation22. The emitted radiation from radioisotopes damages the
targeted cells via direct ionisation or producing free radicals (water species, see Fig-
ure 2.6). Both direct and indirect cell damage is dependent upon the charge, mass and
energy of the emitted particles. Alphas are relatively heavy and positively charged par-
ticles (i.e. +2) containing two protons and two neutrons (i.e. a helium nucleus). Alpha
decay generally leads to an energetic recoil daughter nucleus with 2 fewer protons and
2 fewer neutrons.
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However, beta particles are negatively charged electrons that are emitted from the
nucleus of a decaying atom (neutron–rich nucleus) in a spectrum of energies. EC and IC
are other decay processes that result in ejecting relatively less energetic electrons (most
commonly from the K shell). These processes result in vacancies which are rapidly
filled by electrons transiting from higher energy shells. This leads to a cascade of elec-
tron transitions which move the vacancy toward the outermost shell in the atom. During
these electron transmissions, characteristic X-ray photons or Auger electrons (including
Coster-Kronig or super Coster–Kronig monoenergetic electrons) can be emitted. Ad-
ditionally, the energetic recoil daughter nucleus from EC and alpha decay could also
contribute to cell damage22.
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Alpha, low energy beta particles (b ) and Auger electrons have a short range in tissue
(ranging from few nanometers to few cell diameters) and they are more ionising than
energetic beta particles. They can produce more ionisation along most of their track (see
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Figure 2.5: The ionisation tracks of an emitted alpha particle with E˜ = 5:5MeV (on left panel)
and beta particle (on right panel) from 241Am source illustrating alpha and beta with E˜ = 65 keV
charge particle tracks in a cloud chamber.
Figure 2.5) and higher linear energy transfer (LET). Therefore alpha and Auger emitters
(e.g. 223R, 125I) are suitable radionuclides for PRRT since they can localise the dose
deposition within the target. Additionally, the long range and low LET beta particles
have an important application in producing a good dose coverage in a larger tumour
with the ability to traverse more cells within the tumour volume23. For example, the
beta emitters such as 90Y and 32P microspheres are commonly used in The Selective
Internal Radionuclide Therapy (SIRT)21. SIRT is a common nuclear medicine cancer
therapy procedure for treating primary and metastatic cancers.
Moreover, through in vitro studies and a better understanding of the radiobiological
models an improvement in RNT with microparticles and nanoparticles may potentially
be developed. The DNA damage is one of the principle targets for including biologi-
cal eﬀects of radiation in in vivo. In an ionisation event, diﬀerent DNA lesions such
as single-strand breaks (SSB) and double-strand breaks (DSB) can be produced. These
lesions may be produced by direct ionisation of DNA (direct eﬀect) or by the interac-
tion of hydroxyl radicals produced in water molecules (i.e. free radicals, see Figure 2.6)
with DNA. Most of the DNA damages can be repaired via diﬀerent biological processes
in a specific time frame (e.g. DNA repair half-life24). The direct ionisation damage
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Figure 2.6: Schematic diagram demonstrating diﬀerent decay processes and consequent emitted
radiations with their DNA damage mechanism.
from high LET particles (e.g. Alpha and Auger electrons) can be produced by a single
radiation event. The high LET particles generate a dense ionisation cluster along their
track which results in DSB. However, low LET particles (e.g. beta particles) mostly
result in inducing SSB due to fewer ionisations along their track. In indirect radiation
damage, the ionisation radiation firstly ionises the water molecules and then produces hy-
droxyl radicals. Then the hydroxyl radicals diﬀuse and react with the DNA molecules
(e.g. up to 5 micrometer) causing damage and disruption to their physiological pro-
cesses (figure Figure 2.6). The production of free radicals and thus DNA damage can
further be enhanced by using oxygen rich nanoparticles such as SPIONs25. Addition-
ally, Coulomb explosion is another after-nuclear eﬀect that could cause DNA damage26
(see Figure 2.6). Radionuclides decaying via EC process result in a heavily positively
charged and chemically reactive daughter atom that can destroy the DNA molecular
structure in the neutralisation processes27. The linear quadratic (LQ) model (equation
2.1) is one of the most common radiobiological model which is used to describe the
biological eﬀect (e.g. DNA damage and repair) and cellular dose response for diﬀerent
type of radiations and for a particular cell types28.
ln(SF) = [aD+bD2] (2.1)
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Where SF is the survival fraction, D is the dose in Gy, a is the cell kill per Gy of the
initial linear component and b is the cell kill per Gy2 of the quadratic component of the
survival curve. The second term of the LQ model, bD2 represents the accumulated and
repairable damage which is insignificant for high LET radiation (e.g. alpha particles).
The LQ model is a reasonable method of evaluating the dose response when deliver-
ing a dose at a constant and high dose–rate. However, in RNT, the dose–rate is highly
dependent upon the physical and eﬀective half-life of the therapeutic radioisotope29.
Commonly in RNT, the dose–rate is exponentially decreasing and therefore the kinetics
of DNA DSB induction, repair and misrepair must be considered30. The extended LQ
model (equation 2.2a) incorporates the Lea-Catcheside factor (G)31 to account for these
extra parameters and provide a more accurate dose response for RNT. The RNT time can
be varied between hours to days and therefore for long irradiation time if the physical
and eﬀective half-life are similar, the G factor can be simplified to equation 2.2c.
-ln(SF) = aD+b GD2 (2.2a)
G=
2
D2
Z ¥
 ¥
D˙(t)dt
Z t
 ¥
D˙0(t 0) e m (t t
0) dt 0 (2.2b)
G¥ =
l
l +m
=
t1=2
T1=2+ t1=2
(2.2c)
Where G is the Lea-Catcheside factor, T1=2 and t1=2 are the radionuclide andDNA re-
pair half-life, l and m are the radionuclide decay constant and DNA repair, respectively.
The first integral represents the physical absorbed dose and the second integral over t 0
refers to isolated SSB. The integral over t also refers to the second SSB of remaining un-
repaired DNA strand to cause lethal damage (DSB). The exponential term describes the
repair and reduction in SSB!DSBprocess due to decreasing the dose–rate. Thismodel
demonstrates that the eﬃcacy of RNT is dependent on the initial dose-rate at which dose
is delivered. The RNT dose–rate is inversely proportional to the radionuclide half-life
for a given total dose. Therefore a longer half-life radionuclide (e.g. T1=2 ! ¥ and
G¥ ! 0) such as 90Y or 32P delivers dose at a relatively lower rate. Therefore, higher
initial activity (to obtain higher initial dose-rate), and a larger total dose delivered is
required, to achieve an optimal cellular dose response.
Additionally, RNT needs to be reliably assessed with personalised dosimetry calcu-
lations to accurately evaluate the eﬃcacy and safety of the therapeutic radionuclide in
both clinical and research settings. The existing standard computational based dosime-
try techniques such as OLINDA/EXM32 can perform dose calculations for an individual
patient’s critical organs. However, these methods are based on two major assumptions
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which could lead to inaccurate predictions of deterministic biological eﬀects, including
tumour response and normal tissue toxicity. Firstly assuming uniform activity distribu-
tion with a constant dose–rate in the source organ and secondly assuming static tumour
volume. However, a personalised dosimetry of RNT can bemodelled with high accuracy
by utilisingMonte Carlo (MC) particle simulations. Currently availableMC simulations
toolkits such as GEANT433 and GATE34 are utilised to develop a range of dosimetry
models for RNT. The GEANT4 toolkit was initially developed at CERN (Conseil Eu-
ropeen pour la Recherche Nucleaire) for investigating the collisions of high energy par-
ticle and detecting the secondary and newly secondary particles productions. In the past
decade, GEANT4 and other GEANT4–based toolkits (e.g. GATE and TOPAS35), have
been utilised to investigate the interaction of radiation (e.g. charge particles) with bio-
logical tissue at subcellular, cellular and organ scale. These applications can be used to
simulate the stochastic processes of particle emission, hit distribution, associated energy
and dose deposition within a specific tissue or organ.
In summary the development of a theranostic radiolabelled SPIONs (radio-SPIONs)
is a new emerging field of nanomedicine and nuclear medicine which utilises physics,
nuclear-chemistry, radiobiology and computational modelling for enhancing cancer ther-
apy and diagnosis.
2.2 Nanoparticles in Medicine
In recent years, nanomaterials have played an important role in the evolution of cancer
theranostics1. NP applications in medicine range from medical contrast imaging agents
to molecular carriers for targeted drug delivery into individual cells. Particles with size
of less than 100 nm are considered NPs36. They have a good biological mobility and
their surface is highly chemically reactive due to their large surface area–to–volume
ratio. Additionally they can exhibit useful optical and magnetic properties. Quantum
Dot (QD), polymer–based, magnetic NP and other types of NP with a range of medical
applications have been developed based on these nano scale properties and Section 2.2.1
highlights the major contributions of medical NPs to modern medicine.
2.2.1 Quantum Dot and Polymer based Nanoparticles
QDs are inorganic semiconductor NPs with quantised states of electrons and holes37.
Restricting the mobility of electrons and holes at the nano scale causes a quantum con-
finement eﬀect which is responsible for the optical properties of NPs such as QD38.
Generally the size of these NPs range from 2 to 10 nm in diameter and the optical prop-
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erties of each QD is unique to their size39. QDs under ultraviolet (UV) illumination emit
fluorescent light with a wavelength inversely proportional to NP size. This is mainly due
to the electronic energy levels configuration. At a nano scale, the change in electronic
energy levels become discrete and when the size of a semiconductor NP becomes less
than its exciton Bohr radius, the energy gap between the conduction and valence bands
increases38 (see Figure 2.7). QDs are suitable for molecular probing of physiological
processes and studying patho-physiology39,40,41.
.
Figure 2.7: Illustration of the quantum confinement eﬀect of QDs and their application in
optical imaging in vivo. a) the quantum confinement eﬀect in a nano-semiconductor and the size
dependency of QDs on the wavelength of their emitted light from a QD after UV illumination,
b) the confocal microscope images of cells with QDs uptake in the cell (showing arrows), c)
multicolor QDs for in vivo imaging. Figure b and c were reproduced from41 and42 respectively.
Additionally, a range of other NPs have been developed for drug delivery and medi-
cal imaging. These NPs vary from biological materials (e.g. phospholipids-liposomes,)
to chemical substances such as a coated magnetic NPs43.
2.2.2 Magnetic Nanoparticles
Magnetic particles are those particles that upon an applied magnetic field show a re-
sponse and they generally consist of few to thousands of atoms. Magnetic materials can
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be categorised into five main types; ferromagnetic44, paramagnetic45, diamagnetic46,
antiferromagnetic47, and ferrimagnetic48. Ferromagnetic (i.e. iron, Fe) and paramag-
netic (i.e. gadolinium, Gd) materials are commonly used in the development of SPIONs
or magnetic complex nano molecules49. In ferromagnetic (e.g. iron Fe3O4, g-Fe2O3)
and paramagnetic materials such as gadolinium (e.g. Gd3+ ions) each atom has a net
magnetic moment due to its unpaired electrons50,51,52. The magnetic properties of mi-
cro and nano materials is a consequence of magnetic moments associated with indi-
vidual atomic electrons (e.g unpaired electrons). The electron magnetic moment in an
atom originates from the orbital motion of electrons around the nucleus and the electron
spin itself (see Figure 2.8). Therefore, each atomic electron behaves similar to a small
Figure 2.8: Schematic diagram showing the magnetic moment produced by an electron spin
(red arrow) and orbiting around the nucleus (white arrow).
magnet with orbital (defined by principal quantum magnetic number, mlmB ) and spin
magnetic moments mB ( mB, Bohr magneton; +mB (spin up) and  mB (spin down)).
Due to the Pauli exclusion principle53 in an atom, orbital moments as well as the spin
moments of some electron pairs cancel each other. Therefore, there is a total cancel-
lation of the orbital and spin moments in atoms with full electron shells or subshells.
Thus magnetic materials are generally composed of atoms having incomplete electron
shells. The number of unpaired electrons for Fe3+ and Fe2+ in ferrimagnetic materials
such as maghemite (g-Fe2O3) and magnetite (Fe3O4), is 5 and 4 respectively (equation
2.3a, 2.3b).
Fe3+ : [1s2 =2s2 2p6 =3s2 3p6 =3d5] (2.3a)
Fe2+ : [1s2 =2s2 2p6 =3s2 3p6 =3d6] (2.3b)
The Fe3O4 materials chemically contain Fe3+ and Fe2+ and their crystal structure can
be defined using the following formula, Fe3+ (A)[Fe2+Fe3+](B)O4 54. In the formula A
represents the tetrahedral position of Fe3+ ions surrounded by four O atoms and B is
the octahedral position for a mixture of Fe2+/ Fe3+ ions (see Figure 2.9.a,c). However,
most Fe atoms in g-Fe2O3 structure are in the Fe3+ state and the oxidation of Fe2+ is
compensated by cation vacancies54. Although both g-Fe2O3 and Fe3O4 materials in
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Figure 2.9: a) The crystal structure of magnetite, oxygen, Fe2+ and Fe3+ atoms are shown in
white, green and brown respectively. b) SPION acts as a large paramagnetic atom with a huge
spin upon an applied magnetic field (B0), c) illustrate the electronic coordination for Fe2+ and
Fe3+. The electron shown in black colour (with opposite spin) can be exchanged between two
octahedral coordination and aﬀect the crystal magnetisation. Figure a and b were reproduced
from54 and55.
bulk system are classified as ferromagnetic materials, at a scale less than 20 nm they of-
ten exhibit a superparamagnetic property54. Upon an applied magnetic field the SPION
acts as a large paramagnetic atom with a huge spin48 (see Figure 2.9 b). SPION’s total
magnetisation is composed of two components; the surface spins and the core of the
particle. At nano-scale, the contribution to magnetisation from atoms at the SPION’s
surface becomes more significant56. In a SPION, atoms in the surface experience dif-
ferent environments than atoms in the core. This is mainly due to atomic vacancies,
the variation in atomic coordination and lattice disorder which consequently aﬀect the
SPION’s magnetisation. These factors are important in developing the SPION-based
medical applications. In summary for medical SPIONs the following properties must
be considered57,48,17,58,59:
1. Nanoparticle size: preferred to be in the range 10-50 nm to:
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 Maintain their colloidal stability and resist aggregation.
 Reduce the dipolar interactions and minimise particle aggregation upon ap-
plied magnetic field.
 Increase the surface area-to-volume ratio for eﬃcient coating and labelling
which also leads to decreasing agglomeration ( increasing the circulation
time).
 Ensure the chemical stability of SPION in the physiological environment
(e.g. pH = 7).
 To avoid precipitation due to gravitation forces.
2. High saturation magnetisation; apart from the SPION size, the transverse relaxiv-
ity (r2) depends on the saturation magnetisation. The magnetisation of SPIONs
in an external magnetic field can be increased by increasing the magnetic field
strength. However, SPIONs can reach a saturation state where an increase in
applied external magnetic field cannot increase their magnetisation any further.
Therefore, higher magnetisation saturation suggests a greater impact on the T1
and T2 relaxation processes at clinical field strengths. This is one of the key char-
acteristics of SPIONs. The optimisation of the saturation magnetisation is an
eﬃcient method to achieve SPIONs with high MRI sensitivity46.
3. The magnetic nanoparticles should be biocompatible and non-toxic. This can be
achieved by utilising a biocompatible coating.
2.3 Superparamagnetic IronOxideNanoparticles (SPIONs) forCan-
cer Theranostics
Due to the physical and chemical properties (e.g. highly reactive surface and magneti-
sation) of SPIONs, they have attracted enormous attention in cancer diagnosis and ther-
apy. SPIONs in vivo can perform actively (targeting a tissue or an organ) or passively.
Peptide or antibody labelled SPIONs act as an active carrier for targeting the organ or
tissue of interest. However, passive SPIONs mainly rely on the polymer type and par-
ticle size to achieve accumulation at the target site. Hydrophilic SPIONs with dextran
and polyethylene glycol (PEG) surfaces are able to evade the reticuloendothelial system
(RES) as well as resisting the opsonisation (destruction by an immune cell) which leads
to increasing their biological half-life (circulation time) and the probability of targeting
a specific cell60,61,5. Moreover SPIONs with a size of less than 30 nm can also slowly
extravasate from vascular space to interstitial space, from where they can be taken up by
immune cells (monocytes/macrophages) and delivered via lymphatic vessels to lymph
nodes. These passive SPIONs can remain in normal nodal tissue and reduce MRI signal
intensity, thereby enhancing contrast against any metastatic lesions in the node14.
18
SPION-based MRI is becoming one of the common imaging modalities that oﬀers
excellent intrinsic soft tissue contrast at high resolution15. Although in cancer imag-
ing and diagnosis the current MRI resolution might be suitable for imaging the tumour
macro-environment at high resolution, both the resolution and sensitivity might not be
adequate for imaging and characterising the tissue micro-environment such as lymph
node metastases15 (see Figure 2.10). Therefore, the relatively poor sensitivity of MRI
is one of the limitations for accurate diagnosis at the micro scale16. Additionally recent
clinical studies have shown that a large dose of SPION is required to produce a suﬃcient
contrast for lymph node micro-metastases imaging which could in some patients result
in hypersensitivity reaction and other potential side eﬀects16. As discussed previously,
SPIONs have a highly active surface which is ideal for radiolabelling therapeutic and
diagnostic radionuclides. Radio-SPIONs oﬀers a novel platform for combining MRI
with other molecular imaging modalities such as PET to reduce the SPION dose and
reduce the risk of these side eﬀects. The current imaging modalities, as well as these
Figure 2.10: Demonstration of SPION-based MRI for lymph node metastases. a) Following
intravenous injection, SPIONs can be taken up by macrophages and delivered via lymphatic
vessels to lymph nodes. The SPIONs remain in normal nodal tissue and reduce MRI signal
intensity, thereby enhancing contrast against any metastatic lesions in the node. b),c) Com-
parison of conventional (top panel) and SPION-based (bottom panel) MRI in detecting lymph
nodes (LN) macro and micro metastases respectively. In both cases, the administered SPION
has enhanced the metastases characterisations. This figure was reproduced from5.
two key properties of SPIONs have led to the development of multifunctional SPIONs
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as a multimodal imaging platform for enhancing cancer diagnosis.
2.3.1 SPION-based Magnetic Resonance Imaging (MRI)
Conventional MRI relies on the magnetic properties of 1H atomic nuclei (water protons)
as a source of signal for imaging. The relaxation of water protons can occur via longi-
tudinal (T1, spin-lattice ) and transverse (T2, spin-spin) relaxation processes62. The
recorded relaxation signals are generally reconstructed into gray–scale images. These
images reveal a cross–sectional area with varying densities of the water protons and their
interaction with surrounding tissues. Diﬀerent tissues with diﬀerent biological states re-
sult in diﬀerent T1 and T2 relaxation times which lead to contrast in the MR images.
Upon an external magnetic field (e.g. B0 of MR magnet) SPIONs in a target tissue can
further aﬀect (by inducing local magnetic inhomogeneities) both of the relaxation pro-
cesses and thus the contrast. The use of SPIONs to enhance water proton relaxations
(e.g. T1 and T2) is explained by the outer-sphere relaxation theory55 (see Figure 2.11).
According to the Koeing-Keller model63 (equation 2.4), the transverse and longitudinal
times can be expressed as the following:
T1;2 =
dD
k g2 m2CJ(w;tD)
(2.4)
Figure 2.11: Schematic diagram illustrating the eﬀect of induced magnetic field by SPION and
its eﬀect on water proton. Figure was reproduced from13.
where d is the diameter of the SPION, D is the diﬀusion coeﬃcient of water, k is a
constant, g is the gyromagnetic ratio of the water proton, m is the magnetic moment
of the SPIONs, C is the concentration of the SPIONs and J(w;tD) is the spectral den-
sity function. For the longitudinal (spin-lattice) relaxation T1, the magnetic moment m
is directly related to the unpaired electrons. While for the T2 relaxation, the magnetic
moment m is for the unpaired electrons and the electron interactions in the crystal struc-
ture. Furthermore, equation 2.4 shows that both T1 and T2 relaxations are inversely
proportional to the size of the SPION. Based on outer-sphere theory the water proton’s
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relaxation processes in tissue containing SPIONs will be aﬀected by an external applied
magnetic field and result in changing the image contrast. The induced magnetic spins
from SPIONs under the applied magnetic field mainly perturb the transverse relaxation
process of water protons. The large magnetic moment of SPIONs generate a strong and
local magnetic field gradients in their vicinity. This field inhomogeneity gives rise to
accelerated loss of phase coherence of the surrounding water proton spins which conse-
quently results in darkening of images (and thus SPIONs are a negative contrast agent).
One of the important applications of negative contrast agents (CA) is detection and char-
acterisation of lymph node cancer metastases (see Figure 2.12).
Figure 2.12: Demonstrating the mechanism of negative CA in lymph node imaging; a) a con-
ventional T2–weighted MR image of the lymph node showing the whole lymph node is associated
with cancer metastases, b) the T2–weighted MR image of the lymph node with enhanced con-
trast produced by SPIONs showing only two small metastatic regions (e.g. hyper intense foci).
Figures a) and b) were reproduced from14.
In the past 20 years, SPIONs have been used as a negative CA in tumour specific
molecular MR imaging showing great promise for more accurate imaging and diag-
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nosis. Many SPIONs with diﬀerent sizes and coating materials have been developed
and commercialised by pharmaceutical companies. A number of commercialised SPI-
ONs which have undergone or are currently going of clinical trials for CA MR imag-
ing is listed in Table 2.1. Among these SPIONs, Ferumoxytol (Feraheme R FH, with
formula Fe5874 O8752:C11719 H18682 O9933 Na414) is a FDA–approved NP for treating
anaemia, but is increasingly being studied oﬀ-label as an MRI contrast agent, including
for lymph node diagnostics15. Additionally, FH is progressively reported as an alter-
native to gadolinium-based contrast agents for MR angiography (MRA), especially for
patients with renal failure64. Thus, FH SPION (core size, d  6 nm) with a hydrody-
namic diameter of 30 nm and biocompatible carboxylated polymer65 has shown great
promises for potential biomedical applications20.
SPION Coating agent Size (nm) Relaxometric properties (at 1.5 T mM 1 s 1) Application
Resovist66 Carboxy-dextran 45-60 151 Liver imaging and cellular labelling
Ferumoxtran-1067 Dextran T10,T1 15-30 65 Lymph nod imaging
Ferumoxytol65 Carboxy-dextran 17-30 64 Lymph nod imaging
Ferropharm68 Citrate 7 33 Blood pool agent and cellular labelling
Table 2.1: List of common commercialised SPIONs with their physico-chemical properties.
2.3.2 Radio-SPIONs
Although MRI provides images with great soft-tissue contrast and high spatial resolu-
tion, it lacks sensitivity for lymph-node metastases detection69. The lymphatic system
is a common route for cancer metastasis and therefore accurate detection and metastasis
characterisation is of critical significance in treatment. One eﬀective strategy to over-
come this limitation is the use of radio-SPIONs. Due to the highly active surface of
SPIONs, their surface can be functionalised for radiolabelling therapeutic or imaging
isotopes. It has been suggested that radio-SPIONs potentially can induce adequate sig-
nals in both Positron Emission Tomography (PET) and MR imaging modalities with
desired high sensitivity and spatial resolution. When both signals are combined in a
complementary manner, the lymph node can be imaged with high accuracy4 3.
2.4 Radiolabelling techniques for Theranostic Nanoparticles
Current investigations and developments in radiolabelling small molecules, peptides,
proteins and SPIONs have gained increasing attention for cancer theranostics applica-
tions1. Many chelate-based radio-SPIONs and non-magnetic radio–agents have been
reported which typically use diﬀerent chelators to radiolabel SPIONs or other type of
NP with a range of medical radioisotopes18. However, current nuclear medicine (both
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therapeutic and diagnostic) radioisotopes require diﬀerent chelators to form stable com-
plexes in vivo. This is due to the uniqueness of each radionuclide chemistry. Therefore,
selecting a chelator for suﬃcient in vivo stability is a highly challenging task70. Thus
chelate–free radiolabelling techniques have fuelled great interest for radiolabelling SPI-
ONs with radioisotopes.
2.4.1 Selection of Radionuclides
In general the design of a radiolabelled agent (radio–agent) includes three main parts; ra-
dionuclide selection, appropriate biofunctional chelating agents for the immobilisation
of the radiometal and a targeting agent71. The use of radiometals is currently increas-
ing due to their relatively cost-eﬀective cyclotron production as well as their suitable
chemistry for radiolabelling19. Radiometal nuclei generally decay via five main de-
cay process; alpha (a2+), beta (b ), positron (b+), electron capture ( g and e ) and
internal conversion (g or e ). The emitted alpha and beta particles have a range of
energies with diﬀerent ionisation ability and are mainly used in radionuclide therapy.
However, positron and gamma emitter radionuclides are commonly used in PET72 and
SPECT73,74.
The physical (e.g. half-life) and chemical characteristics of radioisotopes (e.g. ox-
idation state), energy and range of emitted particles are important factors for an ideal
PET radionuclide. The physical half-life of a PET radionuclide should be long enough
for desirable biodistribution but short enough to minimise radiation exposure to the pa-
tient75. The range of emitted positrons in tissues also aﬀects the spatial resolution of
PET images76. A positron with smaller energy limits the particle range and thus allows
for optimising the spatial resolution. The range of positron particles in tissue can be esti-
mated analytically using equation 2.577. Although, positrons annihilate when they lose
their momentum, there is always a finite uncertainty in a near–zero momentum state,
hence there is an uncertainty in their range.
Rmax =
(
0:412E
1:265 0:0954 ln(Eb )
b 0:01 Eb  2:5MeV
0:530Eb  0:106 Eb > 2:5MeV
(2.5)
Furthermore, the physical decay should involve a high branching ratio (BR, number
of beta decay to the total decay) to optimise the delivered activity to the patient (e.g.
higher BR! less activity). Additionally, the chemical properties of the isotopes such
as ionic charge radius and oxidation state are important chemical factors in chelate-based
or SPION radiolabelling74 as these two factors aﬀect their chemical bonding. A list of
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current PET imaging isotopes with their physical properties are listed in table Table 2.2.
Radioisotope Half-life76 (h) Eb+ (MeV)76 BR (%)76 Rb+(mm)76
18F78 1.83 0.25 96.7 0.6
68Ga79 1.03 0.84 87.7 3.1
89Zr80,81,82,83 78.4 0.39 22.7 1.1
64Cu84,85,86 12.7 0.28 17.6 0.7
Table 2.2: Common clinically used PET radioisotopes with their physical characteristics.
Most SPIONs and immunoconjugates87 are slowly-accumulating agents that require
a long time to accumulate in the targeted tissue. Therefore the physical half-life of an
ideal PET isotope for radio-SPIONs or radioimmunoconjugates needs to match the in
vivo pharmacokinetics of these agents88. 64Cu89 and 86Y90 isotopes have been used in
traditional PET radioimmunoconjugate imaging but due to their relatively short physi-
cal half-life both of these isotopes possess limitations that impede their suitability for
human clinical imaging91. Among the current available PET imaging radioisotopes,
89Zr is suggested to have near-ideal physical and chemical properties for radio-SPION
or radioimmunoconjugate PET imaging91,20. 89Zr can be produced in a cyclotron via
the 89Y(p,n)89Zr nuclear reaction. It is relatively less expensive to produce 89Zr than
other PET isotopes since it uses 89Y metal (which has 100% natural abundance) as the
target for producing 89Zr19. The physical decay profile of 89Zr isotope is presented in
t1=2 = 15:7s
m89Y
t1=2 = 78:41h
89Zr
stable
89Y
....... EC= 76.6%, b+ = 22.3%
....... IT= 100%, Eg = 908.7 keV
Figure 2.13: Decay scheme of 89Zr.
Figure 2.13. The 89Zr isotope not only has a favourable physical half-life for imaging,
but due to the short range of their emitted positron it can also produce high resolution
images82,76. From a chemical aspect, 89Zr metal (from Group IV) exists primarily as a
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+4 ion in aqueous solution. Zr4+ is considered as a hard cation with a highly charged
ion and an eﬀective ionic radius of 0.83 Å91,19,80. These physical and chemical prop-
erties also result in achieving a high radiochemical yield and purity for radiolabelled
89Zr-SPIONs or immunoconjugates depending on radiolabelling technique.
Similarly, for designing therapeutic radio–SPIONs, radionuclide selection includes
choosing an appropriate biofunctional carrier and a targeting agent. In addition to phys-
ical (e.g. emission characteristics, half-life, etc.) and chemical (e.g.ionic radius, oxida-
tion state etc.) properties of the isotopes, the geometrical consideration is one of the
main factors in designing a therapeutic radio–agent. One of the main objectives in RNT
is to deliver a lethal dose to all cancer cells within a tumour volume while minimising
the toxicity to normal tissues92,74. Therefore selecting a therapeutic isotope is also de-
pendent upon the geometrical configuration of a specific tumour.
The geometrical factor can be categorised into two main classes; relatively large
tumours (macro volume) and cancer metastases (micro volume). 90Y radionuclide is
a beta particle emitter with maximum and minimum energy of 0.933 MeV and 2.280
MeV, respectively93, corresponding to an average and maximum range of 4 mm and
11.3 mm in water34. 90Y is suggested to be one of the suitable radionuclide for treat-
ing both macro and micro tumours as it has a good cross-fire that can navigate through
most of the cells within the tumour23. Furthermore, the short range particles such as
energetic alphas and low energy betas have the advantage of delivering radiation locally
(see Figure 2.14). Isotopes such as 223Ra, 213Bi and 177Lu emit alpha and beta parti-
cles with average energy of 5.87 MeV and 0.15 MeV with corresponding average range
(in water) of 47mm and 200 mm respectively. These radioisotopes are suggested to be
ideal isotopes for targeting small tumour volumes and cancer metastases94,95. Addition-
ally, the physical and eﬀective half-life of each radionuclide defines the rate at which
the radiation dose is delivered. The dose–rate is an important factor in the therapeutic
eﬀectivenesses of low LET particles. Due to the sparsely ionising nature of low LET
particles, they mainly damage cells via sequential SSB (see Figure 2.14). Moreover,
the eﬀective half-life of a radionuclide decays exponentially over time. Therefore these
two factors can aﬀect the kinetics of DNA DSB induction (via sequential SSBs) and the
overall dose response. Moreover, some therapeutic radioisotopes have multi-emissions
(b  as well as g) decay and thus they are considered as theranostic radionuclides. For
example, the emitted beta particles from 177Lu can be considered for therapy while the
emitted gammas can be utilised for SPECT imaging.
Therefore in designing a theranostic radio-SPIONs and other radio–agents, it is im-
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Figure 2.14: Comparison of radiation emitted from two radiopharmaceuticals: a and c) illus-
trates the radiolabelled 90Y-DOTATOC-SSR2 (the somatostatin receptor subtype-2) and 213Bi-
DOTATOC-SSR2 and their mechanism of cell killing. The low LET emitted beta particles from
90Y generally result in repairable SSB while the high LET alpha particles from 213Bi cause un-
repairable DSB; b and d) comparing the beta and alpha particle range in tissue. Beta particles
with an average range of 3 mm (90Y), have a larger cross-fire radiation (about 75 cell diameters)
and could cause lateral damage. In contrast, alpha particles with a shorter range (maximum
80mm) only navigate a few cell diameter (e.g. 2 cell diameters). The range in the figure corre-
sponds to the maximum energy of beta and alpha particles. This figure was reproduced from96.
portant to consider the discussed factors in selecting radioisotopes for both RNT and
medical imaging. In addition for an eﬀective RNT, the radiobiological parameters of
therapeutic isotopes are other factors that need to be attained for developing therapeutic
radio-SPION applications. This topic will be discussed in more detail in Section 2.5. A
summary of current clinical radionuclides for RNT is listed in table 3.5.
Radioisotope Half-life (days) Decay mode eEa (MeV) [%] eEb  (MeV) [%] Eg (keV) [%]
90Y97,98 2.6793 b  93 – 0.93[100]93 –
67Cu86 2.5899 b , g 99 – 0.19 [20], 0.12 [57]99 93[16], 185[49]99
177Lu100,101 6.71102 b , g 102 – 0.15 [79]102 208 [11]102
223Ra103,104 11.43105 a , b , g 105 5.72 [52]105 – 0.27[14]105
213Bi96,95 0.032106 a , b , g 106 5.87 [2]106 0.49 [65.9], 0.32 [31]106 0.44 [26]106
225Ac107,108 10109 a , g 109 5.83 [51]109 – 0.1 [3.5]109
Table 2.3: List of available therapeutic radioisotopes used in RNT.
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2.4.2 General isotope radiolabelling techniques
In the process of designing therapeutic and diagnostic radiolabelled agents, diﬀerent nu-
clear and radiochemistry methods (mainly chelate-based) have been developed88,110,74.
Depending on the chemistry of the isotopes as well as the type of molecular carrier,
these techniques cover a wide range of chemical reactions. The general and current ra-
diolabelling methods are listed as the following:
1. Isotope exchange (IE)111: Atoms in the molecular carrier are replaced by isotopes
of the same element but with diﬀerent mass numbers (e.g. 127I, and 131I). This
technique is mainly used for radioiodineation radiopharmaceuticals112 (e.g 125I-
triiodothyronine (T3) production).
2. Biofunctional chelation (BFC)113: A chelating agent is conjugated to a protein
(or antibody or SPION) and to radiometal ions. BFC provides a covalent bonding
to the biomolecule of interest. This technique is widely used for developing both
therapeutic and diagnostic radiopharmaceuticals such as 89Zr-EDTA (ethylenedi-
aminetetraacetic)114,89Zr-DTPA19, (diethylenetriaminepentaacetic acid) for PET
imaging and 90Y-DOTA-TATE115 or 177Lu-DOTA-TATE116 for RNT.
3. Heat Induced Radiolabelling (HIR)20: This method is based on metal ion binding
and heat-induced radiolabeling of SPION core surface with the p, d and f block
metal radionuclides (e.g. 89Zr, 64;67Cu).
For all of the above radiolabelling techniques the following factors play an important
role: biocompatibility, stoichiometry, charge and the size of SPIONs or chelators, solu-
bility, stability and biodistribution117. The current medical radioisotopes (e.g. 89Zr, 90Y,
177Lu and 64Cu) require diﬀerent chelators to form stable complexes in vivo. Therefore
selecting a chelator for suﬃcient in vivo stability is a challenging task70. However, a
recent novel chelate-free HIR technique was developed which can be used to radiolabel
a range of metallic isotopes with SPIONs20.
2.4.3 SPION radiolabelling
Current SPION radiolabelling methods can be generally classified into two classes;
chelate based pre–radiolabeling or post–radiolabeling, and chelate–free HIR. In the first
technique, the medical isotope is firstly chelated by a chelator (e.g. DFO, Deferoxamine
mesylate salt) and then labelled with a SPION3, or the chelator is attached to a SPION
first and then the medical isotope is radiolabelled88 (see figure 2.15). The third tech-
nique is a chelate-free method to radiolabel the metallic radioisotopes directly with the
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surface or internal structure of a SPION utilising metal ion bonding (e.g. electrostatic
interaction of positively charged metal ion with negatively charged SPION core surface)
via heat. The surface of the SPION core can become negatively charged in a basic so-
lution. This is due to the dissociation of hydroxyl groups "Fe–OH" and formation
Figure 2.15: Schematic diagram illustrating three general radiolabeling techniques using metal-
lic radionuclides and NPs. This figure was reproduced from88.
of [Fe–O]  at the surface of the core118. This negatively charged surface creates the
ideal surface for labelling the positively charged radiometal ions such as 89Zr4+, 90Y3+,
177Lu3+, 223Ra2+, 64;67Cu2+, 68Ga3+ and in general all the p, d and f block radiomet-
als118,20. Additionally, the ionic bond energy of metal ions with the negatively charged
surface is directly proportional to their charges and inversely proportional to their dis-
tance (Coulomb’s law). Therefore, smaller metal ions (e.g. smaller ionic radius IR) of
higher charge (or higher Oxidation State OS) result in a stronger electrostatic interaction
with negatively charged SPION core surface and thus stronger bonding with the surface
and higher Radiochemical Yield (RCY). Nevertheless, a previous study20 has shown
that the electrostatic interaction is not enough and additional heat and mechanical stir-
ring is required to help with bonding radiometal ions to the high-aﬃnity binding site
of the surface. Thus, the HIR technique mainly applies heat rather than covalent adjust-
ment to strongly bond the radiometals to SPIONs. HIR includes three steps. The first
step is loading which loads the FH SPION with radiocations (e.g. 89Zr4+) by heating
(120 0C, 2h) to induce bonding between a SPION and radiocation. The second step is
stripping which involves incubating the reaction mixture (the radiolabelled SPIONs and
unreacted radiocations) with a chelator (e.g. DFO). DFO chelator binds to unreacted ra-
diocations in the mixture and radiocations that are loosely bonded to the FH SPION core
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Figure 2.16: Schematic diagram illustrating HIR process.Abbreviations: DC, dextran coating;
DFO, deferoxamine mesylate salt; HIR, heat induced radiolabelling.
and strips them119,120,121. The rationale for "stripping" in the HIR process is analogous
to vigorous washing procedures used when synthesising particles for column aﬃnity
purification122. Here a tight, covalent coupling of a biomolecule (one involved in aﬃn-
ity purification) is accompanied by some weaker biomolecule-to-particle interactions.
Finally, the third step is purification by Size Exclusion Chromatography (SEC) which
involves excluding the radioactive-chelate complexes (with low molecular weight) from
the radiolabelled SPIONs122. Figure 2.16 briefly illustrates the HIR procedure.
There are three main limitations of the HIR technique. The first limitation is the
selection of radionuclide; short half-life isotopes cannot be utilised for radiolabelling
considering the required time (3-4 h) for a complete HIR procedure. Secondly, gener-
ally most radiocations are supplied in acid and, therefore the radiocation neutralisation
must be performed in a manner to prevent the formation of a nonmagnetic radiocation-
SPION due to the acid lability of FH. Acid can dissolve iron oxides and the HIR must be
carried out at neutral or basic pH (e.g. 7.5-9). Therefore, a proper pH control needs to
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be utilised to monitor the pH level of the reaction mixture during the procedure with the
use of microliter quantities of radioactive reaction mixture. In addition, an appropriate
stripping method and right chelator must be used to obtain an accurate radiochemical
analysis. Thirdly, heat-induced NP aggregation must be considered for applying the
HIR technique for SPIONs other than FH. This is mainly due to the coating of SPIONs.
FH SPION core is coated with carboxylated polymer which makes FH SPION stable
even at high temperature (e.g. 120 0C)119,120,121,122. The HIR technique is a newly de-
veloped technique. Thus, although there are a number of studies119,120,121,122 that have
used the HIR technique and radiolabelled-FH SPION, they are mainly focused on PET
and SPECT imaging and they have not investigated further development or optimisation
of the HIR radiolabelling technique.
Moreover, there are two major physical processes that can aﬀect the stability of a
chelate-based radio-SPION or any other radio–agents; the bond rupture and recoil ef-
fect123. Both of these processes result from nuclear decay of the radiolabelled isotope.
Radioisotope decay that involves the production of isomeric daughter nuclides (with ex-
cited nucleus) result in internal conversion IC (g emission from nuclear de-excitation)
which consequently leads to ejecting an inner electron (from K or M shells). Similarly
radioisotopes decaying via the EC process can self-ionise their daughter atom by re-
moving an electron from the inner atomic shells (e.g. absorption of K shell electron by
nuclear proton). Both of these processes initiate an Auger cascade leaving the atom in
a highly charged state which can break the chemical bond between a chelator and the
radiolabelled isotope. This after-eﬀect of nuclear decay is known as "bond rupture"123.
The bond rupture eﬀect is also used in isotope production and purification. An example
is shown in Figure 2.17. 177Lu radioisotope can be separated from 177mLu-DOTATATE
complex via bound rupture eﬀect. 177mLu decays to 177Lu via the IC process and after
the nuclear decay it self-ionises (initiating Auger cascades) the daughter atom which
results in breaking the bond and freeing 177Lu from the DOTATATE complex (see Fig-
ure 2.17). Similarly it has been shown that the energetic recoiled daughter nuclide from
the initial decay of a b  (or EC!Auger emission) emitting radio–agent (e.g. 125I, 111In
, 89Zr) can be freed from the chelator (e.g. DOTA) and even get ejected out of the target
cell124.
Although generally, these after-decay eﬀects might not have a great impact on the
chelate-based radio–agents or radio-SPIONs, it can cause breaking of the loosely bonded
radioisotopes from a chelator. Moreover, the chelate-based radio–agents can also poten-
tially interact with native chelators in the bloodstream (e.g. albumin) resulting in dis-
sociation of the isotopes from their molecular chelator. A recent study125 showed that
90Y can be freed from 90Y-DOTA due to its transchelation reactions in vivo. However,
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Figure 2.17: a) The 177mLu ! 177Lu decay scheme. b)The bond rupture process; the 177mLu
(shown in red) labelled to a highly stable DOTATATE complex. During 177mLu decay, the
emitted photon from nuclear de-excitation (IE) absorbed by inner shell electron and initiated
the Auger electron cascade and leaves the daughter nuclide in a highly charged state which
consequently breaks the chemical bonds and frees 177mLu from the DOTATATE complex (shown
in yellow). This figure was reproduced from123
chelate-free radiolabelling techniques such as HIR oﬀers a great platform for develop-
ing a more stable radio-SPION for in vivo applications. Moreover, recent studies have
shown that high radiochemical yield and purity can be achieved for DFO chelate-based
radiolabelled antibodies91 and Silica nanoparticles126. This has been achieved either by
functionalising the surface structure of Silica nanoparticles or radiolabelling antibody
via DFO chelation. Moreover, these studies have shown that their approaches can lead
to favourable pharmacokinetics, clearance profiles and high tumour uptake in human
melanoma models in vivo91,126.
In addition, a recent study has also investigated the time-dependent stability of the
chelator-free radiolabelled SPIONs in vivo. This study has shown that radiolabelled
SPION displayed excellent stability under extreme chemical and biochemical challenges
in vitro127.
2.4.4 Radio-SPION Multimodal Medical Imaging
NP imaging is one of fast growing fields of medical imaging for diﬀerent types of can-
cer as well as associated metastases (see Figure 2.18) . Early diagnosis and accurate
characterisation of primary tumours and their associated metastases are critical factors
for the patient’s prognosis58. Although great eﬀorts have been devoted to improving
the current medical imaging modalities, the combination of PET and MR imaging has
attracted tremendous interest and PET/MRI scanners have become more commercially
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Figure 2.18: A timeline showing the evolution of NPs imaging and diagnosis. The upper part
and lower parts represent the development of NPs and imaging modalities respectively. This
figure was reproduced from128.
available129. Although PET imaging provides high sensitivity tracking of radiotracer
in vivo it lacks specific anatomical details. Multimodal PET/CT (computed tomogra-
phy) imaging was introduced to overcome this issue. The CT imaging provides excel-
lent structural information with some limitations in imaging soft tissue and complex
anatomy (e.g. head and neck area and in the pelvis)130. Moreover, the amount of ra-
diation dose from repeated PET/CT scans is a critical concern especially for paediatric
patients131,132. In contrast, MRI oﬀers an excellent soft tissue contrast and spatial res-
olution and allows more accurate tumour characterisation (e.g. tumour location, size,
and invasion) compared to CT or any other imaging modality129. Additionally, MRI
does not involve ionising radiation. Thus PET/MRI using radio-SPIONs can overcome
some of the PET/CT limitations including reducing the dose related with the diagnostic
examination by approximately half129.
Although MRI provides images with high soft- tissue contrast, it still lacks sensi-
tivity for lymph-node metastases detection69. Radio-SPIONs can potentially play an
important role in cancer imaging especially in imaging lymph node micro-metastases.
For example when bothMRI and PET signals are combined in a complementary manner,
the lymph node can be imaged with high accuracy4,14.In summary, radio-SPIONs can
be utilised as a dual contrast agent for multimodal imaging such as PET/MRI to further
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Figure 2.19: Multifunctional radio-SPIONs for multimodal imaging: a) illustrates the possible
combinations of diﬀerent imaging modalities via modifying SPION surface chemistry and mag-
netic parameters such as magnetic susceptibility (c), saturation magnetisation (ms), anisotropy
(k), relaxation time (tN), Brownian relaxation time (tB). b) PET/CT/MR fusion of radio-SPION
(i.e. 89Zr-FH) distribution (e.g. uptake of radio-SPION in the brachial and axillary nodes) in a
mouse model with detailed soft tissue and structural information illustrating the advantage of
multimodal imaging. These figures were reproduced from3,4
enhance cancer diagnosis and imaging.
2.5 Radionuclide Biology
Current clinical therapeutic radionuclides can be classified based on the nature of their
radiation properties such as LET, 50-230 keV/mmfor alpha particle emitters, 0.2 keV/mm
for beta emitters and 4-26 keV/mm for Auger electron emitters133,23. In targeted radionu-
clide therapy (TRT) which is a type of nuclear medicine therapy procedure, radionu-
clides that emit particles with short range (high LET), such as 223Ra ,177Lu and 67Cu
are used100,134.
Additionally, the eﬀect of dose–rate in RNT and EBRT dose response can be clas-
sified into low, medium and high dose–rates (LDR, MDR and HDR, respectively)29,28.
It is also well known that radiation delivered at high dose–rates is biologically more
eﬀective than the same dose delivered at a low dose–rate29. As the dose–rate in RNT
is not constant but is mono-exponentially decreasing (considering the physical half-life
only), the kinetics of DNA double strand break (DSB) induction, repair and misrepair
play an important role in the therapeutic outcome. Although there are reports regard-
ing the eﬀects of EBRT in vitro and of the dose–rate eﬀect24,135 until recently, there
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have been relatively few studies investigating RNT dose–rate eﬀects in vitro, or in ani-
mal systems136,137,138,139 140. Consequently, the biological principle of RNT is less well
developed.
2.5.1 A DNA-based approach
The emitted radiation (e.g. a , b , g , Auger, conversion electron and heavy charged re-
coiled daughter nuclide) from therapeutic radionuclides penetrating through a tissue can
ionise atoms (and consequently break molecular bonds), and produce free electrons and
ions. They can induce toxicity to cancer cells via direct ionisation or indirect production
of free radicals. In principle, DNA is the main target for biological eﬀects of ionising
radiation30. As cellular composition is mainly water141, water radiolysis is one of the
main sources for DNA damage142. The main reactions occurring during water radioly-
sis are shown in Figure 2.20. If ionising radiation passes suﬃciently close to the DNA
double helix, upon the radiolysis process, the produced reactive free radicals (specifi-
cally OH with 10 ms life time which is 1000 longer than ions lifetime142) interact
with the DNA molecule (e.g. extracting electron from the helix structure) and break a
single or multiple DNA strands. This is known as indirect radiation DNA damage. The
ionisation radiation could also directly ionise the DNA molecule resulting in single and
double or multiple strand breaks (see Figure 2.21). It has been suggested that  70%
of radiation DNA damage is due to the indirect eﬀect143. There are two main chemi-
Figure 2.20: The three main stages of water radiolysis production. Figure was reproduced
from144.
cal changes induced in DNA via direct or indirect radiation damage; the single strand
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break (SSB) and double strand break (DSB). The SSB is when a radiation event ionises
a single strand from the DNA molecule and results in removal of one pair of the DNA
bases. However, DSB occurs when a radiation event breaks two DNA strands at the
same point or in close proximity to each other142,145. The SSB is generally known to
be sublethal damage since the repair of broken strands could happen during the DNA
synthesis phase of the cell cycle. Additionally, upon incomplete or misrepair processes
cell mutation could occur. In the case of DSB, it is suggested that if the two strand
breaks are suﬃciently close, DNA has less chance to repair and therefore this is con-
sidered potentially lethal damage (i.e. mitotic cell death). However, if the separation
Figure 2.21: Direct DNA damage by low and high LET ionising charged particles. Diﬀerent
types of DNA strand breaks are shown in the right panel. Figure reproduced from145.
of two breaking points (both in time and in physical space) is suﬃciently distant from
each other, then the cell has an opportunity to repair the first break before the second
lesion occurs23 (see Figure 2.21). Radiation damage production is highly dependent
upon LET and dose–rate. The energy, range and LET of a particular radiation governs
the ionisation production (and thus SSB and DSB) while dose–rate controls the rate at
which these SSB and DSB occur. For high LET particles, the density of ionisation and
energy deposition events along the radiation track increases (e.g. the mean separation
between energy deposition events is 2 nm which is comparable to DNA double helixs
diameter117) and consequently the probability for inducing DSB (at the same point in
the DNA) increases (see Figure 2.22). Moreover at higher dose–rate the portability of
sequential DNA strand hit increases and therefore the production rate of SSB!DSB
can compete with the DNA repair half-life. Since in RNT the LET and dose–rate varies
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Figure 2.22: DNA DSB induced by high and low LET radiation in human cell nucleus by
visualising g-H2AX foci (white dots). Cells were irradiated by a) 137Cs (g) source and b) high
LET nitrogen ions (e.g 160 eV/nm) to deliver 1 Gy. Figure reproduced from142
for diﬀerent types of radiation emitted from a radionuclide, it is important to consider
the kinetics of DSB creation, repair, and misrepair to estimate the radiation induced cell
lethality.
In addition to direct ionisations on the DNA molecule by emitted particles from a
radionuclide, the recoiled daughter nuclide from the decay process itself can result in
amplifying the damage via the "Coulomb explosion" eﬀect124. The Coulomb explosion
is another physical process that could cause DNA damage. Radionuclides decaying via
internal conversion and electron capture can potentially result in a heavily positively
charged and chemically reactive daughter nuclide that can destroy the DNA molecular
structure in the neutralisation processes22,27 (see Figure 2.6). Radioisotopes such as 125I
and 99mTc have been shown to release heavily and positively charged daughter nuclides
which can result in creating a large cluster of ionisations. For example, 125I decays by
electron capture to 125mTe (in the excited state). Then 125mTe de-excites via internal con-
version resulting in the release of approximately 21 electrons per decay and leaving the
stable 125Te daughter nuclide with 21 residual positive charges. The highly positively
charged 125Te atom itself creates further extensive ionisation and excitation in the neu-
tralisation process. The "Coulomb explosion" eﬀect relies on the initial recoiled energy
of the daughter nuclide124. Although the recoil distance is generally small (e.g 1.5-60
nm for ions with 2-20 keV124), it can induce DNA damage when they are within close
proximity of the DNA22. This eﬀect could also be thought of as internal hadron therapy
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at the nano scale. There is limited experimental and theoretical study of the "Coulomb
explosion" eﬀect, however a few studies have suggested that the DNA damage from
recoiled daughter nuclides should be considered in RNT124 22.
2.5.2 Linear Quadratic (LQ) model
The Linear Quadratic (LQ) model (see Equation (2.1)) was an approach to model the
cellular response to the radiation damage induction processes; lethal DSB produced by
a single hit from a radiation event and two sublethal SSB produced at diﬀerent times
(but occurring in close physical proximity to each other) by two diﬀerent hits from two
separate radiation events117. The LQ model is based on four main premises146:
1. Single tracks of a radiation event through a cell can induce lethal damage which
is proportional to absorbed dose.
2. DSBs induction is proportional to absorbed dose.
3. Repair for DSBs follows a first–order rate constant m (= ln2t1=2 , where t1=2 is the
repair half-life).
4. Misrepair of DSB induced by two separate radiation events is proportional to the
absorbed dose squared.
Low LET radiation such as electrons emitted from 90Y and 32P radionuclides23 with
less ionisation density (with the mean separation between energy deposition events of
» 2 nm ) along their track results in less DSB production per specific absorbed dose.
This allows cells to repair the radiation–induced damage. Therefore the second term of
the LQ equation becomes more important for evaluating the true cell survival for low
LET particles. However, high LET radiations (e.g. alpha particles or Auger electrons)
induce tracks with higher ionisation densities which limits cell repair. Additionally, the
initial dose–rate (D˙) of radionuclide radiation is inversely proportional to its half-life
(see Equation (2.6)) and it is exponentially decreasing over time147.
D=
Z T
0
D˙(t)dt =
D˙0
l
 
1  e l T (2.6)
This could significantly aﬀect the DSB pair production from two separate radiation
events147,148,149. If the DNA repair half-life of a particular cell is longer than the phys-
ical half-life (or its biological half-life in vivo) of a therapeutic radionuclide, the DSB
pair (from two diﬀerent radiation events occurring at diﬀerent time) production yield
significantly decreases since the rate at which the radiation is interacting with DNA can
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not compete at which the DNA is repaired (m , which in general ranges between 0.5-3
hours28,142 for diﬀerent types of cells). Therefore the simple LQ model was extended to
a time-dependent LQ (see Equation (2.7a)) model150 by including the Lea–Catcheside
G factor151,152 which describes the DNA damage repair occurring between two sepa-
rate ionisation events at diﬀerent times. The G factor can have any value between 0 to 1
and it can be expressed as a function of the radionuclide and DNA repair half-life (see
Equation (2.7b)).
-ln(SF) = aD+b GD2  g Tet (2.7a)
G=
2
D2
Z ¥
 ¥
D˙(t)dt
Z t
 ¥
D˙0(t 0) e m (t t
0) dt 0 (2.7b)
where D=
Z ¥
 ¥
D˙(t)dt
Here m is the DNA repair time constant, g and Tet is the eﬀective tumour cell repop-
ulation rate and treatment time respectively. For a high dose–rate radiation (e.g. short
half-life isotope) the G factor is unity, however, for low dose–rate (e.g. longer half-life)
radiation the G factor approaches zero indicating higher DSB repair. Low LET radi-
ations are more dependent upon dose–rate since most of the DNA damage induction
is from two separate radiation events at diﬀerent times. Therefore, a low LET emitter
radionuclide such as 90Y with long half-life (and thus small G¥ factor) delivers a spe-
cific dose at a relatively lower rate resulting in less cell kill. The dose–rate eﬀect from
diﬀerent radiation sources is summarised in the dose–rate spectrumwhich was first mod-
elled by Hall148 (see Figure 2.23). One eﬀective strategy to compensate for low LET
and dose–rate eﬀect is to utilise radiosensitiser (e.g. SPIONs) and radioenhancer to in-
crease the indirect and direct DNA damage25. SPIONs are oxygen–rich NPs and thus
upon radiation exposure can be used as a generator for reactive oxygen species (ROS)
such as hydrogen peroxide, hydroxyl radical, hydroperoxyl radical and superoxide an-
ion (e.g. H2O2, OH, HO2; O
 
2 ). Moreover, SPIONs consist of relatively high atomic
number of iron atoms (e.g. Z = 26) and upon radiation can increase the production of
relatively higher LET photoelectrons. Additionally, the initial dose–rate (D0) of a low–
dose rate emitter can be increased by utilising higher initial activity.
In summary, for designing therapeutic radio-SPIONs or any other radiolabelled agents,
the radiobiological parameters of RNT must be considered to achieve an eﬀective treat-
ment planning as well as therapeutic outcome74,25.
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Figure 2.23: Dose-rates eﬀect spectrum developed by Hall148 utilised in radiobiology and ra-
diotherapy.
2.6 Radionuclide Therapy (RNT) modalties
Tumours can express specific receptors or antigens which can be utilised in cancer
nanomedicine for targeting specific cancer cells. Recently many receptor or antigen-
based therapeutic radiopharmaceuticals have been developed and utilised in treating
paediatric153,154 , lymphomas155,156 and neuroendocrine tumours157,158,159. In most of
these developed radio–agents, 90Y and 177Lu and 213Bi radionuclides have been applied
for Targeted Radionuclide Therapy (TRT)160,161.
Selective Internal Radionuclide Therapy (SIRT)162,163,164 and Localised Internal
Radionuclide Therapy (LIRT) are other common methods in RNT. Although recent
studies165,166,167,168,169 have shown that RNT modalities are mainly palliative, with de-
signing new strategies based on radio-nanomedicine, modern radiobiology and radioim-
munotherapy RNT has the potential to improve cancer therapy95,170.
2.6.1 Selective Internal Radionuclide Therapy (SIRT)
SIRT approaches use biocompatible radiolabelled resin or silicon microparticles to de-
liver the RNT dose to the tumour171,172. These microparticles are delivered preferen-
tially in the microvasculature surrounding the tumour (causing embolisation) or directly
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inside the tumour via a microcatheter173,174,175 (see Figure 2.24 a). The micro size
(range between 20 and 60 microns) of these particles makes them ideal for radioemboli-
sation as the resin microspheres are small enough to be lodged in the arterioles within
the growing edge of the tumour but are too large to pass through the capillaries and into
the venous system171. Thus they cannot diﬀuse within the internal tumour structure and
this could result in distant or heterogeneous irradiation176. More importantly, these mi-
croparticles are only radiolabelled with a therapeutic isotope such as 90Y (mainly beta
emitters) and accurate imaging of the activity and dose distribution of the treated tumour
is still one of the remaining challenges in the field of SIRT and LIRT177.
Figure 2.24: Illustration of SIRT and LIRT. a) A microcatheter is guided into the hepatic
artery and 90Y-microspheres are administered to deliver beta radiation to the tumour. b) An
endoscopic catheter is guided through the oesophagus into the small intestine. Then endoscope
needle is injected to pancreas and tumour to deliver 32P-microspheres and beta radiation. Figure
a and b were reproduced from178,179 .
Similarly in LIRT (see Figure 2.25 b), silicon microparticles that contain 32P (known
as Oncosil medical device) are utilised for delivering internal radiation to the tumour180.
The 32P microparticle therapy is an active implantable (radiological) medical device for
treating pancreatic cancer179. In LIRT the 32P microparticles are directly injected into
the pancreas tumour using endoscopic ultrasound guiding technique (see Figure 2.25 b).
Based on in vitro studies conducted by OncoSil, it is speculated that the microparticles
accumulate at the point of injection and do not diﬀuse far from this point. This is due to
the suspension of the 32P formulate in a viscous solution which prevents leakage from
the tumour. 32P is one of the most promising radionuclides for LIRT due to its ability
to localise energy deposition (short range beta particles)181. Although SIRT and LIRT
have successfully improved the treatment for liver and pancreatic cancers, there are still
limitations and challenges to overcome. A limitation of SIRT and LIRT is that, they
are only applicable for localised therapy and they can not be applied for treating cancer
metastases. The second limitation is their low dose–rate emission which is not eﬃcient
at conventionally delivered dose184.
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Figure 2.25: a) Pre-90Y therapy; demonstrates PET/CT image of the targeted and a distant
nontargeted tumour (white arrow and white arrowhead respectively ). b) Post-therapy; showing
PET/CT image with the treatment of nontargeted, distant tumour. This figure was reproduced
from182.
However, a recent clinical study has shown that by escalating the total delivered dose,
SIRT can mediate the abscopal eﬀect182 (see Figure 2.25 and Figure 2.26). Since in
SIRT, the delivered radiation is highly localised, it can mediate a systemic anti–tumour
eﬀect (known as the abscopal eﬀect). The term abscopal is from Latin word "ab scopus"
which means far away from the target185. This term is used to refer to the eﬀect of radi-
ation on a non-targeted tumour which is far away from the radiation site186. Although
the abscopal eﬀect does not occur commonly in clinics187, a few hypotheses developed
to explain its mechanism183. Previous studies188 have shown that localised dose depo-
sition in a tumour can cause inflammatory cytokines and therefore increased traﬃcking
and retention of T lymphocytes in the tumour. It is possible that a synergistic eﬀect
may be in play: the initial high rate and localisation of dose deposition inflicts suﬃcient
damage to the tumour that it eventually succumbs to the immune system response. The
immuno-responsive mechanism could include an increased activity of lymphocytes into
the tumour microenvironment, thereby enhancing tumour cell recognition and killing
through upregulation of tumour antigens and induction of positive immunomodulatory
pathways188,189,190,191.
2.6.2 Targeted Radionuclide Therapy (TRT)
Targeted radionuclide therapy is another RNT procedure for personalised therapy. TRT
utilises radiolabelled peptides, proteins or antibodies as biological vectors to target and
internally irradiate the tumours which over–express these specific receptors. Currently
peptide molecules are labelled with the therapeutic isotopes (177Lu, 90Y and 213Bi) us-
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Figure 2.26: Radiobiological mechanism of the abscopal eﬀect: a) In the absence of radiation
(and thus danger signals), the tumour antigen is tolerogenic (e.g suppressing the immune re-
sponse). b) Upon radiation, the induced danger signals from a dying cell, increase the dendritic
cell mediated antigen which consequently leads to activation and upregulation of tumour specific
T cells. TLR stands for Toll-like receptor. This figure was reproduced from183.
ing the most commonly used chelator, DOTA. Peptides are generally biologically active
and thus they can penetrate into tumours more eﬃciently and pass through membranes
more easily. Recent development in TRT has shown great promise in treating cancer
metastases. Due to the high specificity of TRT in targeting tumour cells, radiolabelled
peptides with short range and high LET alpha emitters such as 213Bi192 and beta emit-
ters such as 177Lu193,194 , 88Re195,196,197,198,199, 90Y200, 64Cu201, and Auger-emitter
125I202,203,204,205 can deliver lethal damage to cells with minimal lateral damage. A re-
cent clinical study95 has shown the eﬀectiveness of 213Bi-PSMA therapy in patients with
prostate cancer (see Figure 2.27). 213Bi radionuclide emits high LET alpha and beta par-
ticles at high dose–rate due to its relatively short half-life. Therefore targeting tumour
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Figure 2.27: 213Bi-PSMA-617 TRT; a) Showing the pre-treatment 68Ga-PSMA PET/CT image
of a patient with progressive metastasised castration-resistant prostate cancer (mCRPC). b)
Post-treatment (e.g. 11 months); 68Ga-PSMA PET/CT image of the patient demonstrating the
eﬀectiveness of 213Bi therapy.This figure reproduced from95.
cells (binding to tumour cell surface or penetrating into the cell) with PSMA peptides
and irradiating the tumour with high LET alpha and high dose–rate beta particles can
eﬀectively produce lethal damage (high DSB yield) to destroy a tumour. Despite all
of these advantages, TRT chelate-based radiopharmaceuticals are not fully stable in in
vivowhich results in dissociation of the radiometal from the complex and causes toxicity.
The native chelators in the bloodstream (e.g. albumin) can interact with chelate-based
agents resulting in dissociation of the isotopes from the chelator. For example the dis-
sociation and transchelation reactions of 90Y-DOTA can result in 90Y accumulation in
the bone and lead to bone marrow toxicity125.
Another TRT modality is to target the organ of interest utilising radioisotopes which
have natural organ uptake without using an antibody targeting agent. For example, re-
cently the US FDA approved Alpharadin as a radiotherapeutic206(known as Xofigo)
for treating bone metastases associated with advanced prostate cancer. Alpharadin is
223RaCl2 which in vivo acts as a calcium mimetic and bone-seeking agent. Following
intravenous injection, Alpharadin is drawn to parts of the body experiencing high bone
metabolism and binding to the calcium hydroxyapatite of bone matrix207. 223Ra is an
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alpha emitter with an average energy of 5.7 MeV, corresponding to a range of 50 mm
in water ( few cell diameter). Therefore the bonded 223Ra in bone matrix can deliver
localised dose to adjacent tumour cells, sparing the adjacent bone-marrow208 (see Fig-
ure 2.28).
Figure 2.28: Illustration of Alpharadin therapy of bone metstese.
2.6.3 Towards radio-SPION therapy
Considering the complexity of the chelation radiolabelling chemistry and its instability
in vivo, chelate-free radiolabelling techniques have gained a great attraction in radio-
labeling medical isotopes with SPIONs for cancer theranostics (multimodal molecular
imaging and targeted radionuclide therapy). Currently, there is no experimental or clin-
ical studies using radio-SPIONs in RNT. Most of the current radio-SPIONs are labelled
with diagnostic isotopes and have been utilised in cancer imaging. This could be due to
the instability of chelate-based radio-SPION in vivo and possible toxicity issues. How-
ever, the recently developed HIR technique oﬀers a chelate-free and stabilised radio-
SPION platform which can be utilised in developing suitable radio-SPIONs for in vivo
RNT.
2.7 RNT Dosimetry
Radiopharmaceuticals are required to be assessed with personalised dosimetry calcu-
lations to evaluate the eﬃcacy and safety of the therapeutic RNT in clinical settings.
Consideration of the geometrical factors for both a tumour and radiation source are
critical factors for treatment planning and evaluating the treatment response. The non-
uniformity of tumour geometry, as well as the activity distribution, dose–rate variation
and dynamic change of tumour volume, can highly impact the therapeutic outcome in
RNT. There is a lack of experimental and theoretical dosimetry studies on dynamic tu-
mour masses in RNT. Since the dose–rate in RNT is not constant, the change in tumour
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volume could highly impact the therapeutic outcome. For example, a previous study209
showed that for tumours that are shrinking faster (e.g short shrinking half-life) than the
radionuclide decay rate (or dose–rate), the prescribed dose and the actual absorbed dose
could be significantly diﬀerent (e.g. a correction factor of 10). The existing standard
dosimetry software such as OLINDA32 can perform dose calculations for an individual
patient’s critical organs, however, they do not consider the eﬀect of the dynamic change
of the tumour mass and dose–rate variation. This can potentially lead to inaccurate
predictions of deterministic biological eﬀects, including tumour response and normal
tissue toxicity210. Therefore RNT dosimetry needs to be personalised for more accurate
assessment of a therapeutic radio–agent’s eﬃcacy and safety.
2.7.1 Monte Carlo Simulation
The dosimetry of RNT can be calculated with high accuracy by utilising Monte Carlo
(MC) particle simulations210. Currently, the two of main availableMC software toolkits
for simulating the RNT dosimetry are GEANT433 and GATE34. The GEANT4 toolkit
was initially developed at CERN for investigating particle collisions in High Energy
Physics (HEP) and detecting the secondary particles produced. Soon after the devel-
opment of GEANT4 toolkit for HEP application, it became an essential computational
tool in medical physics and nuclear medicine211,212. Later the GATE software toolkit
(a GEANT4-based platform) was developed by the international OpenGATE collabora-
tion specifically for nuclear imaging and RNT dosimetry applications. Both the GATE
and GEANT4 software toolkits provide features to study and investigate various aspect
of radiation therapy212,213,214 (e.g. external beam radiotherapy EBRT and RNT) and
nuclear imaging215,216,217,218 (e.g. PET, SPECT) (see Figure 2.30). Currently, these
toolkits are commonly used to assess the newly developed RNT radio–agents, evaluat-
ing radiotherapy treatment and designing new strategies for eﬀective radiation therapy.
Other important features of these toolkits are; their ability to model various complex and
non-uniform geometrical structures such as human organs (see Figure 2.29), utilising 3D
patient CT images for treatment planning219,220 and evaluation (see Figure 2.30.b). Ad-
ditionally GATE oﬀers a package called dose–actor for 3D energy and dose mapping
in a specific volume. The dose actor generally represents a cubic sensitive detector that
can be voxelised into 3D rectangular or cubic voxels. A dose actor (as well as the actor’s
voxels) can vary in size and shape depending upon the volume it has been attached to.
Parameters such as dose and deposited energy are stored into this 3D matrix according
to the spatial position of the hit for a given volume. Generally the integral dose as well
as the individual voxel dose is computed by dose-actor and the average dose in a volume
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Figure 2.29: GEANT4 medical application. Mathematical human phantom including internal
organs. This human phantom can be utilised to compute the whole body dose from an external
radiation source or a specific organ dose from internal radioactive source.
Figure 2.30: GATE medical applications; a) Simulation of 3D external beam treatment plan-
ning utilising 3D CT patient images. b) Geometry set–up of cell culture for radiobiological
investigation in RNT.
can be calculated using Equation (2.8a).
D˜=
1
N
n
å
i=1
di (2.8a)
Where N = number of voxels and di = computed dose in each voxel
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Moreover, GATE includes many diﬀerent types of actors with diﬀerent functionality.
These actors are sensitive detectors to record specific information from the interaction
of particles in a volume which the actor is attached to. They can further be modified
with filtering functions available in GATE for a particular measurement or calculation.
Additionally Matlab codes can be integrated with GATE and GEANT4 for constructing
geometries such as a biological cell culture (see Figure 2.30.b). In GATE, the passage of
Figure 2.31: Simulation visualisation of diﬀerent charge particles in GATE; a) alphas with
dense ionisation (red tracks) along their trajectories (shown in blue), b) electron tracks shown
in red, c) proton tracks with relatively less ionisation than alpha, d) Energetic gamma shown as
green tracks.
particles including their interaction within diﬀerent mediums is described by three main
groups of physics processes; Electromagnetic, Hadronic and optical. Each physics pro-
cess is described by a model and a corresponding atomic and/or nuclear cross-section
library (e.g. atomic excitation and ionisation). Each of these processes is described by a
model. In GATE (or GEANT4) the electromagnetic interactions such as Compton scat-
ter and the photoelectric eﬀect of hadrons, protons, electrons, positrons, photons with
a range of energies can be simulated by the electromagnetic processes utilising stan-
dard221, low energy222, PENELOPE223 and DNA224 models (see Figure 2.31). The
interaction (including elastic and inelastic) of hadrons and heavy ions with the nucleus
of a target atom is described by hadronic processes. The hadronic processes are de-
scribed by a variety of physics models available in GEANT4 hadronic physics packages.
These models generally can be categorised into high, medium and low energy. The high
energy model is based on string theories and utilised for high energy inelastic interac-
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tions and the low energy model is commonly used for simulating nuclear de-excitation
processes225,226. An example of utilising hadronic models to simulate the interaction of
a proton beam and its associated dose deposition in the target is shown in Figure 2.32. In
Figure 2.32: GEANT4 simulation, illustrating the proton beam dose distribution calculated
utilising 3D patient CT images.This figure was reproduced from227.
summary GATE/GEANT4 is a powerful simulation toolkit that can be utilised in many
diﬀerent fields of medical physics and nuclear medicine to investigate the interaction
of radiation with matter at the atomic and nuclear level. GATE/GEANT4 simulation
toolkit oﬀers a personalised dosimetry platform for RNT (e.g radio-SPIONs and other
radiotherapeutic agents) by providing important features such as incorporating patient
data (e.g. 3D CT images of targeted organ), constructing complex geometries (e.g. ir-
regular tumour shape) and simulating dynamic target and source volume.
2.8 Motivation and rationale for the work in this thesis
The core aim of this thesis is to develop and evaluate a chelate-free radio–nanoplatform
for multimodal imaging (in particular simultaneous PET/MRI) and RNT with the future
potential for clinical translation into diagnosis and therapy of lymph node metastases.
Therefore the work presented in this thesis consists of four main studies:
As discussed in Section 2.6, SPIONs have attracted great attention in the field of
nanomedicine due to their highly reactive surface and superparamagnetic properties.
Section 2.4 also presented that SPIONs can be radiolabelled with radio-tracers for multi-
modal imaging (PET/MRI) utilising the chelate-free radiolabelling technique. So Chap-
ter 3 presents experimental work to extend the current SPION radiolabelling technique
with two common therapeutic and theranostic isotopes 90Y and177Lu. This chapter
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includes materials and methods for radiolabelling three diﬀerent SPIONs with radio-
tracers commonly used in the clinic (89Zr, 177Lu) and radio-therapeutic (90Y) isotopes
applying a chelate-free technique.
Section 2.3 and Section 2.4.4, presented the limitations of current imaging modal-
ities and the importance of designing dual PET/MRI agents to enhance the diagnosis
of lymph node metastases associated with many types of cancer such as colorectal and
prostate. Chapter 4 presents a series of phantom experiments which were performed
as an important proof of concept of the FH SPION platform for multimodal imaging.
The aim of this study was to develop a chelate-free radiolabelled nanoparticle platform
for simultaneous Positron Emission Tomography (PET) and Magnetic Resonance Imag-
ing (MRI) that provides significant image quality and (potentially) diagnostic gain from
integrating the high contrast resolution of MRI with the high sensitivity of PET. This
study will be extended into future work for performing in vivo imaging of lymph node
metastases using 89Zr–FH in mice with developed colorectal cancer metastases.
In Section 2.3 the current RNT radiobiology concept and theory were presented.
In this chapter it was shown that the physical properties of a therapeutic radionuclide
(such as LET and dose–rate) and biological parameters (such as DNA repair half-life for
a specific cancer cell type) can highly impact the RNT dose response at cellular and sub-
cellular levels and thus these factors need to be considered in developing a therapeutic
radio–SPION or radio–agent. Chapter 5 presents the proof of concept for 90Y-FH RNT.
An in vitro study was performed whereby the radiobiological parameters of 90Y were
derived for three diﬀerent human colorectal cancer cell lines and benchmarked with ex-
ternal beam radiotherapy (EBRT). Future works for this study include performing in
vivo 90Y-FH and 177Lu treatment of lymph node metastasis (in mice with developed col-
orectal cancer metastases) and monitoring treatment delivery with PET/MRI.
As discussed in Section 2.4.1, in designing a therapeutic radio–agent, selection of a
therapeutic radionuclide is also dependent upon two other main factors; target geome-
tries and nature of emitted radiation. Also in Section 2.6, it was discussed that although
90Y (at high dose-rate) and 177Lu can be eﬀective in RNT, the high LET alpha emit-
ters such as 223Ra and 213Bi are the most eﬀective radionuclides for treating metastases
since they can deliver highly localised dose with minimal lateral damage. Moreover as
presented in Section 2.7, the eﬃcacy and safety of a therapeutic radio–SPION or radio–
agent needs to be assessed with personalised dosimetry calculations. Additionally, it
was also discussed that there is a lack of experimental and theoretical dosimetry stud-
ies on dynamic tumour masses in RNT. Therefore, Chapter 6 presents a Monte Carlo
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simulation study that investigates the sub-cellular mechanisms of dose delivery of the
radionuclide 223Ra when treating metastases. Importantly, these results also suggested
that 223Ra could be used together with the FH Nano-platform as an eﬀective therapeu-
tic isotope for metastatic cancer. Therefore the radiolabelling procedure developed in
Chapter 3 could be extended to radiolabelled FH SPIONs with 223Ra in future work.
Finally, the findings of these studies are summarised in Section 7.2.
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Imagination is more important than knowledge. For
knowledge is limited to all we now know and under-
stand, while imagination embraces the entire world,
and all there ever will be to know and understand.
Albert Einstein
3
Heat Induced Radiolabelling (HIR)
Thework presented in this chapter (only Section 3.1.1–3.2) will be submitted to the Com-
mercialisation, Development & IP unit (CDIP) at the University of Sydney for patent
protection.
This section presents the experimental methods and results for radiolabelling FH
NP with three diﬀerent common medical radioisotopes (i.e. 89Zr, 177Lu and 90Y) . The
image analysis for the phantom images and TEM NP characterisation are discussed in
Chapter 4. Additionally, similar radiolabelling procedures and radiochemical analyses
were applied to label 89Zr and 177Lu radioisotopes with two diﬀerent SPIONs ( g– Fe2O3
with core sizes 10 and 25 nm in average diameter). The aim of these additional exper-
iments was to investigate the potential of applying the HIR technique to radiolabelling
diﬀerent SPIONs rather than FH. A summary of experimental work and results are pre-
sented in the Section 3.4.
3.1 FH HIR
3.1.1 Materials
FH NPs were obtained from AMAG pharmaceuticals (Waltham, MA, USA). The origi-
nal vial contained 510mg elemental iron per 17ml (30mg/ml). Three 89Zr batches were
obtained from Perkin Elmer. All of 89Zr sources were in 1M oxalic acid with a specific
activity of 1.9 GBq /ml (72.0 MBq/0.038 ml, batch number: ZIRG3221), 1.86 GBq /ml
(68.9 MBq/0.037 ml, batch number: ZIRG1821) and 851.2 MBq /ml (76.8 MBq/0.090
ml, batch number: ZIRG2311) respectively. 177Lu was obtained from the radiochem-
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istry research group at Royal North Shore Hospital (RNSH) with activity concentration
of 2 GBq/ml (1 GBq/0.5 ml, batch number:139179-012). 90Y was also obtained from
the radiochemistry research group at RNSH (Perkin Elmer/ batch number C103116)
with activity concentration of 2.34 GBq/ml (3.29 GBq/1.41 ml).
The chelex-treatedwater with pH=10was prepared according to the online batch pro-
tocol (Sigma-95621-100G-F) and purified overnight by using a 0.2 mm filter (Thermo
Scientific, Nelgene Disposable Filter Unit, 450-0020). One M and 25 mM Na2CO3
(Sigma-S7795-500G) was used for neutralisation and pH adjustment of reaction mix-
tures. 20mMand 10mMofDeferoxaminemesylate salt (DFO) (Sigma-D9533)was pre-
pared and used to quench the reactions. For Size Exclusion Chromatography (SEC), PD-
10 columns (GE Healthcare) eluted with 0.9% saline was used. Volume fractions were
counted on a Wizard 2480 (Perkin Elmer) gamma counter. Purified radiolabeled SPI-
ONswere concentrated using anAmicon 30 kDaMCcentrifugal filter (Sigma-Z717185).
The TLC (Thin Layer Chromatography) plate used was a Strong Cation Exchange TLC
plate made by Sorbent Technologies (Cat: 1224026). TLC plates were pre-soaked at the
origin section by chelexed water and dried by a small fan immediately before use. The
developed radio-TLC plates were divided to 1 cm pieces and the radioactivity of each
piece was measured using a Wizard 2480 (Perkin Elmer) gamma counter. Table 3.1
lists the isotopes used with their physical and chemical properties. Also a list of key
materials used are presented in Figure 3.1.
Radioisotopes Atomic mass Atomic Radius (pm) Ionic Charge Ionic Radius (pm) Initial Activity, A0 (MBq)
Zr 89 155 +4 83 18.5
Y 90 180 +3 115.9 30
Lu 177 175 +3 111.7 15
Table 3.1: List of radioisotopes with their physico-chemical properties. Note that A0 is the
intial amount of activity used per experiment.
3.1.2 Radiolabelling methods
FH NPs was radiolabelled with 89Zr utilising the HIR technique. FH NPs were radio-
labelled with 177Lu and 90Y using the modified/optimised HIR procedure. Radio-TLC
and SEC measurements were performed to obtain the radiochemical yield and purity
(RCY and RCP respectively) for each radiolabelled product. Finally phantom imaging
studies were performed to evaluate the radiolabelled FH and other SPIONs capability
in PET/CT, SPECT/CT and PET/MR imaging.
54
The HIR procedure was described in Chapter 3, Section 2.4.3 . However some mod-
ifications were made to the basic HIR as well as the radiochemical analysis technique,
that are needed for labelling FH with the therapeutic isotope 90Y (beta emitting) and
with the theranostic isotope 177Lu (beta and gamma emitting). Radiolabelling FH with
these two isotopes has not previously been attempted. The modification and optimisa-
tion to HIR technique is listed as per the following:
1. For 90Y labelling of FH, the amount of initial activity was increased from 18
MBq (which was the activity used for 89Zr-FH radiolabelling in previous pub-
lished procedure20) to 30 MBq/1mg Fe to escalate the loading capacity (number
of 90Y3+ ions per FH core). This is a critical factor for labelling isotopes for ther-
apeutic applications, as opposed to imaging, which only requires trace amounts
of radioactivity. Since the clinical Fe dose is below 5 mg/kg per patient weight,
radiolabelling higher amounts of activity per FH iron (Fe(mg)) enables delivery
of a desirable radiation dose with a lower FH iron dose. Additionally, this is an
important factor for radiolabelling short half-life isotopes (e.g. 64Cu). Increasing
the initial activity can provide a higher metal ion (e.g. 64Cu) to FH nanoparticle
ratio and provides suitable timing for logistics (i.e. isotope delivery).
2. A heating vortex technique was developed for mixing the reaction mixture. The
use of magnetic stirrer bar can cause heterogeneous mixing (FH and radioisotope
ions) within the reaction volume and this aﬀects the RCY and causes heteroge-
neous activity distribution within the labelled FH NPs. As the magnetite core of
FH is superparamagnetic, a magnetic stirrer bar can have an impact on the reaction
mixture, causing FH NPs to be more closely packed around the bar. Additionally,
a small percentage of the FH NPs as well as the radioactivity may be lost due to
their attachment to the magnetic stirrer bar. Therefore, the basic HIR technique
was modified by replacing the magnetic stirrer bar with a heating vortex technique
that was developed by assembling an orbital shaker with a silicon oil bath heater.
Moreover, this technique is advantageous for preparing large volumes of radio-
labelled products (e.g. > 5ml). This technique was applied to both the 90Y and
177Lu radiolabelling procedures.
3. A bremsstrahlung-based techniquewas developed for radiochemistry analysis. This
technique needed to be developed because 90Y is not a direct gamma emitter and
thus the conventional gamma counter method used in the basic HIR technique
(used for 89Zr radiolabelling) cannot be used. The newly developed technique
can also be used to calculate the RCY and RCP for any other non-gamma emit-
ting isotopes.
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3.1.3 89Zr radiolabelling
Three identical samples from the first batch, two for radiochemical analysis and one for
phantom imaging were prepared. For each sample, firstly the reaction mixture was pre-
pared by adding 20 ml 89Zr (A0  18.5 MBq, mZr  0.0125 nmoles, NZr;atoms  7.5
1012) and 50 ml chelexed water into a 0.3 ml glass vial. Then the pH of reaction mix-
ture was adjusted to 8-9 by adding 20 ml Na2CO3 (1M) gradually. Next 33.3 ml (1 mg,
mFe 17900 nmoles, NFe;atoms 1071017, NFH  184 1013) of FH nanoparticle
was added to the reaction mixture and the total volume was brought up to 200 ml by
adding 96.7 ml chelexed water. The final pH of reaction mixture was measured to be
 8.5-9. Finally, a magnetic stirrer bar was fitted within the glass vial. Then the glass
vial was placed in a silicon oil bath and the reaction mixture was heated for 2 hours at
120-130 0C. Next the reaction mixture was cooled down in an ice bath for 15 minutes
under stirring. Finally, 5 ml of DFO quenching agent ( pH 7.5, 20mM) was added
to quench the reaction by reacting with remaining free 89Zr ions and dissociating the
loosely-bound 89Zr ions from the FH NP. The quenching process performed for 15 min-
utes under room temperature incubation and magnetic stirring. The second 89Zr batch
was used for PET/MR imaging samples. Similar HIR and purification procedures were
applied to prepare the 89Zr-FH samples. The activity of the purified 89Zr-FH product
was measured to be 17.2 MBq. A summary of the experimental procedure is shown
in Figure 3.2.
3.1.4 177Lu radiolabelling
After naturalisation and dilution of the original 177Lu source, three identical samples
from the same batch, two for radiochemical analysis and one for phantom imaging were
prepared. For each sample, firstly the reaction mixture was prepared by adding 20 ml
177Lu (A0  15MBq, mLu  0.0206 nmoles, NLu;atoms 1.21013) and 50 ml chelexed
water into a 0.3ml glass vial. Then the pH of the reaction mixture was adjusted to 
8-9 by adding 20 ml Na2CO3 (1M) gradually. Next 33.3 ml (1 mg) of FH NPs was
added to the reaction mixture and the total volume was brought up to 200 ml by adding
96.7 ml chelexed water. The final pH of reaction mixture was measured to be  9.
Finally, the glass vial was placed in a heating vortex silicon oil bath (see Figure 3.3.e)
and the reaction mixture was heated for 2 hours at 120-130 0C under vortexing. Next the
reaction mixture was cooled down in an ice bath for 15 minutes under vortexing. Finally,
5 ml of DFO quenching agent (pH 7.5, 20mM) was added to quench the reaction by
reacting with any remaining free radioactive 177Lu3+ and dissociating the loosely-bound
177Lu3+ ions from the FH. The quenching process was performed for 15min under room
temperature incubation and vortexing. The activity of the final and purified product was
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measured to be  13.5 MBq. A summary of the 177Lu-FH radiolabelling experimental
procedure is shown in Figure 3.3.a,b.
3.1.5 90Y radiolabelling
After naturalisation and dilution of the original 90Y source, two identical samples from
the same batch, both for radiochemical analysis, were prepared. For each sample, first
the reaction mixture was prepared by adding 38 ml 90Y (A0  30 MBq, mY  0.0166
nmoles, NY;atoms  1013) and 50 ml chelexed water into a 0.3 ml glass vial. Then the
pH of reaction mixture was adjusted to  8-9 by adding 40 ml Na2CO3 (1M) gradu-
ally. Next 33.3 ml (1 mg) of FH NPs was added to the reaction mixture and the total
volume was brought up to 250 ml by adding 88.7 ml chelexed water. The final pH of
reaction mixture was measured to be 9. Finally, the glass vial was placed in a heating
vortex silicon oil bath (see Figure 3.3) and the reaction mixture was heated for 2 hours
at 120-130 0C under vortexing. Next the reaction mixture was cooled down in an ice
bath for 15 mins under vortexing. Finally, 10 ml of DFO quenching agent (pH 7.5, 20
mM) was added to quench the reaction by reacting with any remaining free 90Y3+ and
dissociating loosely-bound 90Y3+ ions from the FH. The activity of the final and puri-
fied product was measured to be 28.5 MBq. A summary of the 90Y-FH radiolabelling
experimental procedure is shown in Figure 3.3.
Figures:
Figure 3.1: List of materials: a) Feraheme; b) Na2CO3; c) saline; d) chelex; e) DFO.
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Figure 3.2: Experimental set-up for 89Zr-FH radiolabelling: a) the 89ZrCl4 source; b) preparing
the reaction mixtures; c) heating and stirring reaction mixtures; d,e,f) cooling and quenching
the reaction mixtures.
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Figure 3.3: Experimental set-up for 177Lu-FH and 90Y-FH radiolabelling: a,b) the 177LuCl3
source vial and prepared reaction mixturses; c,d) 90YCl3 source and the prepared reaction mix-
tures; e,f) heating vortex system for heating and stirring reaction mixtures. The heating vortex
technique was used for heating, cooling and quenching the reaction mixtures.
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Figure 3.4: Experimental set-up for preparing 89Zr-FH PET/MR samples: a) the hot cell
for radiolabelling; b) preparing the reaction mixtures; c,d) final diluted 89Zr-FH samples for
PET/MR phantom.
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3.1.6 Radiochemical analysis
For both89Zr-FH and 177Lu-FH, RCY and RCP analysis was performed using SEC and
TLC methods. The RCY and RCP of 90Y-FH reaction mixture and final product was
also measured using a bremsstrahlung-based TLC and SEC technique.
SEC measurements:
The reaction mixtures were loaded on PD-10 columns and saline (pH  7.4) was used
for volume elution. The radiolabelled products were separated from the chelated DFO
complexes using  12 ml saline. This process was performed by collecting 40 volume
fractions at 200 ml (the first 35 volume fractions) and 500 ml (the last 5 volume frac-
tions). PD-10 column analysis: After the reaction mixture was loaded on the PD-10
column, first 2.3 ml of saline was used to separate the89Zr-FH from89Zr-DFO within
the column (see Figure 3.5.a). As the 89Zr-DFO complex has a much smaller size com-
pared to 89Zr-FH, it passes through a larger volume of the mesh structure of the PD
column. Thus, after applying the first 2.3 ml saline, the89Zr-FH eluted down the col-
umn faster than the89Zr-DFO complex. Next, by loading  9.7 ml saline, 40 volume
fractions were collected (see Figure 3.5.b). The first 15 collected volumes contain the
radiolabelled89Zr-FH (brown colour solutions) and the last 5 volumes included the89Zr-
DFO. Similarly, the final 177Lu-FH and 90Y-FH products were firstly separated from the
177Lu-DFO and 90Y-DFO complexes and then collected at 200 ml volume fractions (see
Figure 3.5.c,d). Next, the activity of each eluted volume (for both89Zr-FH and 177Lu-
FH) was measured by a gamma-counter and an elution curve was plotted (counts vs
volume). Since 90Y is a mainly beta emitting radionuclide, the gamma-counter protocol
was modified by setting the energy window to 2-2000 keV to detect the produced sec-
ondary bremsstrahlung radiation emitted by the beta particles. Then the 90Y-FH elution
curve was plotted (counts vs volume).
The second prepared samples for each reaction mixture was also purified using a PD-
10 column and collected with 0.1 ml saline (see Figure 3.6.a,b). Next, to concentrate the
product, the purified sample plus 2ml saline was loaded onto a 50 kDaMCAmicon filter
for centrifugation (at the speed of 4000 rpm under room temperature) (see Figure 3.6.c).
The final purified product was then collected at 200 ml (see Figure 3.6.d) with 100%
recovery (see Figure 3.6.e). Finally, PD-10 column analysis was also performed for the
purified product to calculate the RCP.Moreover, the activity of five 90YCl3 samples with
A0  30MBq (v= 200 ml) were measured using bremsstrahlung detection. Results were
compared with the activity of the final and purified 90Y-FH product to further validate
the accuracy of the method as well as the RCY and RCP calculations.
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TLC measurements:
The RCY and RCP were further confirmed by radio-TLC analysis. 21 ml of each of
the reaction mixtures and the final purified product (89Zr-FH, 177Lu-FH and 90Y-FH)
was spotted at the origin of the TLC plates and it was developed using chelexed water
as the solvent (see Figure 3.7.a). The89Zr-DFO and 177Lu-DFO complexes, remained
at the origin and 89Zr-FH was eluted with the solvent front (see Figure 3.7.b). Next
each TLC plates were cut to 1 cm pieces and each peace was read by a gamma-counter
and the results were plotted (counts vs volume). TLCs for 90Y-FH reaction mixture and
the product were measured using the described bremsstrahlung-based technique. The
radiochemical analysis is presented in Figure 3.9–3.11.
Figures:
Figure 3.5: PD-10 elution (SEC) for 89Zr-FH, 177Lu-FH and 90Y-FH samples: a) PD-10 column
with loaded 89Zr-FH reaction mixture and separation of 89Zr-DFO complex, similar procedure
was applied to seprate the 177Lu-DFO and 90Y-DFO complexs; b,c,d) collected volume fractions
(e.g. 200 ml) from 89Zr-FH, 177Lu-FH and 90Y-FH elutions. The red arrows indicates the
direction at which the elution volume was collected.
62
Figure 3.6: PD-10 purification and product collection: a,b) PD-10 column with loaded 90Y-
FH and 90Y-DFO complex separation; c,d) concentrating and collecting the final product using
Amicon 30 kDa MC centrifugal filter; e) Amicon centrifugal filter after collecting the product
showing 100% recovery (e.g. no 90Y-FH residual in the filter). Similar method was applied for
collecting the final 89Zr-FH and 177Lu-FH products.
Figure 3.7: Radio-TLC for 90Y-FH reaction mixtures and final product: a) prepared radio-TLCs
with  1m1 90Y-FH reaction mixture spotted at origins; b) Developed radio- TLC elutions with
chelexed water; separating 90Y-FH NPs from 90Y-DFO complex. Similar method was applied
for 90Y-FH final product, 89Zr-FH and 177Lu-FH reaction mixrure and final product samples.
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Figure 3.8: Analytical radio-TLC and PD-10 elution (40 at 0.2 mL fractions) activity profiles
for reaction and purified 89Zr-FH samples with calculated RCY and RCP.
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Figure 3.9: Analytical radio-TLC and PD-10 elution (40 at 0.2 mL fractions) activity profiles
for reaction and purified 177Lu-FH samples with calculated RCY and RCP.
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Figure 3.10: Analytical radio-TLC and PD-10 elution (40 at 0.2 mL fractions) activity profiles
for reaction and purified 90Y-FH samples with calculated RCY and RCP.
Figure 3.11: Activity of five 90YCl3 samples with 30 MBq radioactivity were measured and
compared against the 90Y-FH product using the bremsstrahlung-based technique.
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Figure 3.8, Figure 3.9 and Figure 3.10 present the volume elution activity and radio-
TLC profiles for the 89Zr-FH, 177Lu-FH and 90Y-FH reaction mixtures and purified prod-
ucts, respectively. As the 89Zr-DFO, 177Lu-DFO and 90Y-DFO complexes are smaller in
size (and molecular weight) than 89Zr-FH, 177Lu-FH and 90Y-FH products, they travel
through a larger volume of the mesh structure of the PD column. Thus, after apply-
ing the first 2.3 ml saline, the radiolabelled-FH products (i.e. 89Zr-FH, 177Lu-FH and
90Y-FH) eluted down the column faster than the radiocation-DFO complexes (i.e. 89Zr-
DFO, 177Lu-DFO and 90Y-DFO). Therefore, after applying another 12 ml saline, the
first 15 collected volumes contained the radiolabelled-FH products (brown colour so-
lution in Figure 3.5).
Additionally, for radio-TLC profiles, the radiocation-DFO complexes remained at
the origin (R f= 0.0) and radiolabelled-FH products were eluted with the solvent front
(R f  1.1). The average decay corrected RCY and RCP were presented in Table 3.2.
Both RCY and RCP results were further confirmed with radio-TLC measurements. Our
RCY and RCP values were remarkably similar to results obtained in a previous study20
for 89Zr-FH product. These results further demonstrate the robustness and reproducibil-
ity of the HIR technique. Additionally, as it was shown in Figure 3.9 and Figure 3.10,
with further development and optimisation of HIR, we have successfully radiolabelled
two 177Lu-FH and 90Y-FH products with high RCY and RCP for the first time.
Radiolabelled-FH Product RCY (%) RCP(%)
89Zr-FH 920.7 980.6
177Lu-FH 910.6 950.9
90Y-FH 960.8 980.9
Table 3.2: A summary of measured RCY and RCP for radiolabelled-FH products.
Additionally, results presented in Figure 3.11 further validated the newly developed
bremsstrahlung-based technique for radiochemistry analysis. The activity of five 90YCl3
samples with 30 MBq radioactivity were measured separately and compared against the
90Y-FH product. The ratio between the average measured activity (i.e. 30 MBq) of
90YCl3 samples and the 90Y-FH product was 95%. This is consistent with the measured
RCY = 960.8% from the volume elution activity and radio-TLC measurements. This
technique can be utilised for future HIR experiments involving beta or alpha emitting
isotopes.
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3.1.7 Phantom images
All the images were acquired using clinical scanners:
Scanner type Scanner brand Scan
PET/CT Siemens Liver
SPECT/CT Siemens Liver
MRI 3T Philips T2-weighted spin echo
PET/MRI
Siemens (PET)
3T Siemens (MR)
Liver
T2-weighted turbo spin echo
Table 3.3: Clinical scanner specifications and imaging protocols.
Series dilutions of the final (and concentrated) 89Zr-FH and 177Lu-FH products were
prepared in 4 large and micro phantoms (see Figure 3.12) to evaluate the performance
of radiolabelled nanoparticles in PET/CT, MRI, SPECT/CT and simultaneous PET/MR
imaging. Both 89Zr-FH and 177Lu-FH products were diluted in deionised water/saline
and kept overnight before the PET/CT and SPECT/CT scans. Large and micro phan-
toms contained  1.8 ml and  700 ml of the final purified products respectively. A
summary of phantom specification with 89Zr-FH dilution is presented in Table 3.4–3.5.
Figure 3.13 and Figure 3.14 show PET/CT and SPECT/CT of 89Zr-FH and 177Lu-FH
at diﬀerent concentrations. A line-profile of both large and micro PET were measured
using ImageJ to quantitatively confirm the uniformity of the activity distribution within
the radiolabelled nanoparticle dispersion (Figure 3.13 inset –a*). Additionally, the line-
profile measurements further confirmed the stability of 89Zr-FH. Free 89Zr in each sam-
ple would cause heterogeneous activity distribution across the samples and lead to a
non-linear line-profile. However, the measured line-profile of the PET sample images
were constant and linear showing the purity of the radiolabelled samples. TheMR scans
of 89Zr-FH and 177Lu-FH samples were performed after 4 days and images are shown in
Figure 3.15. The MR images also proved the stability of the radiolabelled nanoparticles
in deionised water/saline. Additionally, the PET/MRI scans for 89Zr-FH samples are
shown in Figure 3.16 for a range of concentrations.
Phantom Volume Diameter  Length (mm)
Large 1.8 ml 11.6
Micro 700 ml 180  5
Table 3.4: Summary of phantom specifications.
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Figure 3.12: Designed MRI phantoms: a) large phantoms with 1.8 ml volume for a range of
89Zr-FH and 177Lu-FH concentrations; b) micro-phantoms with 700 ml volume for similar range
of concentrations, c–f) position of phantoms at imaging time.
Phantom number Vial 1 Vial 2 Vial 3 Vial 4 Vial 5
Sample mass (kg) 0.0018 0.0018 0.0018 0.0018 0.0018
Fe mass (mg) 0 0.36 0.18 0.09 0.045
Fe mg/kg 0 200 100 50 25
Fe concentration (mM) 0 3.57 1.79 0.89 0.45
Activity (MBq) at imaging time (PET/CT) 0 4.93 2.47 1.23 0.62
Activity (MBq) at imaging time (PET/MRI) 0 5.12 2.56 1.28 0.64
Micro-Phantom number Vial 1 Vial 2 Vial 3 Vial 4 Vial 5
Sample mass (kg) 0.05 0.0007 0.0007 0.0007 0.0007
Fe mass (mg) 0 0.14 0.07 0.035 0.0175
Fe mg/kg 200 100 50 50 25
Fe concentration (mM) 0 3.57 1.79 0.89 0.45
Activity (MBq) at imaging time (PET/CT) 0 1.92 0.96 0.48 0.24
Table 3.5: Phantom specifications and summary of 89Zr-FH dilution. Vial 1 contained only
deionised water only.
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Figure 3.13: PET images for the large and micro phantoms in axial and coronal view for a range
of 89Zr-FH activities (0–4.93 and 0-1.92 MBq respectively); inset–measured activity profiles for
89Zr-FH PET images in both phantoms (showing the unifrom activity distribution); b) CT scans
of both phantoms at diﬀerent 89Zr-FH concentrations (0 -6.43 mmoles Fe) in axial and coronal
view; c) PET/CT images of both phantoms.
Figure 3.14: SPECT/CT scans of both large and micro phantoms at diﬀerent 177Lu-FH con-
centrations.
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Figure 3.15: a) T2-weighted spin-echo MR images in coronal view of large (top row) and micro
(bottom row) phantoms containing varying concentrations of 89Zr-FH, with corresponding Fe
concentration ranging from from 0 mM (water) to 3.57 mM (TR=2500 ms and TE=90-15 ms);
b) T2-weighted spin-echo MR images in coronal view of large (top row) and micro (bottom
row) phantoms containing varying concentrations of 177Lu–FH, with similar Fe concentration to
89Zr-FH samples.
Figure 3.16: T2-weighted turbo spin-echo MR images (top row) and simultaneous PET-MR
images (bottom row) of phantom vials containing varying concentrations of 89Zr-FH, with cor-
responding Fe concentrations and radioactivities, as indicated (MR images acquired using repe-
tition time, TR=2500 ms and echo time, TE=90 -10 ms).
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3.1.8 Transmission Electron Microscopy (TEM) characterisations
A separate non-radioactive 90Zr–FH sample was prepared by labelling 20 ml of 90Zr
(8.2 mmoles, Natom  4931016) with 33.3 ml FH (1 mg, mFe 17.9 mmoles, NFe
atoms  1071017, NFH  184  1013) using HIR and similar purification method
(see Figure 3.17.a-h). This provides a molar ratio of about 1 Zr atom to  2 Fe atoms
Figure 3.17: 90Zr-FH sample preparation using HIR technique for TEM imaging: a) heating
and mixing the reaction 90Zr-FH mixture; b,c) purification and concentration processes; d) the
final purified and concentrated 90Zr-FH product; e) prepering diluted sample for TEM imaging;
f) placing a drop of the diluted 90Zr-FH sample on the SiO (silicon monoxide) TEM gird;
positioning the TEM grid on gird hole of the TEM handle; h) TEM images were acquired using
JEOL-2100 200 keV and presented a) unlabelled FH and b) FH labelled with 90Zr (scalebar is
20 nm).
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or about 2939 Zr atoms per FH NP (5878 Fe atoms). Next, the final product was diluted
(at 0.001 w/w %) for TEM imaging. The 90Zr-FH and unlabelled FH samples were then
images using JEOL-2100 200 keV TEM (see 3.17.c,d). Images were analysed using
ImageJ and Matlab software (presented in Chapter 4) to investigate the change of signal
intensity in labelled 90Zr-FH compared to unlabelled FH samples.
3.2 90Y-FH dosimetry simulation for tumour micro-metastases
AMonte Carlo simulation platform was developed to calculate the dosimetry of 90Y-FH
therapy for tumour micro-metastases and the potential of FH nanoparticles to enhance
dose. Monte Carlo simulations were performed with the GATE open-source software
toolkit, which is a GEANT4 based platform developed by the international OpenGATE
collaboration and is ideal for radionuclide dosimetry applications. A micro tumour vol-
ume was modelled as a sphere with radius of 0.25 cm (m = 65 mg) placed in a water
phantom (2.5  2.5  2.5 cm3). The tumour volume was uniformly filled with water.
Next 1% (tumour mass) of 90Y-FH (A0  0.3 MBq, 0.65 mg of Fe) was distributed uni-
formly within the spherical tumour (see Figure 3.18.a). A0 = 0.3 MBq (1% of 30 MBq)
resulted in approximately a total of 1011 beta particles emitted from the 90Y-FH source
and deposited  262 Gy in the tumour volume. A similar simulation was performed
with only 90Y source in the tumour volume and the average dose to the tumour volume
was calculated to be  233 Gy. These simulation results show that 1% FH can enhance
dose deposition in the tumour volume by 11%. Each FH core contains 5874 Fe atoms,
therefore by adding 1% FH to the tumour volume, the eﬀective atomic number (iron
oxide core of FH) and density of the tumour increases. This leads to absorbing more en-
ergy per beta particles track (shortening their range within the tumour volume) and thus
higher total energy deposition within the tumour. The 2D dose distribution histograms
of the tumour volume are presented in Figure 3.18.c,d. Further theoretical and in vitro
studies were performed to investigate the cell kill mechanisms of 90Y RNT at cellular
level. Findings of these studies are presented in Chapter 5.
3.3 Yttrium–FH application in proton therapy
Furthermore, a novel idea is proposed to utilise the non-radioactive 89Y-FH in proton
therapy as a theranostic agent. Currently proton therapy is one of the most accurate
modalities of EBRT228. A proton beam that penetrates through tissues, loses energy
mainly by coulombic interaction with outer shell electrons (causing excitation and ion-
isation) at the entry region with minimal loss of energy (no significant particle deflec-
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Figure 3.18: a) Geometry set-up in the GATE simulation for 90Y-FH therapy. A micro tumour
was modelled as a sphere with 0.25 cm radius. Red and green tracks represent emitted beta
particles and scattered photon trajectories, respectively. b, c) 2D dose distributions for spherical
tumor models with 90YCl3 and 90Y-FH source respectively. The 2D-histograms were calculated
from the corresponding 3D dose distributions integrated along the z–axis.
tion). As the protons travel further in the tissue, energy deposition increases rapidly and
reaches its apex near the end of its track, known as the Bragg peak (see Figure 3.19.a).
The non-elastic nuclear reaction of protons with the target nuclei in the irradiated tissue
results in production of positron emitter isotopes within the tissue (a list of produced
isotopes is shown in Table 3.6) which can be imaged with PET for dose quantification
(see Figure 3.21.c). However as only a small amount of activity of these short half–life
isotopes can be produced per delivered therapeutic dose, there is an unideal PET signal
for imaging228.
Nuclear Reaction Threshold E (MeV) Half live (min) Positron Max Energy (MeV)
16O (p, pn)15O 16.8 2.04 1.72
16O (p, 2p2n)13N 5.7 10.0 1.19
16O (p, 3p3n)11C 27.5 20.4 0.96
14N (p, pn)13N 11.4 10 1.19
14N (p, 2p2n)11C 3.22 20.4 0.96
11C (p, pn)11C 20.6 20.4 0.96
Table 3.6: Major positron emitter production reaction in tissue228.
As it was mentioned in Section 2.4.1, 89Zr radioisotope can be produced with high
activity yield and chemical purity in a cyclotron via the 89Y(p,n)89Zr nuclear reaction.
Similarly 89Y-FH NPs in a biological target can be activated into 89Zr-FH upon the pro-
ton irradiation. Therefore the proposed idea is to dope a layer of 89Y around the FH
core NPs utilising the modified HIR method (similar to 90Y-FH radiolabelling proce-
dure) and use it as a PET signal enhancer in proton therapy. A Monte Carlo simulation
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was performed to investigate this idea and a summary of the methods and results are
presented.
Methods: Monte Carlo simulations were performed with the GATE.07 software
toolkit. A spherical tumour with radius of 0.25 cm (m = 65 mg) was placed at the centre
of a cubic water phantom (11 cm each side). The soft tissue (ICRU Four-component)
was used as the martial of the spherical tumour. Next, tumour volume was uniformly
filled with 1% (mass ratio) 89Y-FH. The spherical volumewas irradiated with an 83MeV
(with 5 mm diameter and zero angle divergence) proton beam to deliver an absorbed
dose of 22 Gy (see Figure 3.19.b). The 89Y(p,n)89Zr nuclear reaction has a high nuclear
interaction cross–section at energy close to 14.20 MeV (see Figure 3.20.a). Therefore
the position of the tumour volume inside the water phantom and initial energy of proton
beam was chosen in order to achieve: 1- proton tracks with energy of 14.20 MeV (see
Figure 3.20.c) inside the tumour volume, 2- Bragg peak within the center of the tumour
(see Figure 3.22 and a,b) and minimise the impurity from proton beam interaction with
Fe atoms (lower nuclear interaction cross–section for 56Fe(p,n)56 at 14.20 MeV ) within
the FH core (see Figure 3.20.b). The produced activity, A0 of 89Zr was calculated (using
Equation (3.1)) from the number of activated 89Zr (i.e Nt) within the tumour volume.
Similarly, the activity of other produced isotopes was obtained.
Nt =
Z ¥
0
A0 e l t dt  A0=l (3.1a)
A0 = Ntl (3.1b)
Results are shown in Figure 3.21.a,b. These preliminary simulation results suggest that
adding 1% of 89Y-FH in the tumour volume can potentially enhance the PET signal by
 30 % (i.e. A0 89Zr/A0  total). Moreover, since the half–life of 89Zr is 3.1 days, this
will allow for oﬀ-line PET imaging which is currently not practical. The calculated dose
deposition also showed that 1% of FH in the tumour volume can enhanced the dose de-
position by 12%. A possible reason for dose enhancement is increasing tumour mass
density (by adding 89Y-FH). Increasing the density of the tumour results in absorbing
more scattered protons within the tumour volume and thus increasing the deposited dose.
75
Figure 3.19: a) Schematic diagram demonstrating the interaction of proton beam with a biolog-
ical tissue: Bragg peak and isotope productoin, b) GATE simulation geometry set-up. Blue and
red tracks represent protono beam and scattered electrons respectively. The green tracks are 511
keV photons produced from positron (emitted from produced 89Zr) and electron annihilation.
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Figure 3.20: a,b) The nuclear interaction cross–section for 89Y(p,n)89Zr and 56Fe(p,n)56Co
nuclear reactions. c) The spectrum of energy deposition per proton track inside the tumour.
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Figure 3.21: a,b) Radionuclide production histrogrm and activity curves for produced radioiso-
topes within the spherical tumour, respectively. c) Three diﬀerent methods for PET dose qun-
tification in proton therapy: (i), in-beam PET, which uses PET detection panels integrated
with the beam delivery system; (ii), oﬀ-line PET, the patients walk to a nearby PET facility;
(iii) in-room PET, which uses a stand-alone, full-ring PET scanner positioned in the treatment
room to scan the patient soon after treatment. Figure c was reproduced from228.
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Figure 3.22: a, b) 2D energy distributions of spherical tumour with and without 89Y-FH,
respectively; top row demonstrates the proton beam eneryg depostion wihtin the water phantom
as well as in the spherical tumour and bottom row showing the energy depostion in the tumour
only. The energy deposited from other isotopes were not included. The 2D-histograms are
calculated from the corresponding 3D energy distributions integrated along the z–axis.
79
3.4 SPION HIR
This section presents the additional radiolabelling experiments performed with two dif-
ferent SPIONs to investigate the potential of utilising HIR technique in radiolabelling
diﬀerent NPs rather than FH.
Two diﬀerent g– Fe2O3 SPIONs (10 and 25 nm in average diameter) which were de-
veloped in–house with sterically stabilising polymer coatings229 were provided by the
School of Chemistry at the University of Sydney. The original vials contained 14.5 and
13.3 mg/ml Fe for 10 nm (small NP, SNP) and 25 nm (large NP, LNP) SPIONs respec-
tively. SNPs and LNPs were radiolabelled with 89Zr (with A0  18 MBq and 10 MBq
respecitvely). LNPs were also radiolablled with 177Lu (with A0  15 MBq). The RCY
and RCP for each radiolabelled SPIONwas calculated using similar SEC and radio-TLC
procedure explained in Section 3.1.6. Series dilutions of the final (and concentrated)
89Zr-LNP and 89Zr-SNP products were prepared in two sets of phantoms to evaluate
the performance of radiolabelled NPs in PET/CT and simultaneous PET/MR imaging.
Additionally the relaxometric properties of SNP and LNP were measured using Nuclear
Magnetic Resonance (NMR) spectroscopy. Moreover, a separate non-radioactive 90Zr
sample was prepared by labelling 20 ml of 90Zr (8.2 mmoles, Natom  4931016) with
70 ml (e.g. 1 mg) of LNP for TEM characterisation. A summary of the radiochemmical
analysis, phantom and TEM images and the relaxometric measurements are presented
in Figure 3.23– 3.28.
Figure 3.23: Experimental set-up for radiolabelling LNPs and SNPs with 89Zr : a) LNP and
SNP source vials; b) HIR process; c) radio-TLC development; d) PD-10 elution; e) purified
and final 89Zr–LNP product; f) phantoms with diluted 89Zr–LNP and SNP sample inside the
PET/CT scanner. Similar exprimental procedure was applied to label 177Lu with LNP.
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Figure 3.24: Analytical radio-TLC and PD-10 elution (40 at 0.2 mL fractions) activity profiles
for a) reaction and purified 89Zr with LNP and SNP with calculated RCY and RCP, b) the
177Lu-FH reaction mixute with only calcualted RCY.
Figure 3.25: PET/CT images for 89Zr–LNP and SNP; a) only PET images in coronal view,
b) PET/CT images in sagittal view; c) PET/CT images at axial views d) PET/CT images in
coronal view.
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Figure 3.26: a) T2–weighted spin-echo MR images at TE = 60, 30 and 15 ms which were
acquired using a 3T clinical Philips MR scanner, b,c) LNP and SNP T2 transverse relaxation
measurements as a function of echo time, d) 7T NMR T2 relaxivities as a function of 10 and
25 nm SPION concentration. The LNP with larger r2 (and thus shorter T2) causes a greater
contrast at similar concentration to SNP. This is mainly due to creating a greater local magnetic
field inhomogeneities. LNP creates a higher contrast compare to SNP due to its larger diameter.
The eﬀect of NP size in T2 transverse relaxation (the outer–sphere theory) and thus the contrast
was discussed in more detials in Section 2.3.1
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Figure 3.27: T2-weighted turbo spin-echo (TSE) MR images (top row) and simultaneous PET-
MR images (bottom row) of phantom vials containing varying concentrations of 89Zr-LNP, with
corresponding Fe concentrations and radioactivities, as indicated (MR images acquired using
TR=2500 ms and TE=90 -10 ms).
Figure 3.28: 90Zr-LNP sample preparation using HIR technique: a) heating and mixing the
90Zr and FH mixture; b,c) purification and concentration processes; d) the final purified and
concentrated 90Zr-LNP product. TEM images for e) labelled LNPs (a zoomed region of figure
e is shown in f) and h) unlabelled LNP; g) The Selected Area Electron Diﬀraction (SAED)
pattern of unlabelled LNP (g–Fe2O3) with indicated crystal planes.TEM images were acquired
using JEOL-2100 200 keV.
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Figure 3.24 presents the volume elution activity and radio-TLC profiles for (a) 89Zr-
NPs (for both SNP and LNP) and (b) 177Lu-NP (only LNP). The measured RCY and
RCP for both 89Zr-NP products were up to approximately 84% and 96%, respectively.
Additionally, for 177Lu-LNP the measured RCY was approximately 86%. These results
further demonstrated that the chelate-free HIR technique can be applied for radiola-
belling SPIONs other than FH and obtain high RCY and RCP. A series of dilutions
of 89Zr-NP products (both SNP and LNP) were prepared in 4 separate phantom vials
with diameter, length and volume 11.6 mm, 32 mm and 1.8 ml, respectively, that were
inserted into a round holder used for simultaneous PET/CT imaging. All the 89Zr-NP
products were diluted in deionised water and a fifth vial containing only deionised wa-
ter was also prepared. Immediately after preparation of the radioactive samples, the
phantom vials were scanned using a simultaneous PET/CT clinical scanner (Siemens
Biograph 64 slice). A liver protocol was used for the PET scans. Figure 3.25, demon-
strated the PET/CT images of the 89Zr-NP products with various Fe and radioactivity
dilutions. A summary of the phantom vial 89Zr-NP dilutions is also presented in Fig-
ure 3.25.
Samples were also scanned using a 3T Philips Ingenia scanner. As the total mass of
the samples in the vial holder (20 g) was well below the threshold mass (1 kg) for
clinical scanning, a 1 kg liquid water phantom was positioned below the vial holder. A
standard head coil was used for the MRI scans. Multi-slice T2-weighted images were
then acquired at diﬀerent echo times (TE) from 15 ms to 60 ms with a repetition time
(TR) of 2000 ms using a spin echo (SE) sequence, with flip angle 900, field of view
(FOV) = 100  100 mm2, matrix = 320  320 and slice thickness = 2 mm. As it is evi-
dent from Figure 3.26 (a), the LNP with larger r2 (and thus shorter T2) causes a greater
contrast at similar concentration to SNP. The LNP creates a higher contrast compared
to SNP due to its larger diameter. This is mainly due to creating greater local magnetic
field inhomogeneities in the presence of an applied external magnetic field. The eﬀect
of NP size on T2 transverse relaxation (e.g. the outersphere theory) and thus the contrast
is discussed in more detail in Section 2.3.1.
Furthermore, another set of the 89Zr-NP (only LNP) were scanned by a simultaneous
PET/MRI scanner (Siemens Biograph 3T mMR). Similar PET and MR imaging proto-
cols described in Table 3.3were used to acquire both PET andMR images. The PET/MR
images also demonstrated the LNPs at a specific activity of  697 MBq/mmol (0.56
MBq/0.045 mg Fe/56mg/mmol), where the PET signal is weak, at a lower Fe concen-
tration (i.e. 0.45 mM Fe) can still cause a considerable MRI contrast (see Figure 3.27).
Additionally, the relaxometric parameters of unlabelled NPs (both SNP and LNP) were
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measured using a 7T NMR spectrometer and results were presented in Figure 3.26 (b-
d). The measured T2 relaxivities were consistent with the previous published study229.
The Selected Area Electron Diﬀraction (SAED) pattern of unlabelled LNP shown in
Figure 3.28 (g) also confirmed that the internal crystal structure of LNP is (g-Fe2O3).
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Purpose: The aim of this study was to develop a chelate-free radiolabeled nanoparticle 
platform for simultaneous Positron Emission Tomography (PET) and Magnetic 
Resonance Imaging (MRI) that not only provides contrast-enhanced diagnostic imaging, 
but also provides significant image quality gain from integrating the high spatial resolution 
of MRI with the high sensitivity of PET. 
 
Methods: A commercially available nanoparticle (Feraheme®, FH), based on a super-
paramagnetic iron oxide nanoparticle (SPION) core, was used as the nano-platform. FH 
was labeled with the PET radioisotope 89Zr using a novel chelate-free radiolabeling 
technique, heat induced radiolabeling (HIR). Radiochemical yield (RCY) and purity (RCP) 
were measured. Transmission Electron Microscopy (TEM) characterization of labeled FH 
was carried out using the non-radioactive isotope 90Zr. Simultaneous PET-MR imaging 
was performed with different 89Zr-FH concentrations. The MR images were quantitatively 
analyzed to determine the relaxometric and contrast-enhancing properties of 89Zr-labeled 
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FH. The signal-to-noise ratio (SNR) was calculated before and after integrating the PET 
and MR image data. 
 
Results: Radiochemical analysis demonstrated a high RCY (92%) and RCP (98%) of the 
89Zr-FH product, thereby confirming the efficiency and robustness of the chelate-free HIR 
technique. The TEM analysis confirmed that the isotope atoms adsorb onto the SPION 
surface. The simultaneous PET-MRI scans confirmed the capability of the 89Zr-FH nano-
platform for this multi-modal imaging technique. Furthermore, the relative contrast image 
analysis showed that 89Zr-FH radio-nano-platform can combine PET and MR images in a 
complementary manner to achieve high quality imaging using a minimal dose of radio-
isotope and Fe.  
 
Conclusion: We achieved a high RCY and RCP (up to 98%) of 89Zr-FH which. Moreover, 
the non-radioactive 90Zr labelling results demonstrated that high loading capacity of ions 
per FH nanoparticles can be achieved using HIR technique. The hybrid PET/MRI scans 
confirmed the capability of the 89Zr-FH Nano-platform for this multi-modal imaging 
techniques. Furthermore, the relative contrast image analysis showed that 89Zr-FH Nano-
platform can combine PET and MR images in a complementary manner to result in an 
image with higher accuracy.  
 
 
Keywords: SPIONs, radiolabeling, MRI, PET, multimodal imaging. 
 
 
Introduction 
Superparamagnetic iron oxide nanoparticles (SPIONs) represent a class of 
nanoparticles with arguably the most promising potential for clinical translation. 
Their strong magnetic susceptibility, attributable to their nanoscale geometric 
confinement, enhances contrast in magnetic resonance imaging (MRI), which is 
an essential diagnostic clinical imaging modality. Indeed, a number of SPION-
based nanoparticles have already demonstrated valuable clinical applications in 
oncology, neurology and cardiology [1] [2] [3]. SPIONs thus represent an attractive 
nanoparticle platform for versatile clinical nanomedicine applications. 
 
Feraheme (AMAG Pharmaceuticals, Waltham, MA, USA) is a nanoparticle 
comprised of an ultra-small (»5 nm diameter) SPION core and a carboxylated 
polymer coating, giving an effective hydrodynamic diameter of »30 nm. Since 
being FDA-approved for treating iron-deficiency anemia, Feraheme has attracted 
considerable attention and is increasingly being used off-label as an MRI contrast 
agent, not only as an alternative to conventional gadolinium-based agents, but also 
because of its unique and favorable pharmacologic, metabolic and imaging 
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properties [4]. In particular, FH has proven to be an effective biological marker of 
inflammation, as a result of being uptaken from the blood pool by immune cells 
(see figure 1). Thus, FH-enhanced MRI can be used to non-invasively detect 
monocyte/macrophage trafficking and localize inflammatory lesions [5] [6].  
 
In a series of ongoing studies [7] [8], Feraheme was used as a nanoparticle 
platform to label a range of radio-isotopes commonly used in nuclear medicine, 
particularly Positron Emission Tomography (PET). Importantly, radiolabeling was 
achieved using a recently developed technique, heat-induced radiolabeling (HIR) 
[9], that is chelate-free and is thus more favorable for clinical applications than 
conventional labeling methods that rely on different chemical chelators unstable 
and/or alter nanoparticle biodistribution in vivo [10] [11].  
 
The motivation for radiolabeling FH with PET tracers is to take advantage of multi-
modal PET-MRI technology, which is proving invaluable in a growing number of 
clinical imaging applications [12] [13] [14]. Simultaneously acquired PET-MRI 
integrates the high sensitivity of PET with the spatial resolution and soft tissue 
contrast provided by MRI. FH is most often used to enhance dark contrast against 
tissue, by virtue of its ability to quench the MRI signal by shortening the transverse 
(spin-spin) relaxation time, T2. However, dark contrast can be difficult to discern in 
a clinical setting, especially for some applications such as detection and diagnosis 
of metastases in the lymph nodes, which are typically only »1-2 cm in diameter 
and display intra-nodal contrast variations in FH-enhanced MRI when metastases 
is present [15] [16]. Furthermore, increasing the FH Fe dose is not desirable 
because FH aggregation can affect the MR-derived attenuation maps needed by 
PET in simultaneous PET-MRI [17]. FH radiolabeled with a PET tracer can thus 
take advantage of the high sensitivity bright signal from PET to readily detect the 
presence of FH in regions where the MRI contrast is too low and/or the signal too 
noisy. Conversely, anatomical features, such as a lymph node, can be identified 
with MRI, which has a spatial resolution (»1 mm in standard clinical scanners) that 
is typically an order of magnitude better than PET. 
 
To date, relatively few studies have investigated the potential for hybrid PET-MR 
imaging of radiolabeled SPIONs [18] [19] [20] [21]. Our study is the first to use 
chelate-free radiolabeling and, to the best of our knowledge, to acquire 
simultaneous PET-MR image data. We used the PET tracer 89Zr, which in a 
previous study [Normandin et al. 2015] was labeled to FH using HIR and PET/CT 
images acquired to obtain the 89Zr -FH biodistribution in healthy mice. Here, we 
focus our attention on acquiring, for the first time, simultaneous PET-MR images 
using phantoms containing 89Zr-FH to demonstrate proof of principle of how hybrid 
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PET-MRI can provide a gain in image quality that would otherwise not be possible 
with either image modality alone. 
Materials and methods 
Materials 
Feraheme (FH, AMAG Pharmaceuticals, Waltham, MA, USA) has the non-
stoichiometric formula Fe5874 O8752:C11719 H18682 O9933 Na414. A single 17 ml vial of 
FH containing 510 mg elemental iron (30 mg Fe/ml) was used in this study. 89Zr 
(half-life 78.41 hrs) was obtained from Perkin-Elmer (batch number ZIRG3221) in 
its +4 oxidation state, 89Zr4+, in 1 M oxalic acid with a specific activity of ≈1.9 
GBq/ml (72.0 MBq/0.038 ml). 
 
Chelex treated water with pH = 10 was prepared according to the online batch 
protocol (Sigma-95621-100G-F) and purified overnight by using a 0.2 µm filter 
(Thermo Scientific, Nelgene Disposable filter Unit, 4500-0020). 1 M of Na2CO3 
(Sigma-S7795-500G) was used for neutralization and pH adjustment of reaction 
mixtures. 20 mM of deferoxamine mesylate salt (DFO) (Sigma-D9533) was 
prepared and used to quench the reactions. Size exclusion chromatography 
(SEC), PD-10 columns (GE Healthcare) and 0.9% saline were used for sample 
purification and radiochemical analysis. Volume fractions were counted on a 
Wizard 2480 (Perkin-Elmer) gamma counter. Purified radiolabeled samples were 
concentrated using an Amicon 30 kDa MC centrifugal filter (Sigma-Z717185). A 
strong cation exchange radio-thin layer chromatography (radio-TLC) plate was 
used (Sorbent Technologies, Cat#: 1224026). The TLC plates were pre-soaked at 
the origin section by chelexed water and dried by a small fan immediately before 
use. 
 
A silicon monoxide (SiO) grid was used for transmission electron microscopy 
(TEM). TEM micrographs were acquired using the 200 keV JEOL-2100.  
 
1.8 ml (with diameter and length of 11.6 and 32 mm respectively) glass vails were 
used as phantoms (see figure 4). All phantom images were acquired using a 
clinical PET-MRI scanner (Siemens Biograph 3 T mMR). A standard liver protocol 
was used for the PET scan and a T2-weighted turbo spin echo sequence was used 
for the MRI scan. 
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Experimental methods 
Heat-induced radiolabeling (HIR) 
HIR was carried out according to the published protocol [9]. Briefly, three identical 
FH samples were prepared, two for radiochemical analysis and one for phantom 
imaging. For each sample, the reaction mixture was prepared by adding 20 µl 89Zr 
(mZr ≈ 0.0125 nmoles, Natoms ≈ 7.5x1012, with A0≈18.5 MBq) and 50 µl chelexed 
water into a 0.3 ml glass vial. The pH was adjusted to ≈ 8-9 by gradually adding 
20 𝜇l Na2CO3 (1 M). Next 33.3 µl FH (1 mg, mFe ≈ 17.9 µM, NFe atoms ≈ 107x1017, 
NFH ≈ 184 x1013) was added to the reaction mixture and the total volume was 
brought up to 200 µl by adding 96.7 µl chelexed water. The final pH was measured 
to be ≈ 8.5-9. A magnetic stirrer bar was fitted within the glass vial, which was then 
placed in a silicon oil bath and the reaction mixture was heated for 2 hours at 120-
130 0C. Next the reaction mixture was cooled in an ice bath for 15 minutes under 
stirring. Finally, 5 µl of DFO (pH ≈ 7.5, 20mM) was added to quench the reaction 
by reacting with remaining free 89Zr ions and dissociating any loosely-bound 89Zr 
ions from the FH nanoparticles. The quenching process was performed for 15 
minutes under room temperature incubation and magnetic stirring. A summary of 
the experimental procedure is shown in figure 2.  
 
Radiochemical analysis  
Size exclusion chromatography (SEC) and radio-thin layer chromatography (radio-
TLC) were performed to obtain the radiochemical yield and purity (RCY and RCP). 
 
The reaction mixtures were loaded on PD-10 columns and saline (pH ≈ 7.4) was 
used for volume elution. 89Zr-FH was separated from the chelated 89Zr-DFO 
complexes using ≈ 12 ml saline. This process was performed by collecting 40 
volume fractions at 200 µl. After the reaction mixture was loaded on a PD-10 
column, 2.3 ml of saline was used to separate the 89Zr-FH from 89Zr-DFO within 
the column (figure 3a). Next, by loading ≈ 9.7 ml saline, 40 volume fractions were 
collected (figure 3b). The activity of each eluted volume was measured by gamma 
counter and an elution activity curve was plotted. Next, to concentrate the 89Zr-FH 
product, the purified sample plus 2 ml saline was loaded on to a 50 kDa MC Amicon 
filter for centrifugation (at 4000 rpm under room temperature). The final purified 
product was then collected at 200 µl (figure 3b). Finally, PD-10 column analysis 
was performed for the purified product to measure the RCP. The RCY and RCP 
were further confirmed by radio-TLC analysis: 2x1 µl of both the reaction mixture 
and final purified product (89Zr-FH) was visually located at the origin of the radio-
TLC plates. Each radio-TLC plate was then cut into 1 cm pieces, each of which 
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was readout using the gamma counter. The radio-TLC activities were plotted as a 
function of distance. 
 
Transmission electron microscopy (TEM)  
A separate non-radioactive 90Zr-FH sample was prepared with 90Zr-chloride 
solution (nZr ≈ 8.2 µmol, NZr ≈ 493 x1016 atoms) and 33.3 µl FH (nFH ≈ 3.0 nmol, 
NFH ≈ 184 x1013 nanoparticles, nFe ≈ 17.9 µmol, NFe ≈ 107x1017 atoms) using HIR 
and a similar purification method. This provided a Zr-to-FH mole ratio of ≈ 2700 (or 
1 Zr atom to ≈2 Fe atoms), which is more than 5 orders of magnitude larger than 
the Zr-to-FH mole ratio for the radioactive labeling procedure, ≈ 0.0042. The 
purpose of this was to achieve metal ion loading on FH sufficiently high to produce 
a measurable change in TEM and thereby provide additional information on the 
location of binding to the SPIONs. The final product was diluted (at 0.001 w/w%) 
before TEM imaging using the JEOL-2100 at 200 keV. Images were analyzed 
using ImageJ and Matlab software to determine the change in signal intensity in 
90Zr-labeled FH particles compared to unlabeled FH samples. The change in 
average radial transmission profile between unlabeled and labeled FH was then 
calculated and the corresponding change in volume, 𝛿𝑉, was used to calculate the 
labeling yield (LY): 
 
 𝐿𝑌 = ()*,,()*   (1) 
 
where 𝑚./,0 = 𝜌./𝛿𝑉 is the total mass of labeled Zr and 𝑚./	≈ 750 µg is the total 
initial mass of Zr (nZr ≈ 8.2 µmol). 
 
Phantom imaging  
A series of dilutions of 89Zr-FH samples was prepared in 4 separate phantom vials 
with diameter, length and volume 11.6 mm, 32 mm and 1.8 ml, respectively, that 
were inserted into a round holder used for simultaneous PET-MR imaging (figure 
4). All the 89Zr-FH samples were diluted in deionized water and a fifth vial 
containing only deionized water was also prepared. Table 1 summarizes the 
phantom vial 89Zr-FH dilutions.  
 
Immediately after preparation of the radioactive samples, the phantom vials were 
scanned using a simultaneous PET-MRI clinical scanner (Siemens Biograph 3 T 
mMR). As the total mass of the samples in the vial holder (»20 g) was well below 
the threshold mass (»1 kg) for clinical scanning, a 1 kg liquid water phantom was 
positioned below the vial holder. A liver protocol was used for the PET scans. A 
 7 
standard head coil was used for the MRI scans. Multi-slice T2-weighted images 
were acquired at different echo times (TE) from 10 ms to 90 ms with a repetition 
time (TR) of 2000 ms using a turbo spin echo (TSE) sequence, with flip angle 900, 
field of view (FOV) = 100 × 100 mm2, matrix = 320 × 320, slice thickness = 2 mm. 
The mean magnitudes of T2-weighted TSE image signal intensities were obtained 
within manually drawn circular regions of interest (ROIs) using ImageJ software 
for each sample. The transverse relaxation time T2 and corresponding relaxation 
rate R2 = T2-1 for each sample were obtained by fitting a mono-exponential function 
to the mean ROI image intensities for a given FH Fe concentration at different TE: 
 
 𝐼 = 𝐼4exp(- :;:< 	)   ,   (2) 
 
where I0 represents the mean image intensity in the absence of T2 weighting for 
each ROI. R2 was determined from the exponential fits for the four different FH Fe 
concentrations. The transverse relaxivity rate, r2 (mM-1s-1), was calculated from the 
slope of the linear fit to the R2 versus FH Fe concentration [22] [23] .  
To quantitatively analyze the PET-MR images, we used two metrics: a relative 
contrast to water (RCW) metric for the contrast-enhanced MR images acquired at 
a single TE; and the signal-to-noise (SNR) ratio. The RCW was defined in terms 
of the difference between the logarithm of mean image intensities of the phantom 
vials containing the FH contrast relative to that of the water-only vial: 
 RCW	 ≡ 	 BC(DEF/DH,EF)IBC(DJ/DH,J)BC DEF DH,EF 	= 	1 −	 MN,JMN,EF    , (3) 
 
where subscripts “FH” and “w” refer to Feraheme and water, respectively. This was 
calculated for the MR images acquired at TE=90 ms. The RCW defined by 
equation (3) is more useful than one defined in terms of linear intensity difference, 
which cannot be directly related to R2 and hence, to the FH Fe concentration. 
Equation (3) was thus used to determine a critical [Fe] below which FH contrast is 
ineffective. 
 
The SNR of the PET-MR images is defined as 
 
    SNR = 	 DsigTsig   ,  (4) 
 
where Isig is the mean intensity of the image signal and ssig is the standard deviation 
of the image signal. Equation (4) was used to calculate SNRPET and SNRMRI for 
the simultaneously acquired but separate PET and MR images, respectively. The 
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higher spatial resolution of the MR images was used to improve image quality by 
removing (i.e. setting to zero) excess PET image pixels that did not overlap with 
the MRI pixels. The SNR values for the resulting spatially-resolved PET images,  𝑆𝑁𝑅PET∗ , were then calculated and compared with the corresponding values for the 
original, unmodified PET images. 
 
Results 
Radiochemical analysis  
Figure 5 presents the volume elution activity and radio-TLC profiles for the 89Zr-FH 
reaction mixture and purified product. As the 89Zr-DFO complex is smaller in size 
than 89Zr-FH, it passes through a larger volume of the mesh structure of the PD 
column. Thus, after applying the first 2.3 ml saline, the 89Zr-FH eluted down the 
column faster than the 89Zr-DFO complex. After applying another 12 ml saline, the 
first ≈15 collected volumes contained the radiolabeled 89Zr-FH (brown color 
solution, figure 3b). The 89Zr-DFO complex remained at the origin (𝑅Y = 0.0) and 
89Zr-FH was eluted with the solvent front (𝑅Y ≈ 1.1). The average decay corrected 
RCY was 92 ± 1% with RCP of ≈98%. The activity of purified 89Zr-FH product was 
measured to be ≈17.2 MBq. Both RCY and RCP results were further confirmed 
with radio-TLC measurements. Our RCY and RCP values are remarkably similar 
to results obtained in a previous study [13] reporting on chelate-free HIR of FH, 
thus demonstrating the robustness and reproducibility of this technique.    
Transmission electron microscopy (TEM)  
Figure 6 a and b present the TEM images of unlabeled and labeled FH. These 
images represent transmission of the TEM beam through the electron-dense 
particle cores.  Figure 6c shows the average transmission profile for unlabeled and 
labeled FH. After labeling with 90Zr, the average particle diameter increases by 
≈10% and the mean signal intensity decreases by ≈25%, thus indicating a higher 
electron density per labeled nanoparticle. Additionally, the average signal intensity 
at the edges of the transmission profile for labeled FH is lower by ≈11%, which 
further indicates an increase in electron density at the surface of the nanoparticle. 
These results suggest that the 90Zr ions bind predominantly to the surface layer of 
the magnetite core. The labeling yield (LY) was calculated using equation 1, with 
the change in volume per FH particle   
  𝛿𝑉 𝑁Z[ = 4 3𝜋	{(𝑟0)a − 𝑟b0)a ≈ 	57	𝑛𝑚a 
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where 𝑟0	and 𝑟b0 are the mean radii of the labeled and unlabeled nanoparticles, 
respectively (cf. figure 6c), and NFH ≈ 184 x1013 nanoparticles. This gives 𝑚./,0≈ 
682 µg and hence, 
  
  𝐿𝑌 ≈ gh<	ijkl4	ij ×	100% ≈ 91	%  
 
Phantom imaging  
Figure 7(a) presents the simultaneous PET-MR images of the phantom vials 
containing varying amounts of 89Zr-FH, with A0 = 0.64 - 5.12 MBq and [Fe] = 0-
3.58 mM, each corresponding to 0.8 MBq/µmol Fe. The T2-weighted MR images 
are also presented separately to clearly show signal quenching by FH. At constant 
TE, the dark contrast of FH against water positively correlates with Fe 
concentration. At a constant Fe concentration, the magnitude of dark signal 
intensity depends on the length of TE relative to the relaxation time T2, which is 
determined by FH Fe concentration. This is quantified further with T2 
measurements. Figure 7(b) shows measured activity profiles for 89Zr-FH PET 
images in the phantom containing the highest activity (i.e. 5.12 MBq). 
 
Figure 8(a) shows the mean intensity of the ROI in the measured T2-weighted MR 
images (figure 6, bottom panel) as a function of TE, showing the T2 values inferred 
from the exponential fit (equation 2) to each set of data with the same FH Fe 
concentration. We measured the T2 relaxation time for water in a separate 
experiment as its T2»2 s is considerably longer than the longest TE time used in 
the imaging studies (90 ms). At constant TE, comparison of figures 7(a) (bottom 
panel) and 8(a) clearly demonstrate dark contrast against water due to T2 
shortening by FH, with measured values in the range 4.4-28 ms. At constant Fe 
concentration, the ratio TE/T2 determines the degree of signal quenching, as 
predicted by equation (2). The longest T2»28 ms (corresponding to the lowest Fe 
concentration studied, 0.45 mM) provides sufficient signal quenching only for TE 
³30 ms, as is evident from the MR images in figure 7.  
 
Figure 8(b) shows the corresponding plot of R2 values as a function of [Fe] and a 
linear fit to the data, implying a transverse relaxivity r2≈64 mM-1s-1, which is 
consistent with the range 60-70 mM-1s-1 measured in the HIR 89Zr-FH study by 
Normandin et al. (2015) [7]. 
 
Figure 9(a) plots the RCW as a function of Fe concentration. The curve shows 
values of RCW > 90% at [Fe] > 0.1 mM, but it predicts a dramatic drop at values 
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below this critical Fe concentration. This concentration corresponds to a dose of 
approximately 5 mg Fe/kg, which coincides with the Fe dose administered clinically 
for contrast-enhanced MR lymph node imaging with FH [16] [15]. These results 
suggest that lower Fe doses are likely to be ineffective for this application. 
 
Figure 9(b) shows plots of SNRMRI values calculated from each of the phantom vial 
images in Figure 7 using equation (4). Values of SNRMRI>10 are achieved at all TE 
for the highest FH Fe concentration studied (3.57 mM), which indicates good 
image quality. For the lowest concentration, [Fe] = 0.45 mM, SNRMRI drops from 
»9 at TE=90 ms to »1 at TE=10 ms. At TE=90 ms, linear interpolation of the SNRMRI 
data indicates that a detection limit of SNRMRI = 2 is reached at [Fe]»0.05 mM. 
Table 2 lists the mean intensity, variance and corresponding SNR values for the 
MR images acquired at TE=90 ms and the PET images. Although the SNR values, 
SNRMRI and SNRPET, are similar, comparison of the mean intensities, IMRI and IPET, 
and variances, 𝜎rMD  and 𝜎𝑷𝑬𝑻, shows that whereas the MR signal is quenched, the 
PET signal is strong and conversely, the MR images are considerably less noisy 
than the PET images. 
 
As shown next, high SNR image data can be obtained by combining the PET and 
MR images in a way that takes advantage of PET sensitivity and MRI spatial 
resolution to increase signal and reduce noise. 
 
Figure 10(a) and (b) show MRI (at TE = 90 ms) and PET images of phantom vials 
with largest and smallest  89Zr activity and Fe concentration, with an ROI indicating 
the vial boundary spatially resolved from the MR image. Also shown is a modified 
PET image, where pixels not overlapping with the MRI pixels have been set to 
zero. Table 3 lists the corresponding values for the mean intensity, variance and 
SNR for the PET images before and after modification. These results demonstrate 
the principle of integrating the high spatial resolution of MRI with the high sensitivity 
of PET to achieve an overall image quality exceeding that which could be achieved 
separately with either MRI or PET. Table 3 shows that the improvement in SNRPET 
is attributable to both an increase in mean intensity and a decrease in noise, but 
the reduction in noise (signal variance) is the dominant factor. 
 
Discussion 
Radiochemical analysis  
The radiochemical analysis (figure 5) demonstrates that under basic conditions 
(pH~ 8-9) 89Zr4+ ions (in either oxalate or chloride anions) react thermally with the 
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FH core and result in high RCY and RCP. These results are also consistent with a 
pervious study and confirm the efficiency and robustness of the novel HIR 
technique. The iron oxide core surface has negative charge potential in a basic 
environment. This is mainly due to the dissociation of hydroxyl groups “Fe–OH” 
and formation of [Fe–O]- at the surface of the FH core. Therefore, the positively 
charged metal ions are attracted by the unshared electron pairs of [Fe–O]-. This 
makes the iron oxide core surface ideal for labelling positively charge metal ions 
such as 89Zr4+, 90Y3+, 177Lu3+, 223Ra2+, 64,67cu2+, 68Ga3+. Additionally, the ionic bond 
energy of metal ions with a negatively charged surface is directly proportional to 
their charge and inversely proportional to their distance (Coulomb’s law).  
Therefore, smaller metal ions (smaller ionic radius) and/or higher charge (or higher 
oxidation state) results in a stronger electrostatic interaction and thus stronger 
bonding with the surface and a higher radiochemical yield (RCY). Nevertheless, a 
previous study has shown that the electrostatic interaction is not enough and 
additional heat and mechanical stirring is required to help with biding 89Zr4+ions or 
in general any other metals to high-affinity binding site of the surface. This study 
[9] also demonstrated that 89Zr4+(IR=73 pm, OS=4) and 64Cu2+ (IR=83 pm, OS=2) 
ions have the highest RCY (≈92%) and lowest RCY (66%) respectively. 
 
The activity-profile measurements of the PET phantom images (figure 7b) further 
confirm the stability of 89Zr-labeled FH nanoparticles. Any free 89Zr in the samples 
would introduce heterogeneity in the activity distribution leading to a non-linear line 
profile across the sample, which is not evident in the measured activity profiles. 
This simple phantom analysis should be extended to a more comprehensive 
quantitative assessment to investigate the stability of labeled 89Zr in vivo. Zr is a 
bone seeking metal and therefore any free 89Zr could preferentially accumulate in 
bone [24][25][26][27]. It is also important to note that 89Zr primarily decays via 
positron emission (23%) and electron capture (77%) to 89mY (excited Yttrium 
nucleus) which decays to 89gY (stable 89Y) via internal conversion (1%) [28]. Both 
electron capture and internal conversion decay processes lead to ejection of an 
inner electron (K or M shell) from the atom, potentially causing Auger cascades 
[28]. After the cascade the atom is in a highly charged state and therefore the 
chemical bounds between such radiolabeled atom and a chelator or nanoparticle 
can be broken [29]. A recent study has shown that this after-effect nuclear decay, 
known as “bond rupture”, is responsible for breaking and freeing 177Lu from the 
177mLu-DOTATATE chelator [29]. Additionally, each nuclear decay event can also 
rupture chemical bonds in neighboring radiolabeled molecules and nanoprticles 
and result in freeing these metals from the chelator or nanoparticle [30]. Thus, the 
“bond rupture” effect could play an important role in the stability of 89Zr-FH or 
generally any radiopharmaceutical. 
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Transmission electron microscopy (TEM)  
The TEM images (figure 6a,b) of the electron-dense core in both unlabeled and 
90Zr-labeled FH nanoparticles exhibit no noticeable qualitative differences. No 
obvious signs of aggregation are evident, in contrast to that observed by [9], who 
found that aggregation increased the average hydrodynamic diameter of 90Zr-
labeled FH particles to »150 nm, as measured by dynamic light scattering, at Zr-
to-FH molar ratios >125. Quantitatively, however, the relative decrease in signal 
intensity and increase in core diameter in the 90Zr-labeled FH transmission profile 
(figure 6c) indicates that 90Zr atoms bind preferentially to the surface layer of the 
SPION rather than inside the magnetite crystal lattice. Our TEM analysis is 
consistent with electron spin resonance studies by [9]. Additionally, the high 
labeling efficiency (LY ≈ 91%) at high Zr concentration further demonstrates the 
high metal ion loading capacity of FH, as well as the efficiency and robustness of 
the HIR technique. We were able to label ≈4.5x105 Zr atoms per FH particle, 
whereas in the radiochemical reaction, given the amount of specific activity for 89Zr 
(≈0.9 GBq/ml), the loading is only ≈1 Zr atom per 24 FH particles. 
Phantom imaging  
The measured transverse relaxivity for 89Zr labeled FH, r2 ≈64 mM-1s-1, is 
consistent with r2 for unlabeled FH, ≈65 mM-1s-1 [31]. This confirms that 89Zr and 
the radiolabeling procedure have not altered the superparamagnetic property of 
the nanoparticle core in FH. RCW results show critical [Fe] ≈ 0.1 mM below which 
FH contrast drops dramatically. 
 
Additionally, these results suggest that at this Fe concentration due to a lower 
specific activity, the PET signal could be very weak. In a clinical scenario, this 
means that if the uptake of FH NPs (from an initial FH dose) in a volume of interest 
(e.g. a lymph node) is less than 0.1 mM, FH cannot effectively cause contrast in 
MR images. For example, the amount of FH uptake in the lymph node (and thus 
the Fe concentration) depends on the initially delivered Fe FH and the uptake 
mechanism of macrophages in delivering the FH NPs in lymph nodes [15]. Further 
in vivo experiments are required to investigate these parameters which are not in 
the scope of this study. Moreover, we have shown that FH NP has a high metal 
ion loading capacity and high labelling efficiency (LY ≈ 91%) can be achieved even 
at high Zr concentration (from 1 Zr atom per 24 FH NPs to 4.5 x 105 Zr atoms per 
FH NP). Therefore, the radiolabelled 89Zr-FH can be prepared at higher 
concentrations of 89Zr (higher Zr activity per Fe mole) to enhance the PET signals 
at lower Fe FH concentrations. This then becomes a trade-off between PET-MRI 
SNR and delivered radiation dose (Fe and 89Zr) to the patient. 
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Moreover, SNR results show that image quality can be dramatically improved by 
integrating the spatial resolution provided by MR imaging into the PET images. 
SNRPET increases by up to a factor of ≈60, to a maximum value of ≈530 for the 
phantom samples in our study. This demonstrates the advantage that 
simultaneous PET-MRI provides to imaging applications that require high SNR as 
well as high contrast. 
  
 
Conclusion 
We achieved a high RCY (92%) and RCP (98%) of 89Zr-FH which confirms the 
efficiency and robustness of the novel and chelate-free HIR radiolabeling 
technique. Moreover, the non-radioactive 90Zr labelling results demonstrated that 
high loading capacity of ions per FH nanoparticles can be achieved using HIR 
technique. The hybrid PET/MRI scans confirmed the capability of the 89Zr-FH 
Nano-platform for this multi-modal imaging techniques. Furthermore, the relative 
contrast image analysis showed that 89Zr-FH Nano-platform can combine PET and 
MR images in a complementary manner to result in an image with higher accuracy. 
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Tables 
 
 
Table 1 Summary of 89Zr-FH dilutions in phantom vials prepared for PET-MR imaging 
 
 
 
 
 
 
Abbreviations: FH, Feraheme; PET, positron emission tomography; MR, magnetic resonance. 
 
 
Table 2 Mean intensity, variance and corresponding SNR values for the MRI (at TE=90 ms) and 
PET phantom images at different FH Fe concentrations and initial 89Z activities  
 
Fe (mM) A0 (MBq) IMRI  IPET 𝝈𝑴𝑹𝑰 𝝈𝑷𝑬𝑻 SNRMRI SNRPET 
0.45 0.64 8.1 31 0.89 11 9.0 3.7 
0.89 1.28 0.93 81 0.098 20 9.2 5.2 
1.79 2.56 9.1x10-3 151 9.0x10-4 24 10 7.6 
3.75 5.12 5.2x10-7 242 4.4x10-8 28 11 8.8 
Abbreviations: A0, initial activity; I, mean intensity; s, variance; SNR, signal-to-noise ratio; MRI, 
magnetic resonance imaging; PET, positron emission tomography. 
 
 
Table 3 Initial 89Z activity and mean intensities and variances of PET images before, IPET and 𝝈𝑷𝑬𝑻, and after, IPET* and 𝝈𝑷𝑬𝑻 ∗, integrating MRI spatial resolution information. Corresponding 
SNR values are also shown.  
 
 
 
 
 
 
 
Phantom number Vial 1 Vial 2 Vial 3 Vial 4 Vial 5 
Fe mass (mg) 0 0.045 0.090 0.18 0.36 
Fe mg/kg 0 25 50 100 200 
Fe concentration (mM) 0 0.45 0.89 1.79 3.57 
Activity at imaging time (MBq) 0 0.64 1.28 2.56 5.12 
A0 (MBq) IPET IPET* 𝝈𝑷𝑬𝑻 𝝈𝑷𝑬𝑻 ∗ SNRPET  SNRPET* 
0.64 31 64 11 3.4 2.8 19 
1.28 81 183 20 1.8 4.1 102 
2.56 151 232 24 0.91 6.3 255 
5.12 242 255 28 0.48 8.6 531 
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Figures 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
Figure 1 Following intravenous injection, FH SPIONs slowly extravasate from vascular space to 
interstitial space, from where they can be taken up by immune cells (monocytes/macrophages) and 
delivered via lymphatic vessels to lymph nodes. The FH SPIONs remain in normal nodal tissue and 
reduce MRI signal intensity, thereby enhancing contrast against any metastatic lesions in the node.   
Abbreviations: FH, Feraheme; SPIONs, superparamagnetic iron oxide nanoparticles. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2 Experimental procedure for 89Zr-FH radiolabelling. 
Notes:  Left panel - a) 89Zr-oxalate batch; b) preparation of reaction mixtures; c) heating and stirring 
reaction mixtures; d,e,f) cooling and quenching reaction mixtures. Right panel – schematic of the 
HIR process.  
Abbreviations: FH, Feraheme; SPION, superparamagnetic iron oxide nanoparticle; CDC, 
carboxy-dextran coating; DFO, deferoxamine mesylate salt; HIR, heat induced radiolabelling. 
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Figure 3 SEC using PD-10 analysis for 89Zr-FH. 
Notes: a) PD-10 column loaded with 89Zr-FH reaction mixture showing separation of 89Zr-DFO 
complex; b) eluted volume fractions (at 200 μl) from PD-10 elution. 
Abbreviations: SEC, size exclusion chromatography; PD-10, polypropylene desalting 10 ml 
column; DFO, deferoxamine. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4 PET-MR imaging phantoms. 
Notes: Phantom vials (11.6 mm x 32 mm, V = 1.8 ml) containing 89Zr-FH dilutions with varying FH 
Fe concentrations and 89Zr initial activities prepared for simultaneous PET-MR imaging. 
Abbreviations: PET, positron emission tomography; MR, magnetic resonance; FH, Feraheme. 
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Figure 5 Radio-chemical analysis of 89Zr-FH radiolabeling. 
Notes: Analytical radio-TLC and PD-10 elution (40 at 0.2 mL fractions) activity profiles for reaction 
and purified 89Zr-FH samples with calculated RCY and RCP. 
Abbreviations: radio-TLC, radio thin layer chromatography; PD-10, polypropylene desalting 10 ml 
column; RCY, radiochemical yield; RCP, radiochemical purity.  
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Figure 6 TEM images of FH and corresponding transmission line profiles. 
Notes: a) unlabeled FH (UL-FH) and b) 90Zr –labeled FH (L-FH) (scalebar is 20 nm); c) average 
transmission profile of FH in each image.  
Abbreviations: TEM, transmission electron microscopy; FH, Feraheme.  
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Figure 7 MR and PET-MR phantom images. 
Notes: a) Top panel – T2-weighted TSE MR images of phantom vials containing varying amounts 
of 89Zr-FH with corresponding concentrations of FH Fe (in mM), as shown, acquired at different TE. 
Circles indicate ROIs used for image analysis. Bottom panel – simultaneous PET-MR images of 
the vials with varying 89Zr activities (in MBq), as shown. b) Measured activity profiles for 89Zr-FH 
PET images in the phantom containing the highest activity (i.e. 5.12 MBq). 
Abbreviations: TSE, turbo spin echo; MR, magnetic resonance; FH, Feraheme; TE, echo time; 
PET, positron emission tomography; ROI, region of interest. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a)	
b)	
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Figure 8 MRI intensity decay curves and transverse relaxation rate. 
Notes: (a) Mean intensity of the ROIs in the MR images shown in figure 6, as a function of TE, 
showing corresponding FH Fe concentrations and T2 inferred from an exponential fit. (Error bars 
on data points are too small to be visible.) (b) Corresponding R2 values plotted as a function of FH 
Fe concentration and a best linear fit.  
Abbreviations: ROI, region of interest; MR, magnetic resonance; TE, echo time; FH, Feraheme; 
T2, T2 relaxation time. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9 MRI RCW and SNR values for the MRI phantom images. 
Notes: RCW plotted as a function of FH Fe concentration (cf. equation 2), showing data points for 
the MR phantom images acquired at TE=90 ms. Also, SNR values for the MR images acquired 
using different TE for the different FH Fe concentrations in the phantom vials.  
 
Abbreviations: SNR, signal-to-noise ratio; MR, magnetic resonance; TE, echo time; FH, 
Feraheme, RCW, relative contrast to water; FH, Feraheme; MR, magnetic resonance; TE, echo 
time. 
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Figure 10. MR and PET images of phantom vials containing a) 3.75 mM FH Fe with (5.12 MBq 
activity from the labeled 89Zr) and b) 0.45 mM FH Fe with (0.64 MBq activity from the labeled 
89Zr): (i) MR image showing spatially resolved vial boundary (blue ROI); (ii) PET image showing 
poorly resolved vial (blue ROI); (iii) PET image after removing pixels that do no overlap with MR 
image pixels in (i). 
Abbreviations: MR, magnetic resonance; PET, positron emission tomography; FH, Feraheme.  
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Abstract
Background: Dose rate variation is a critical factor aecting Radionuclide therapy (RNT) ecacy. Relatively
few studies to date have investigated the dose rate eect in RNT. Therefore, the aim of this study was to
benchmark 90Y RNT (at dierent dose rates) against external beam radiotherapy (EBRT) in vitro and compare
cell kill responses between the two irradiation processes.
Methods: Three human colorectal carcinoma (CRC) cell lines (HT29, HCT116, SW48) were exposed to 90Y
doses in the ranges 1-10.4 Gy and 6.2-62.3 Gy with initial dose rates of 0.013{0.13Gy/hr (low dose rate, LDR)
and 0.077{0.77Gy/hr (high dose rate, HDR), respectively. Results were compared to a 6MV photon beam doses
in the range from 1-9 Gy with constant dose rate of 277Gy/hr. The cell survival parameters from the Linear
Quadratic (LQ) model were determined. Additionally, Monte Carlo simulations were performed to calculate the
average dose, dose rate and the number of hits in the cell nucleus.
Results: For the HT29 cell line, which was the most radioresistant, the = ratio was found to be  31 for
HDR-90Y and  3.5 for EBRT. LDR{90Y resulted in insignicant cell death compared to HDR{90Y and EBRT.
Simulation results also showed for LDR{90Y, for doses . 3Gy the average number of hits per cell nucleus is .
2 indicating insucient delivered lethal dose. For 90Y doses & 3Gy the number of hits per nucleus decreases
rapidly and falls below  2 after  5 days of incubation time. Therefore our results demonstrate that LDR{90Y
is radiobiologically less eective than EBRT. However, HDR{90Y at  56 Gy was found to be radiobiologically
as eective as acute  8 Gy EBRT.
Conclusion: These results demonstrate that the ecacy of RNT is dependent on the initial dose rate at which
radiation is delivered. Therefore, for a relatively long half-life radionuclide such as 90Y, a higher initial activity
is required to achieve an outcome as eective as EBRT.
Keywords: Radionuclide therapy (RNT); External Beam Radiotherapy (EBRT); Yttrium-90
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Introduction
Radionuclide therapy (RNT) is a fast evolving and promising modality of treating
cancer [1]. Targeted RNT, peptide receptor RNT and selective internal RNT are
the most common nuclear medicine cancer therapy procedures for treating dierent
types of cancer metastases [2],[3],[4],[5]. With current radiopharmaceutical capabil-
ities, dierent therapeutic radionuclides such as 223Ra, 213Bi, 67Cu,32P, 177Lu and
90Y can be delivered via microparticles, nanoparticles or small peptide molecules
[6].
Current clinical therapeutic radionuclides can be classied based on the nature of
their radiation properties such as Linear Energy Transfer (LET, which is dened as
the energy deposition per unit length travelled); 50{230 keV/m for alpha particle
emitters, 0.2 keV/m for beta emitters and 4{26 keV/m for Auger electron emitters
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[7],[8]. Radionuclides such as 223Ra () ,177Lu () and 67Cu () which emit particles
with a short range (relatively high LET) are used in Targeted RNT [6],[3]. Due to
the short-range particles emitted by these radionuclides, they need to be either
attached to the surface of the tumour cell or taken up by the cell to deliver a lethal
dose [9]. Alternatively, long-range radionuclide emitters can be labelled with nano
or micro-particles for SIRT [6].
Another important property of therapeutic radionuclides is their physical half-
life which determines the dose rate at which RNT is delivered along with its initial
activity. For a given initial activity, a radionuclide with shorter half-life delivers dose
at higher rate compared to longer half-life radionuclides. The eect of dose rate in
RNT and External Beam Radiotherapy (EBRT) dose response can be classied into
low and high dose rates (respectively LDR and HDR) [10],[11]. It is also well known
that HDR radiation is biologically more eective than the same dose delivered
with LDR [10]. In RNT, as the dose rate decreases exponentially, the kinetics of
DNA double strand break (DSB) induction, repair and misrepair may play a more
important role in therapeutic outcome than in EBRT. Although several in vitro
studies have reported on EBRT dose rate eects [12],[13], relatively few studies to
date have investigated dose rate eects in RNT [14],[15],[16],[17],[18]. Consequently,
the biological principles of RNT are less well developed.
The aim of this study was to establish a platform for experimental and theoretical
90Y RNT in vitro studies and investigate the dierences in delivering EBRT and
90Y RNT (both HDR and LDR). Additionally, this study aimed to compare cell
kill mechanisms between the two irradiation processes. To do this, we investigate
90Y RNT, which is a common treatment for primary and metastasised liver cancer
that initiates from colorectal cancer.
Materials and Methods
Cell culture
As this study involved the measurement of radiation survival for a high number
of samples, the MTS assay was used instead of the standard clonogenic assay. The
human CRC cell lines HT29, HCT116 and SW480 were cultured in RPMI (Roswell
Park Memorial Institute) medium supplemented with 10% fetal bovine serum (FBS)
and incubated at 37 0C in a humidied atmosphere containing 5% CO2. The cells
were assessed by MTS (3-(4,5-Dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-
2-(4-sulfophenyl)-2H-tetrazolium) cell viability assay which is a colorimetric quan-
tication of viable cells. The assay is based on the reaction of MTS tetrazolium
compound by viable cells to generate a colored formazan product that is soluble
in cell culture media. Since the cell culture medium needs to be changed after 8
days, the maximum incubation time was 8 days. However, 90Y requires  15 days to
deliver 98% of the targeted dose. The initial specic activity of 90Y was calculated
to deliver a target dose in 8 days. All experiments were repeated twice to assess
consistency.
External beam radiotherapy (EBRT)
Each cell line was cultured in a 96 well plate and allowed 4 hours incubation before
irradiation. Additionally a control cell plate for each cell line was prepared. All of
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the cell cultures were irradiated with a 6 MV Flattening Filter Free (FFF) Linear
Accelerator (linac) photon beam with a single dose in the range of 1-9 Gy (Varian,
CAUS). All the cell plates were irradiated at a dose rate of  277 Gy/hr, at 100 cm
Source{to{Surface Distance (SSD), with back{scatter and buildup solid water (see
gure 1 a). A 1Gy dose gradient was applied across each plate so each cell culture in
the well (i.e. each column) received a dose with 1 Gy increments. Also Gafchromic
lm was placed under the plates to measure the dose in each well (see gure 1 b).
All irradiated cell plates were immediately returned to the incubator for 8 days
incubation. The EBRT experiment was repeated three times.
90Y Irradiation
90Y is a beta emitting radionuclide with a physical half-life of  2.7 days. The
mean and maximum energy of the emitted betas are 0.933 MeV and 2.280 MeV,
respectively, corresponding to an average and maximum range of 4 mm and 11.3 mm
in water [19],[20]. As mentioned above, each cell line was cultured in a 96 well plate
and allowed 4 hours incubation before adding the 90YCl3 solution. Additionally a
control cell plate for each cell line was prepared. For each cell line, two identical
sets of cell cultures were prepared for irradiation with a uniformly mixed solution
of 90YCl3 in varying concentrations (in 10 dilutions): 1)
90YCl3 solutions with LDR
specic activity of 0.24{2.4 MBq/ml (corresponding to total dose of  1-10Gy); and
2) relatively HDR specic activity of 1.44{14.4 MBq/ml (corresponding to total dose
of  6-62Gy). The pH of prepared solutions were also measured to be  7. A volume
of 20 l from each 90Y dilution was added to each well (see gure 2). Matlab was
used to calculate the dose rate according to
_D(t) =
A(t)
m
= _D0 e  t (1)
where _D0 is the initial dose rate,  is the decay constant, m is the target mass,
T is the total irradiation time (8 days) and A(t) is activity as a function of time
representing the number of beta particles (i.e. number of decays) emitted per second
with energies randomly selected from the 90Y spectrum. The corresponding total
doses were calculated according to
D =
Z T
0
_D(t) dt = _D0
Z T
0
e  t dt =
_D0


1   e T

(2)
for varying 90Y concentrations using the full beta energy spectrum of 90Y. The
physical 90Y absorbed doses were calculated to be  1-10 Gy for LDR and  6-62 Gy
for HDR. Results were also validated by OLINDA [21] and GATE [19] calculations.
Monte Carlo Simulation
A Monte Carlo model was developed in the GATE toolkit [19] to calculate the
average dose to the cell for varying 90Y concentrations. GATE is a Monte Carlo
based platform developed by the international OpenGATE collaboration for ra-
dionuclide imaging and dosimetry applications [19]. All simulations were performed
using GATE version 7.1 [19], which uses GEANT4 10.1.p01 [20]. The low energy
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electromagnetic physics package [22] of GEANT4, which describes electron, photon
and light ion interactions over an energy range of 250 eV-1GeV, was used for all
simulations.
The energy spectrum of emitted beta particles was obtained using GEANT4
[20],[23] and imported into GATE. The stochastic processes of beta emission and
hit distribution, as well as associated energy and dose deposition, were simulated
using Monte Carlo radiation transport within GEANT4. The total number of beta
particles emitted in a single well plate was determined using
HA = A0 Z T
0
e  tdt (3)
where HA represents the total number of nuclear disintegrations (i.e. cumulative
activity) and A0 is the initial activity.
Geometry set-up:
A monolayer of 5000 non-overlapping spherical "cells" was randomly placed at the
bottom of a 200 l cylindrical well (gure 3 a-c) to mimic the actual cell culture
geometry (see gure 3 e and f). The average diameter of the cell lines used in this
study is approximately 15 m [24]. Therefore, cells were modelled as spheres with
diameter 15 m and a nucleus with diameter 5 m. The cells and the well were
uniformly lled with water.
The 90Y source was uniformly distributed throughout the well and between the
cells (random locations outside of the cell volumes). Then 1010 beta particles with
energies randomly selected from the energy spectrum of 90Y were emitted from the
source volume in random directions (see gure 3 d). Finally, results were scaled to
the total number of beta particles which corresponds to the cumulative activity in
the well for 8 days irradiation. Additionally, the modelled cell culture was irradiated
by simulation with a 6 MV FFF linac beam with similar SSD as the experimental
set up. The spectrum of the FFF linac beam was obtained from the GATE software
[19].
Moreover, additional simulations were performed to conrm that the 90Y-RNT
experimental set-up; 1 - results in a uniform dose distribution within the well, 2 -
the amount of cross{re between adjacent wells in the same row does not aect
the targeted dose and 3 - the well containing water can shield/attenuate the active
rows from one another. Two adjacent wells were positioned in three rows; row-1
with active wells containing the highest 90YCl3 radioactivity, 288 kBq in 200 l cell
culture medium in each well, row-2 with wells containing 200 l water and row-3
with another 2 wells only containing 200 l cell culture medium in each well (see
gure 3 g).
Dose actor:
The dose actor (a package within GATE) represents a cubic sensitive detector that
can be voxelised into 3D rectangular or cubic voxels. Parameters such as dose, de-
posited energy, number of ionisations and number of beta particle hits were stored
into this 3D matrix according to the spatial position of the hits for each individual
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simulated cell cytoplasm and nucleus. These parameters were calculated for vary-
ing 90Y activity concentrations used in the experiment. Additionally, the average
number of hits per cell nucleus was calculated as a function of time for each 90Y
activity to investigate the eect of initial dose rate. The number of beta particle
hits per cell nucleus was calculated using:
N=nucleus =
AnHA HN (4)
where An is the total number of decays within day n (where n = 1,2,3,...8) andHN is the average number of beta particle hits to the nucleus corresponding to the
total cumulative activity. For each HA, the corresponding HN was determined from
simulations.
Cell survival study
For each of the EBRT, LDR and HDR{90Y cell irradiation experiments including
their control cell plates, the MTS cell viability assay was added and cells were
incubated at 37 0C for  3 hrs . Next the viability of each cell culture was measured
and  and  parameters were calculated from the linear quadratic (LQ) model [10]:
SF = e (D+D
2) (5)
where SF is the cell survival fraction,  and  are the radiobiological parameters
corresponding to the linear and nonlinear (quadratic) responses to the radiation
dose. The  and  parameters were obtained by tting the LQ model, equation
5, to the measured survival data. The SF was calculated for each cell line using
equation 6 [25]:
SF =
gOD in test wells  gOD in cell free wellsgOD in control wells  gOD in cell free wells (6)
where gOD is the mean optical density. The cell free wells contained the culture
medium only.
The cells are incubated with 90YCl3 for 8 days, however, since the initial dose rate
is exponentially decreasing over time, at a critical time (Tcrit) or dose rate (Rcrit)
the DNA damage (the probability of causing DSB) eectively becomes insignicant
[10]. For an exponentially decreasing dose rate, it is possible to calculate the critical
time (Tcrit) after the start of treatment [10]. Tcrit and Rcrit for all the three lines
are calculated for the highest initial dose rate using equation 7 and 8 [10]:
Tcrit =   1

ln
 0:693
R0Tav

(7)
Rcrit =
0:693
Tav
(8)
where , , R0 and Tav are the decay constant for 90Y, the radiobiological parameter
of the cell line, the initial dose rate of 90Y RNT and the average doubling time of
the cell line respectively.
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Results
Cell culture
Cell density measurements shown in gure 4 were used to nd the optimal number
of cells for both the EBRT and 90Y RNT experiments. The optimal cell densities in
an exponential phase of growth for an 8 day density viability assay were calculated
to be 30, 100, 200 cells/well (in a 96 well plate) for HCT116, HT29 and SW48,
respectively.
Dosimetry
A summary of total dose calculations and simulation results are presented in tables 1
and 2. Figure 5 presents the calculated dose rates with corresponding total doses
for both LDR and HDR{90Y. The activity for each delivered dose was selected to
achieve the target total dose at T = 8 days incubation. In addition a summary of
total dose calculations performed by GATE, Matlab and OLINDA [21] is presented
in table 1. It is evident from gure 5 that dierent 90Y activities correspond to
dierent initial dose rates, with a maximum 220 Gy/s, that decay exponentially
over incubation time. In comparison, EBRT has a higher and constant dose rate,
277 Gy/hr, (i.e.  105Gy/s) with shorter irradiation time, T  1.7 min.
Cell survival
Figure 6 presents the cell survival curves for all three cell lines for both EBRT and
90Y RNT. For each cell line, an EBRT dose >8 Gy and a HDR{90Y dose >56
Gy resulted in similar survival fractions and thus are not shown. Comparing the
EBRT and HDR{90Y survival curves, similarities can be observed. Both EBRT and
HDR{90Y resulted in an exponential dose response. However at doses <19 Gy, the
HDR-90Y survival curve slope is shallower compared to that for EBRT. As the
HDR{90Y dose rate decreases exponentially over the incubation time, for a given
dose, HDR{90Y irradiation resulted in less cell kill than EBRT for all three cell
lines. Figure 6.a (ii) demonstrates the dierence between cell survival for LDR{90Y
RNT and EBRT, showing a negligible response from LDR{90Y RNT and resulting
in negligible dose response compared to EBRT over the dose range studied, 1-8 Gy.
The calculated , values are listed in table 3. In comparison to EBRT, both of the
 and  parameters for HDR{90Y are smaller. This is due to the relatively lower
and exponentially decreasing dose rate of 90Y (i.e. maximum _D0  0.77Gy/hr).
Additionally, the Tcrit for each cell lines is presented in table 4. The Tcrit for all
three cell lines ranged approximately between 3 to 5.5 days. The HT29 cell line has
the shortest Tcrit (i.e.  3 days) which further conrmed that HT29 is the most
radioresistant cell line.
Figure 6.b presents the colorimetric dose response of EBRT at dierent delivered
acute doses (e.g. 1{9 Gy). This gure shows all three cell lines with added MTS
solution and incubated for three hours. The dark brown colour represents a higher
number of viable cells in each well. The HT29 cell line is shown to be the most
radioresistant cell line. This is evident from gure 6.b as more cells survived at
higher dose (darker color). The HCT116 cell line was the most radiosensitive cell
line showing less cell survival at even a low delivered doses (less dark). The =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ratios were determined from the LQ model (equation 5) for both EBRT and HDR{
90Y. For LDR{90Y, the percentage of cell kill was insignicant to obtain meaningful
= values. The alpha values derived from the survival curve were 0.01  0.0029,
0.007  0.0017 and 0.0023  0.001 Gy 1 for HCT116, SW48 and HT29 cell lines
respectively.
Monte Carlo simulation
Figure 7 presents histograms of the number of beta particle hits per cell nucleus
during the 8{day irradiation time for both LDR and HDR{90Y calculated by the
simulations. The number of hits per cell nucleus decreases as the activity decays
with time. The mean separation between energy deposition events at an LET value
of  1 keV/m (i.e. LET of beta particles emitted from 90Y) is larger than the DNA
double helix's diameter (i.e.  2 nm)[26]. Therefore, for a single beta particle hit,
the probability of a DSB occurring is lower for betas with LET above the mean
compare to below the mean [26]. Thus, the minimum number of hits needed to give
a nonzero probability of DSB is  2. It is evident for LDR{90Y that the average
number of hits per cell nucleus is . 2 for doses . 3 Gy during the 8 days irradiation
time. Although for doses & 3 Gy the average number of hits per cell nucleus is & 2, it
decreases rapidly and falls below 2 after  5 days of irradiation for doses . 5 Gy. For
higher doses, N=nucleus . 2 after  7{8 days. For HDR-90Y, similarly, the number
of hits per cell nucleus decreases during the 8 days irradiation time but the average
number of hits per cell nucleus remains above 2 for all 90Y doses investigated. For
EBRT, HN  295 and 30 for 10 and 1 Gy total dose, respectively.
Furthermore, gure 8.a demonstrates a two-dimensional (2D) histogram of the
energy distribution in all 6 wells. As it is evident from gure 8.a, most of the voxels
in each active well receive a similar energy deposition (the red region). Figure 8.b
shows a 2D histogram of beta particle uence for all 6 wells. The beta particle uence
histogram represents the number of particles that entered into each well from outside
(the amount of cross{re between adjacent wells). Figure 8.b demonstrates a beta
particle equilibrium between the adjacent active cell wells. Each active well in row
1 equally received 6% from the adjacent well (the purple region). Additionally the
cross{re between the adjacent wells did not change the total energy deposition in
each well (each well received approximately 61.7 Gy).
Discussion
In comparison to the established clonogenic assay, the MTS (or MTT) assays
are sensitive and accurate methods with several advantages such as requiring
a short time to assess the viability, acquiring the results easily and accurately
[27],[28],[29],[30],[25],[31],[32]. It measures all viable cells thus representing cells from
a true tumour population rather than just clonogenic cells (i.e. cells that can form
colonies) [33],[34].
Previous studies have shown that the cells exposed to the higher radiation doses
cannot regain their exponential growth in a single MTT or MTS assay, and multi-
ple MTS assays are required to obtain measurements of radiation survival that is
comparable to that of clonogenic assays [27],[29]. Although previous studies have
shown that MTS and MTT assays are suitable to investigate the radiation dose-
response analysis [29], the clonogenic assay has been preferred to measure survival
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after radiation exposure, as it measures the sum of all modes of cell death, encom-
passing both early and late events such as delayed growth arrest [35]. Therefore, the
= ratios derived from a metabolic activity assay at a single time point, should
be used cautiously in further radiobiological modelling. Additionally, the cells sus-
taining radiation-induced damage may exhibit delayed eects and there could be a
lag between irradiation and subsequent biological events (e.g. cell cycle arrest, cas-
pase activation) leading to cell death [10],[36]. The acute DNA damage induced by
radiation and the subsequent cellular responses are inuenced by multiple factors
including radiation characteristic, dose rate and cell cycle phase [10],[36]. In RNT,
the dose rate is one of the most important factors inuencing the cell damage, cell
repair and also the eective treatment time. The Tcrit for all three lines ranges
approximately 3{5.5 days. In this study, the MTS assays were performed 8 days
after the initial addition of 90YCl3, on average  4 days beyond these critical times
where the treatment is eectively being insignicant and the delayed eects could
occur. Thus, performing the MTS assay after the actual treatment time could still
include the cell death due to the delayed eects.
The cell survival results provide insight into dierent damage responses to EBRT
and 90Y RNT. With EBRT, the dose was delivered at a constant dose rate of
277Gy/hr in  1.7 min, whereas 90Y was delivered at a lower dose and varying
rate (i.e. 0.013{0.13 Gy/hr and 0.077{0.77 Gy/hr) over 8 days. The dose rate and
nature of radiation clearly aects the nature of cell damage. There are two types
of cell damages: 1) double strand break (DSB), where two proximal DNA strands
are broken simultaneously by a single radiation event causing lethal damage (LD)
(i.e. cell death); and 2) single strand break (SSB), where each DNA strand broken
by independent radiation events. When only a single DNA strand is damaged, the
cell is considered sublethally damaged (SLD) and has the ability to repair itself
typically within in 0.5-3 hours [37]. Therefore at lower dose rates the probability of
accruing two sequential hits to damage before DNA repair is less. Moreover for an
exponentially decreasing dose rate, the probability of DSB is even lower. Therefore
LDR{90Y RNT is less eective at causing lethal damage than HDR{90Y RNT and
EBRT.
The rate of cell kill through the DSB process is measured from the response
component of the survival curve parameterised by . The rate of cell kill through
the SSB process is measured from the quadratic part of the survival curve, param-
eterised by  which is highly dependent on the initial dose rate. The value of 
depends on the the radiation type. For high LET radiation such as alpha particles
DSB dominates the cell kill process and therefore  has higher signicance than
. Therefore, for a low and exponentially decreasing dose rate 90Y source there
is less contribution to SF from the D2 component than from the  term. This is
evident from gure 6 a (i and ii), as SSB repair results in the formation of a shoulder
for the HDR{90Y survival curve. However, as the EBRT dose rate is signicantly
higher than HDR{90Y RNT (by a factor 400), the rate of lethal SSB production is
much higher. Consequently this results in delivering more lethal damage to cells at
an even lower EBRT dose range (compare to 90Y doses). Moreover for LDR{90Y
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(0.013-0.13 Gy/hr), there is even less contribution from the D2 component since
the rate of SSB repair occurs even more rapidly (see gure 6 a (ii)) than the rate of
damage. Simulation results further conrmed that for both of HDR and LDR{90Y,
for smaller delivered activities and doses (i.e. .3 Gy) the average number of hits
per cell nucleus is . 2. Additionally for doses &3 Gy, although the average number
of hits is & 2, the number of beta particle hits per cell nucleus decreases and falls
below 2 after  5 days of irradiation. This is also consistent with the calculated
Tcrit for each cell lines (i.e. 3{5.5 days). This suggests that for LDR-90Y only  1{2
half-lives of delivered dose can potentially cause direct cell nucleus DNA damage.
All three cell lines showed higher sensitivity to EBRT than 90Y. The HT29 and
HCT116 cell lines were the most radioresistant and radiosensitive cell lines respec-
tively. This is also consistent with previous studies [38],[39]. Similar sensitivity for
both cell lines was observed for 90Y irradiation results. The = ratios for both
EBRT and 90Y were derived from equation 5. However several models have been
developed to incorporate the eect of DNA repair and the exponentially changing
dose rate of RNT[10],[37]. The extended LQ model includes the kinetics of DSB
creation, repair, and misrepair to estimate the true fraction of surviving cells in an
irradiated cell population (equation 9a and 9b).
-ln(SF) =  D + G D2 (9a)
G =
2
D2
Z 1
 1
_D(t) dt
Z t
 1
_D0(t 0) e  (t t
0) dt 0 (9b)
where G is the Lea-Catcheside factor and  is the DNA repair time constant [40].
The rst integral represents the physical absorbed dose. The integrand of the sec-
ond integral over t 0 refers to the rst SSB of two DSBs required to cause lethal
damage. Also, the integral over t refers to the second SSB of remaining of two DSBs
to cause the unrepairable lethal damage. The exponential term describes the repair
and reduction in 2 SSB ! DSB process due to decreasing dose rate. For a constant
EBRT dose rate where the dose is delivered acutely and the irradiation time is very
short, the G{factor approaches unity and equation 9a simplies to its the general
from (equation 5). This means the rate of SSB ! DSB process production is higher
than the DNA repair rate and therefore the kinetics of DSB creation are negligible.
In comparison to EBRT, the 90Y RNT dose rate is much lower and exponen-
tially decreasing (equation 1), so the dierence in the kinetics of DSB creation has
more impact on cell survival. The G factor can be derived for 90Y radiation using
equation 10a,10b.
G = 2
 _D0
D
2 Z T
0
e t dt
Z t
 1
e t
0
e  (t t
0) dt 0 (10a)
=
2
   


1   e T
2 1   e (+)T
 + 
  1   e
 2T
2

(10b)
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For long irradiation times (i.e. T ! 1) the G factor reduces to:
G1 =

 + 
=
1=2
T1=2 + 1=2
(11)
where Tand  are the physical half-life of 90Y and DNA repair half-life, respec-
tively. Since the DNA repair half-lives for all the three cell lines were not experimen-
tally derived, an average value (i.e. 1.5 hr) [11] was used in the G factor calculations.
Since the G1 only depends on the physical half-life of 90Y and the DNA repair half-
life, the G factor for both HDR and LDR{90Y RNT is determined using equation
11. Additionally, the irradiation time for EBRT was 1.7 min and thus the G factor
is 1. However for HDR and LDR{90Y, the G factor was calculated (using equa-
tion 11) to be 0.022. Such a small G value suggests less contribution from 2 SSB!
DSB production (e.g.  D2) as the dose rate is relatively lower compared to EBRT.
This is more evident for the LDR{90Y survival curve since for a given dose, the
initial dose rate is  0.013{0.13 Gy/hr. This is also consistent with the simulation
results. For example for LDR{90Y, for smaller delivered activities and doses (i.e. .3
Gy) the average number of hits per cell nucleus is . 2 during the 8 days irradiation
time (see gure 7a). Therefore there will be very low probability for 2 SSB ! DSB
process at this dose rate levels. These results highlight the importance of initial
dose rate in radionuclide therapy.
In RNT dose rate is inversely proportional to the radionuclide half-life for a given
total dose. Therefore, a longer half-life radionuclide such as 90Y delivers dose at a
relatively lower rate for a xed total dose. Equation 11 implies that for a similar ab-
sorbed dose, radionuclides with a shorter half-life could potentially result in better
dose response for RNT. Since radionuclides with shorter half-lives deliver dose at
much higher initial rate, the DNA damage process can compete with DNA repair
rate and thus result in better dose response.
The G1 factor was calculated and plotted (see gure 9) for a few commonly used
isotopes in RNT and emission tomography for comparison. These calculations as-
sume  to be 0.42 hr 1 (ln(0.5)/15 hours). The G1 factor also plays an important
role for high LET radiation. For example 213Bi with a 46 min half-life which decays
2% as high LET alpha and  98% low energy beta particles, delivers dose at a
reasonably high dose rate. Currently 213Bi is the only radionuclide that can deliver
dose at a dose rate close to the EBRT dose rate (GEBRT  1 ; GBi  0:7). The
ability to deliver a very localised dose at very high dose rate has a signicant impact
on the RNT [41]. For both EBRT and 90Y, the HT29 and HCT116 cell lines were
the most radioresistance and radiosensitive cell lines, respectively. HT-29 cells have
the TP53 mutation which may increase the cell resistance to radiation [38]. The
= derived from the HDR{90Y cell survival curve was larger than that derived
from EBRT by a factor of  8 for all three cell lines. This can be attributed to
a relatively lower dose rate of 90Y. Also for each given dose, the total HDR{90Y
absorbed dose (6.2-55.5 Gy) was up to 6 times greater than the EBRT dose (1-9 Gy).
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Additionally, dierent  and  values derived for HDR{90Y RNT and EBRT
reect on the dierent relative radiobiological eectiveness of 90Y RNT compared
to EBRT.
These results are subject to several assumptions. Firstly, for all the calculations
and formalisms, it was assumed that there is no signicant cell repopulation during
8 days of incubation. A more complex formulation is required to oset the repopula-
tion eect [10],[42]. Secondly, it was assumed that 90YCl3 was uniformly distributed
in the well. This assumption was used to calculate the absorbed dose to cells for
each 90YCl3 activity.
Conclusion
We benchmarked the eectiveness of EBRT to 90Y RNT in vitro specic to CRC
cell lines. For the HT29 cell line, we found =  31 for HDR{90Y compared to
3.5 for EBRT. For LDR{90Y we found insignicant cell death at doses <10 Gy
compared to EBRT. Simulation results also demonstrated that for 90Y doses . 3
Gy, the average number of hits per cell nucleus . 2 indicating insucient delivered
lethal dose. Similarly, for 90Y doses & 3 Gy the average number of hits per cell
nucleus falls below 2 after  5 days of incubation time. Our simulation results
also demonstrated that the average number of hits per cell nucleus for EBRT is
 14 times larger than 90Y RNT. Therefore our results demonstrate that LDR{90Y
is radiobiologically less eective than EBRT. However, HDR{90Y at  56 Gy was
shown to be radiobiologically as eective as acute  8 Gy EBRT. These results
demonstrate that the ecacy of RNT is dependent on the initial rate at which
dose is delivered. The RNT dose rate is inversely proportional to the radionuclide
half-life for a given total dose. Therefore, a longer half-life radionuclide such as 90Y
requires a higher initial activity to attain higher initial dose rate, and a larger total
dose in Gy delivered is required to achieve a treatment outcome that is equally as
eective as EBRT.
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Figures
Figure 1: Experimental set-up for irradiating the cells with a 6 MV linac pho-
ton beam: (a) cell plates between two solid water phantoms; (b) position of the
Gafchromic lm.
Gholami et al. Page 15 of 24
Figure 2: Experimental set-up for 90Y. (a) Two sets of 90YCl3 (HDR,LDR) activity
concentrations were added to the cell plates. Each cell line was plated into two plates
with range of 0{62 Gy. The red markers show row of wells that contains the cell
without activity. (b) schematic diagram illustrating (i) the distribution of cells and
90Y source in two 96 well plates for HDR{90Y set (similar set-up was prepared for
LDR{90Y set), (ii) demonstrating a single well containing the 90YCl3 and cells in
RPMI cell medium.
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Figure 3: Geometry set-up in the GATE simulations: (a) and (b) 5000 non-
overlapping spherical cells randomly distributed in a cylindrical well (axial and
cross-sectional views); (c) yellow and red spheres representing the cytoplasm and
nucleus respectively; (d) beta particle tracks (red) in the well; (e) microspcopy im-
age of a cell culture conguration in a single well; (f) zoom-in of image in (e); (g) 6
adjacent wells in three rows; row 1 - active rows with each well containing 288 kBq
90YCl3 in 200 l cell culture medium, row 2 - wells with 200 l of water, row 3 - with
two well only containing 200 l cell culture medium. The red and green tracks repre-
sent emitted beta particles and scattered photons (from the atomic de-excitations),
respectively.
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Figure 4: Linear regression t for the cell density of three cell lines. The red dashed
line indicates the number of cells/well used to culture the cells.
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Figure 5: Dose rate ( _D) and corresponding total dose (D) for dierent 90YCl3
concentrations calculated for T = 8 days: (a) LDR{90Y; (b) HDR{90Y.
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Figure 6: (a) Cell survival as a function of delivered dose for EBRT and (i) HDR{
90Y RNT and (ii) LDR{90Y RNT, (b) MTS colorimetric dose response of EBRT
at dierent delivered acute doses, darker brown color represents higher number of
viable cells in each well.
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Figure 7: Histograms of the average number of beta particle hits per cell nucleus
N=nucleus binned into each day of irradiation and corresponding average number
of hits HN for the total 8{day irradiation time calculated from simulations for (a)
LDR{90Y and (b) HDR{90Y. D is the total dose (D).
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Figure 8: (a) Two-dimensional energy histogram for 6 adjacent wells by integrating
the corresponding 3D energy distribution along the Z direction. The scale bar is in
MeV. (b) Two-dimensional beta particle uence histogram for 6 adjacent wells by
integrating the corresponding 3D uence distribution along the Z direction. Black
dotted circles indicate the edges of the wells.
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Tables
Table 1: Summary of dose calculations for HDR and LDR 90Y activities. ALDR and
AHDR represents the initial activity for the LDR and HDR 90Y sources, respectively.
ALDR (kBq) AHDR( kBq) GATE (Gy) Matlab (Gy) OLINDA (Gy)
LDR HDR LDR HDR LDR HDR LDR HDR
1 48.0 288 10.3 0.1 61.7 0.2 10.4 0.2 62.3 0.2 10.1 0.1 60.6 0.1
2 43.2 259 9.10 0.1 55.5 0.1 9.30 0.1 56.1 0.2 9.10 0.1 54.5 0.3
3 38.4 230 8.10 0.1 49.4 0.1 8.30 0.1 49.9 0.1 8.10 0.2 48.5 0.2
4 33.6 202 7.20 0.2 43.2 0.1 7.20 0.1 43.6 0.1 7.10 0.1 42.4 0.1
5 28.8 173 6.10 0.1 37.0 0.1 6.20 0.2 37.4 0.1 6.10 0.2 36.6 0.2
6 24.0 144 4.90 0.1 30.9 0.2 5.20 0.1 31.2 0.2 5.10 0.2 30.1 0.2
7 19.2 115 4.10 0.2 24.7 0.1 4.20 0.2 24.9 0.1 4.10 0.2 24.2 0.3
8 14.4 86.4 3.10 0.1 18.5 0.1 3.10 0.1 18.7 0.1 3.03 0.1 18.2 0.1
9 9.60 57.6 2.10 0.1 12.3 0.1 2.10 0.1 12.5 0.1 2.10 0.2 12.1 0.2
10 4.80 28.8 1.10 0.1 6.20 0.2 1.00 0.1 6.20 0.1 1.10 0.3 6.10 0.1
Table 2: Summary of GATE simulation results for EBRT and 90Y irradiation. HN ,
Dint represent the average number of hits and integral dose respectively. The sta-
tistical uncertainties are negligible.
EBRT 90Y
Cytoplasm Nucleus Cell Cytoplasm Nucleus Cell
Irradiation time <1.7 min <1.7 min <1.7 min 8 days 8 days 8 days
Total No. hits 3.11 1010 7.38  109 3.85  1010 5.57  109 9.97  108 6.10  109HN 1.25  103 295 1.540  103 122 21 143
Dint (Gy) 4.17  104 8.28  103 5.00  104 4.26  104 7.71 103 5.03  104HD (Gy) 10.5 10.1 10.3 10.4 10.1 10.3
Total No. Ionisations 1.49  1010 6.49 109 2.14  1010 1.11 1010 2.78  109 1.39 1010
Ave No. Ionisations 2.98  107 1.30  106 3.11  107 2.23  107 5.56  105 2.29  107
Table 3: Summary of  and  parameters from EBRT and 90Y-HDR irradiation.
Cell lines HCT116 SW48 HT29
(EBRT ) 0.1981 0.1511 0.0842
(EBRT ) 0.0439 0.0376 0.0239
(=)(EBRT ) 4.510  0.3210 4.0200.4200 3.5310.3110
90Y 0.0350 0.0265 0.0145
G90Y 0.0009 0.0008 0.0005
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Table 4: Critical times (Tcrit) and dose rates (Rcrit) for HDR{90Y RNT. , , R0
and Tav are the decay constant for 90Y, the radiobiological parameter of the cell
line, the initial dose rate of 90Y RNT and the average doubling time of the cell line
respectively.
Cell lines (h 1) (Gy 1) R0 (Gy=h) Tav (h) Tcr it (days) Rcr it (Gy=h)
HCT116 0.0107 0.1981 0.792 20 [43] 5.883 0.1749
HT29 0.0107 0.0842 0.792 23 [44] 3.095 0.3578
SW48 0.0107 0.1511 0.792 24 [43] 5.538 0.1911
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Appendix 1
Figure 9: G1 for common medical isotopes.
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Abstract
Radium-223 dichloride (223Ra) is an alpha particle emitter and a natural bone-
seeking radionuclide that is currently used for treating osteoblastic bone 
metastases associated with prostate cancer. The stochastic nature of alpha 
emission, hits and energy deposition poses some challenges for estimating 
radiation damage. In this paper we investigate the distribution of hits to cells 
by multiple alpha particles corresponding to a typical clinically delivered dose 
using a Monte Carlo model to simulate the stochastic effects. The number of 
hits and dose deposition were recorded in the cytoplasm and nucleus of each 
cell. Alpha particle tracks were also visualized. We found that the stochastic 
variation in dose deposited in cell nuclei (≃40%) can be attributed in part to 
the variation in LET with pathlength. We also found that ≃18% of cell nuclei 
receive less than one sigma below the average dose per cell (≃15.4 Gy). One 
possible implication of this is that the efficacy of cell kill in alpha particle 
therapy need not rely solely on ionization clustering on DNA but possibly also 
on indirect DNA damage through the production of free radicals and ensuing 
intracellular signaling.
Keywords: radionuclide therapy, Monte Carlo modelling, radium-223 
dichloride
(Some figures may appear in colour only in the online journal)
Y Gholami et al
Stochastic simulation of alpha therapy at the sub-cellular level
Printed in the UK
6087
PMB
© 2015 Institute of Physics and Engineering in Medicine
2015
60
Phys. Med. Biol.
PMB
0031-9155
10.1088/0031-9155/60/15/6087
Papers
15
6087
6096
Physics in Medicine & Biology
Institute of Physics and Engineering in Medicine
IOP
0031-9155/15/156087+10$33.00 © 2015 Institute of Physics and Engineering in Medicine Printed in the UK
Phys. Med. Biol. 60 (2015) 6087–6096 doi:10.1088/0031-9155/60/15/6087
6088
1. Introduction
Internal radionuclide therapy is attracting growing interest owing to the potential for more 
specific cell killing and reduced damage to healthy tissue compared to external beam radio-
therapy (Williams et al 2008). Alpha-emitting radioisotopes, in particular, are attractive 
radiotherapeutic agents because of the high linear energy transfer (LET) of alpha particles, 
which thus have the ability to generate a relatively high density of ionization damage over 
relatively short distances, thus increasing the potential for causing lethal double—strand 
breaks on DNA while at the same time limiting damage to surrounding non-target tissue 
(Sgouros 2008).
Recent efforts in alpha particle therapy have focused on Radium-223 dichloride (223Ra), 
which has a favourable half-life (11.4 d) and decay chain (producing four alphas from decay 
through short-lived daughter radionuclides). Additionally, the mean energy of the emitted 
alphas, 5.7 MeV, corresponds to a typical range of less than 50 μm in water, so that energy 
deposition is confined to a very localized region of only 1–2 cells. 223Ra is also a calcium 
mimetic and is thus bone-seeking. Because it is drawn to parts of the body experiencing 
increased bone metabolism, 223Ra can be used without an antibody targeting agent to treat 
bone metastases (Hafeez and Parker 2013). 223Ra binds to calcium hydroxyapatite in the bone 
matrix from whence it can destroy adjacent tumour cells by localized alpha irradiation, spar-
ing the adjacent bone-marrow (Bellmunt 2013). Generally a total activity of ≃21 MBq of 
223Ra is used for treatment. In late 2013, the US FDA approved the 223Ra radiotherapeutic 
Xofigo (formerly known as Alpharadin) to treat bone metastases associated with advanced 
prostate cancer.
Although clinical studies have demonstrated the effectiveness of 223Ra in treating bone 
metastases associated with prostate cancer (Liepe 2009, Cheetham and Petrylak 2012, Hafeez 
and Parker 2013), relatively few studies to date have investigated the dosimetry of this alpha 
particle therapy. In a modeling study, Hobbs et al (2012) compared the absorbed fraction-
based method for dosimetry to a cell-level method and showed that cell-level dosimetry is 
essential to understanding potential marrow toxicity. Their results suggest that increasing 
the amount of radioactivity may not necessarily increase the risk of toxicity, as predicted 
by the absorbed fraction method of dose calculation. On the sub-cellular level, Roeske and 
Stinchcomb (2006) showed that the efficacy of alpha particle therapy depends on source-
target geometry, which determines dose distribution on sub-cell scales.
Their result demonstrates the importance of taking into account the stochasticity in 
alpha particle dosimetry which is inherent because of the relatively small number of par-
ticles involved and the variation of LET with path length. Roeske and Hoggarth (2007) 
also developed a microdosimetric model for determining the distribution of path lengths, 
energy deposited and specific energy for a single alpha particle traversal through the cell 
nucleus.
What has not been directly addressed in previous studies is the distribution of hits 
and dose deposition in cell nuclei by multiple alpha particles corresponding to a typical 
clinically delivered dose. To address this issue, we have developed a Monte Carlo model 
that simulates the stochastic nature of alpha particle dosimetry on the sub-cellular level. 
The model takes into consideration the random emission of multiple alpha particles, cor-
responding to a macroscopic clinical dose, and the nucleus and cytoplasm compartmen-
talisation of cells. The Monte Carlo model was used to calculate the number of hits to 
the cell nuclei as well as the dose deposition. These were compared to the corresponding 
mean values.
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2. Material and methods
223Ra emits four alpha particles per decay, which is 95% of the total energy emitted. The 
remaining 5% of energy is emitted in the form of gammas and electrons (McDevitt et al 1998, 
Brechbiel 2007). The mean energy of the emitted alphas is 5.7 MeV, corresponding to an 
average range of 46 μm in water. The inherently stochastic processes of alpha emission and 
hit distribution, as well as associated energy deposition, were simulated using Monte Carlo 
radiation transport.
2.1. Monte Carlo simulation
Monte Carlo simulations were performed with the GATE software toolkit, which is a GEANT4 
based platform developed by the international OpenGATE collaboration and is ideal for radio-
nuclide imaging and dosimetry applications (Jan et al 2004). All calculations were performed 
using GATE version 6.2, which uses GEANT4 version 9.5.p01 (Agostinelli et al 2003). The 
low energy electromagnetic physics package (Chauvie et al 2004) and Hadrontherapy physics 
package of GEANT4, which describe electron, photon and heavy charged particle interactions 
over an energy range of 250 eV–100 TeV, were used for all simulations. Cells were modelled as 
spheres of diameter 20 μm randomly distributed in a cubic water phantom with side length of 
100 μm. This size was chosen to ensure that alpha particles stop and thus deposit all their energy 
within the phantom. The phantom was embedded in a 1 mm3cubic volume of water. Each cell 
was uniformly filled with water and contained a spherical nucleus with a diameter of 10 μm. The 
cell parameters are representative values only, chosen to resemble an average of possible cell 
dimensions (Roeske and Stinchcomb 2006). In their modeling study, Roeske and Stinchcomb 
(2006) found that in general, smaller cell nuclei require fewer alpha particle hits to achieve 
the same tumour control because the specific energy per hit is larger. A total of 22 cells were 
modeled in the simulation volume, corresponding to the maximum number of cells that can be 
randomly placed in the volume without overlap (see figure 1). This corresponds to a cell packing 
volume fraction of ≃0.1, or equivalently, a number density of ×22 106 clonogenic cells cm−3.
Several studies have shown that Ra-223 does not cross the cell membrane, rather it binds 
to calcium hydroyxyapetite in the extracellular bone maxtrix and preferentially accumulates 
in areas of new bone formation, targeting tumor cells in and around metastases (Philippa and 
Daniel 2012, Bellmunt 2013, Parker et al 2013). Based on this evidence, the alpha particles 
with energy 5.7 MeV were emitted in random directions from random locations throughout the 
phantom, but restricted to locations outside cell volumes. This distribution has also been shown 
to maximise cell kill (Roeske and Stinchcomb 2006). The number of alpha particles emitted in 
the phantom was calculated from the total dose administered clinically. For a typical treatment 
schedule of six intravenous injections with 50 kBq kg−1 of 223Ra, corresponding to 21 MBq for 
a 70 kg patient (Paker et al 2011, Sartor et al 2013), the dose absorbed by the bone endosteal 
cells is ≃16 Gy (Lassmann and Nosske 2013). This is also the absorbed dose used in the model 
of Hobbs et al (2012). Using Monte Carlo simulations, we determined that 17 148 alpha parti-
cles are required to deposit ≃15.7 Gy in the simulation volume (106 μm3 phantom).
2.2. Dose actor
The dose actor (a package within GATE) represents a cubic sensitive detector that can be vox-
elized into 3D rectangular or cubic voxels. Parameters such as ionizations, dose and deposited 
energy are stored into this 3D matrix according to the spatial position of the hit for a given 
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volume. A cubic dose actor (100 μm each side) was attached to the centre of the cubic phan-
tom. Then separate macro files were used to store the results for each alpha particle’s track 
in the cubic phantom and each individual cell’s cytoplasm and nucleus volumes separately. 
The energy deposition and number of ionizations along each alpha particle’s track in the 
cubic phantom as well as each individual sub-cellular component (cytoplasm and nucleus) 
were stored in Root5 as well as HDR and IMG format files. Each IMG file is a 3D matrix 
( × ×100 100 100) with voxel unit of 1 μm. The alpha particle tracks within the cubic phan-
tom as well as each individual cell and cell nucleus were visualized using AMIDE. Then the 
Multiplanar Reformation (MPR) method was used to project the whole volume onto the 2D 
viewing plane from the desired perspective (e.g. the output image in the xy plane). In addition 
to the visualisation, the dose, energy deposition and number of hits for each volume were 
recorded. A hit is defined as an alpha particle intercepting a cell volume (cytoplasm and/or 
nucleus). The phase-space actor was used to obtain the number of hits in the cytoplasm and 
nucleus. The total dose, 15.7 Gy was fractionated into five 3.13 Gy doses. Each simulation was 
repeated with five different random number seeds corresponding to five independent numeri-
cal experiments. For each simulation, we determined that 3430 alpha particles are required to 
deposit ≃3.13 Gy in the simulation volume. Results from these five independent simulations 
were added to calculate the total number of hits for the total dose of 15.7 Gy.
3. Results and discussion
Qualitative visualization results are presented which show the alpha particle tracks in the 
phantom and cell geometry. Quantitative results are also presented which show the relative 
frequency of alpha particle hits to the nucleus and cytoplasm as well as the resulting energy 
deposition in these sub-cellular regions. Average values are also calculated to give an indica-
tion of the corresponding macroscopic quantities.
3.1. Visualization of alpha particle tracks
Figure 2 shows visualizations of the cells and simulated alpha particle tracks in the cubic 
phantom. 2D projections of the 3D alpha particle tracks were fused with the cell geometry to 
visualize the paths of alpha particles in each cell and in the cubic phantom.
Figure 1. Geometry set-up in the GATE simulation: 22 non-overlapping cells were 
randomly distributed in a cubic phantom with side length of 100 μm. The yellow and 
white spheres represent the cell nucleus and cytoplasm, respectively.
5 http://root.cern.ch/
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It is evident from figure 2(b) that there is significant variance in the alpha particle cell hit 
distribution, with some cells receiving more hits than others. Most alpha particles that hit a 
cell traverse the cytoplasm and relatively few traverse the nucleus. The stochastic nature of 
alpha particle traversals through the cells also suggests a large variance in the distributions of 
hits and dose deposition within each cell compartment. This is examined quantitatively in the 
next section.
3.2. Hits and dose distributions
Figure 3 shows frequency histogram plots for the number of alpha particle hits to the cyto-
plasm and nucleus for the five numerical experiments each of which deposits a dose of ≃3.13 
Gy in the simulation volume. The stochastic nature of the hits distribution is evident from 
these histograms, with hits to the cytoplasm and nucleus showing varying distributions across 
the five simulations. The total number of hits and the distribution spread is clearly larger for 
the cytoplasm than for the nucleus. In particular, the majority of cells receive ≳20 hits in the 
cytoplasm, but ≲20 hits in the nucleus for 3.13 Gy deposited dose in the volume, reflecting 
the relative sizes of their volumes (the nucleus volume is 7 times smaller than the cytoplasm 
volume). Moreover, for this dose (and for ≃0.1 cell volume packing fraction), ≃60% of cell 
nuclei receive fewer hits than the average (≃ ±14 2 hits per cell nuclei) while ≃50% of cell 
nuclei receive fewer hits than 1 σ below the average and ≃14% receive no hits at all.
For the total dose of 15.7 Gy (bottom panel in figure 3), the hit frequency histograms show 
that although increasing the dose by a factor of ≃5 results in an increase in the number of cell 
hits by the same factor and all cell nuclei now receive at least one hit, ≃60% of cell nuclei 
still receive fewer hits than the average value (≃ ±68 9 per cell nucleus) and approximately 
half receive fewer hits than 1 σ below the mean (≃59). This demonstrates that increasing the 
number of alpha emissions does not affect the stochastic pattern of hits distribution.
Figure 4 shows frequency histograms for the number of alpha particle hits to the cytoplasm 
and nucleus averaged over the five simulations shown in figure 3. The histogram distribution 
Figure 2. (a) Geometry of the 22 simulated cells in the cubic phantom, with white and 
yellow spheres representing the cytoplasm and nucleus, respectively; (b) alpha particle 
tracks inside the cells, shown as a rendered volume, red and blue denoting tracks in the 
cytoplasm and in the nucleus, respectively.
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is noticeably bimodal, clearly delineating hits to the cytoplasm and nucleus. The mean number 
of hits per cell cytoplasm and nucleus are ≃ ±56 6 and ≃ ±14 2, respectively. On average ≃
2% (i.e. 56/3430) of the total alpha emissions intercept a cell cytoplasm and only ≃0.4% (i.e. 
14/3430) intercept a cell nucleus for 3.13 Gy deposited dose in the volume. Although this 
depends on the cell packing (volume ratio ≃0.1 in this case) we note that a similar value can 
be derived simply from source-target geometry considerations alone, provided all the sources 
decay outside the cells, as simulated here (see Roeske and Stinchcomb (2006)). Assuming the 
probability of source localization inside cells increases with cell packing, the proportion of 
emitted alphas that hit a nucleus will likely increase with cell packing. However, this does not 
guarantee more cell kill because, as pointed out by Roeske and Stinchcomb (2006), alphas 
emitted outside cells are more effective than those emitted inside nuclei owing to the variation 
in LET along an alpha particle’s trajectory on passage through a cell. Thus, in addition to the 
sub-cellular distribution of hits, it is also necessary to consider the sub-cellular distribution 
of dose.
Figure 5 shows plots of the dose deposited in each cell’s cytoplasm and nucleus for a total 
dose ≃15.7 Gy deposited in the simulation volume. Also shown is the corresponding number 
Figure 3. Alpha particle hit frequency histograms for the cytoplasm (left panel) and 
nucleus (right panel). Results for five independent simulations are shown, in each of 
which 3.13 Gy dose is deposited in the total volume containing the cells. The last row 
shows the hit frequency histograms for the total dose (≃15.7 Gy) resulting from the sum 
of the individual simulations.
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of hits in each cell. Cell-to-cell fluctuations in dose deposition are evident; for the mean dose 
of 15.4 Gy deposited in the cell nuclei, the standard deviation is σ≅ 6.4 Gy (i.e. ≃40%). 
Approximately half of the cell nuclei receive less dose than the average and approximately 4 
cells (≃18%) receive less than 1 σ below the mean (≃9 Gy), with one cell nucleus receiving as 
little as ≃4 Gy. Thus, for a delivered total dose (≃15.7 Gy) that is proven to be clinically effec-
tive, a non-negligible fraction of cell nuclei receive a dose that is likely to be insufficient for 
cell kill. It is also evident from figure 5 that the cell-to-cell fluctuations in dose to the nucleus 
differ from the stochastic variations in hits to the nucleus, in contrast to the more correlated 
trend observed for dose and hits to the cytoplasm. This can be attributed to the additional sto-
chastic contribution from variations in alpha particle paths that traverse the cytoplasm to reach 
the nucleus. Thus, in addition to the stochastic nature of emission and hits, the spatial distri-
bution of dose is determined by the variation in Let along an alpha particle’s path. Therefore 
traversal through the nucleus by a single alpha particle with LET that is close to the Bragg 
peak can result in similar energy deposition to that from traversals by multiple alpha particles 
with lower LET (see in figure 5, cell 8 and 10 receive a similar dose to the nucleus, close to 
the mean, but a significantly different number of hits to the nucleus).
These results are interesting because the effectiveness of alpha particle therapy is conven-
tionally attributed to the ability of high LET particles to cause DNA double-strand breaks 
through high density ionisation clustering. The stochastic nature of dose deposition per indi-
vidual cell necessarily implies fluctuations in dose distributed to the nucleus and cytoplasm. 
One possible implication of this is that the efficacy of cell kill in alpha particle therapy need 
not rely solely on dose to the cell nucleus but may also be augmented by indirect DNA dam-
age, through the production of reactive oxygen species in the cytoplasm and ensuing damage-
sensing intracellular signalling pathways. There may also be a role for the bystander effect, 
Figure 4. Alpha particle hit frequency histograms for cytoplasm (blue) and nucleus 
(green) for 3.13 Gy dose deposition. Data points are average values and error bars 
represent the standard error off the mean (SEM) for n   =   5 simulations shown in figure 3.
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with intercellular signalling invoking damage responses to neighbouring cells that are not 
directly hit by an alpha particle (Prise and Sullivan 2009).
We note, however, that these quantitative results are subject to several assumptions. Firstly, 
only a single energy of alpha particle emission (5.7 MeV) was modelled whereas 223Ra 
and its short-lived daughter radionuclides emit four alpha particles with different energies. 
Furthermore, only alpha emission was considered although about 5% of the total energy is 
emitted in the form of gammas and electrons which may contribute to the dose distribution.
Secondly, we have assumed a spherical cell geometry as well as a single cell size (20 μm 
diameter) and nucleus size (10 μm diameter). Roeske and Stinchcomb (2006) performed a 
comprehensive parameter sensitivity study on alpha particle cell hits and tumour control prob-
ability (TCP). They found that decreasing the size of cells and nuclei requires fewer alpha 
particles hits to achieve the same TCP since the specific energy per hit is larger for smaller 
cells. However, this may be offset by the increased volume packing that is possible with 
smaller cells, which implies an increase in average number of cell hits to maintain a given TCP 
within a clonogenic cell population. Roeske and Stinchcomb (2006) found that the average 
number of hits required for a given TCP increases logarithmically with number of cells in the 
population.
Figure 5. Dose deposited in the cytoplasm (blue points) and nucleus (green points) of 
each cell. The upper data points in each panel are for a total dose of 15.7 Gy deposited 
in the simulation volume along with the mean dose ± SEM and ±1 σ (dotted lines).
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It is also worth pointing out that very low energy secondary electrons can cause biological 
damage through ionizations but deposit relatively little dose. The Geant4 low energy elec-
tromagnetic physics model processes used to simulate ionizations have an energy cut-off of 
250 eV (Chauvie et al 2004). While it is possible to simulate ionization processes down to 
even lower energies, this is computationally expensive and beyond the scope of this paper (but 
see Kuncic (2014) and Byrne et al (2013)). Thus, indirect DNA damage could play an even 
more significant role in particle therapy than is currently thought.
4. Conclusion
This simulation study demonstrated the stochastic nature of alpha particle hits and energy 
deposition at a sub-cellular scale. Our results show that for a clinically delivered dose, energy 
is deposited predominantly in the cytoplasm of each cell and that ≃18% of cell nuclei receive 
less than one sigma below the average dose (≃15.4 Gy). This suggests the possibility that the 
stochastic nature of alpha particle dose distribution may limit the opportunity for direct DNA 
damage and there may be a contribution from indirect damage to the efficacy of alpha particle 
therapy for bone metastases associated with advanced prostate cancer.
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Conclusions and future work
7.1 Conclusions
This thesis is motivated by the clinical need to image lymph node metastases and thereby
stage and treat cancer more eﬀectively than is currently possible. Lymph nodes are one
of the main avenues for the dissemination of cancer metastases initiated from diﬀer-
ent types of cancers (e.g. colorectal , prostate and breast cancer). The current medical
imaging techniques have proven to be limited in their capacity to accurately detect lymph
nodes metastases. Additionally, there is no eﬀective relevant targeted therapy apart from
lymph node dissection. Thus, the core aim of this thesis was to develop and evaluate a
unique nanoplatform for non-invasively detecting lymph node metastases, cancer stag-
ing, and delivering targeted therapy to metastatic tumour cells. The nanoplatform, based
on the FDA-approved therapeutic FH NP, consists of a superparamagnetic iron-oxide
nanoparticle integrated with a radiolabel and/or radiotherapeutic, to enable multimodal
PET/MR imaging as well as radionuclide therapy localised at the cellular level. A novel
aspect of this thesis project is that the nanoplatform is chelate-free, which oﬀers a sub-
stantial advantage over existing methods for nanoplatform design, synthesis and in vivo
application. Additionally, another novel aspect of this thesis is the potential to develop
the first nano-platform that can not only detect lymph node metastases, but also deliver
targeted RNT to the metastatic tumour cells with a radio-SPION.
As a foundation upon which to develop a multifunctional radio–nanoplatform, a
chelate-free NP radiolabelling (with range of imaging and therapeutic radioisotopes)
platform was developed, optimised and evaluated (Chapter 3). While previous stud-
ies20 showed that heat-induced radiolabelling can be utilised to radiolabel FH NPs with
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89Zr4+, 111I3+ and 64Cu2+, the radiolabelling platform developed in this thesis, in addi-
tion to 89Zr4+, presents the first attempt at radiolaeblling FHwith 177Lu3+ and 90Y3+ iso-
topes. The high radiochemical yield (RCY 92–95%) and radiochemical purity (RCP
98%) confirmed the eﬃciency and robustness of the novel chelate-free radiolabelling
technique. Additionally the labelled NP characterisations showed that the HIR tech-
nique leads to the radiometal ions which are mainly bound to the surface of the internal
core structure with high loading capacity. The HIR technique was optimised by utilising
heating vortex system for radiolabelling process to enhance the RCY and RCP for iso-
topes with lower oxidation state (weaker binding aﬃnity). Moreover, the HIR technique
was shown to be applicable for radiolabelling diﬀerent SPIONs (with diﬀerent polymer
coating and core size).
While there have been relatively few studies investigating the potential for simul-
taneous PET-MR imaging of radio-SPIONs230,3,231, Chapter 4 presented for the first
simultaneous PET-MR images of radio-SPIONs, thus demonstrating proof of principle
of how hybrid PET-MRI can be used to combined the strengths of PET and MRI for op-
timal imaging of NPs. Additionally, it was demonstrated with sequential MRI and PET
scans, hybrid PET-MRI scans as well as simultaneous PET/CT and SPECT/CT images
that 89Zr –FH and 177Lu–FH can indeed be imaged by multi-modal imaging techniques.
Furthermore, analysis of relative image contrast showed that PET and MR images of
the 89Zr-FH Nano-platform can be combined in a complementary manner using either
sequential or simultaneous PET/MR imaging (Chapter 4).
From the 90Y RNT studies presented in Chapter 5, it was found that although LDR–
90Y resulted in negligible cell death at doses 10Gy, HDR–90Y at56Gy was shown
to be radiobiologically as eﬀective as acute  8 Gy EBRT. These results suggest for
radio-SPION or any other radiopharmaceuticals, a longer half-life radionuclide such as
90Y requires a higher initial activity (i.e. a higher initial dose rate), and a larger total
delivered dose is required to achieve an outcome that is as equally eﬀective as EBRT.
It was also shown that the cell killing mechanism of radiopharmaceuticals (including
future therapeutic radio-SPIONs) is governed by the LET of emitted particles and the
dose–rate in time and space (time-dependent changes in spatial distribution) at which
they deliver radiation.
The preliminary simulation results for 90Y–FH (Chapter 3. Section 3.2) also con-
firm this therapeutic radio-SPION can deliver localised dose and is suitable as a radio-
nanomedicine platform for treating metastases. As FH is comprised of a high atomic
number magnetite core, it is possible that the Fe atoms in the crystal core are activated
by incident electrons emitted by 90Y, causing the emission of additional electrons (in-
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cluding Auger electrons) from Fe atoms that can enhance dose deposition around the
nanoparticle. If this is found to occur, it would imply that internal radionuclide ther-
apy with 90Y (and by extension other therapeutic isotopes) is enhanced by heavy atom
nanoparticle delivery. Further investigation is required to understand the interaction of
beta particles with FH NPs at micro and nano scale. This needs to be investigated.
TheMonte Carlo simulation model developed in Chapter 6 to investigate the stochas-
tic nature of alpha particle hits and dose deposition of 223Ra RNT for metastases at the
sub-cellular level revealed that for a clinically delivered dose (which has been shown
to be eﬀective), energy is deposited predominantly in the cytoplasm of each cell. The
cytoplasm comprises  70% of the cell volume and is mainly made of water. Thus, in-
teractions of densely ionising alpha particles in the cytoplasm can result in production
of many free radicals resulting from water radiolysis (with up 10 ms life time) which
are highly reactive. The produced free radicals can then diﬀuse to the cell nucleus and
damage DNA. Therefore, this suggests the possibility that the stochastic nature of alpha
particle dose distribution may limit the opportunity for direct DNA damage and there
may be a contribution from indirect damage to the eﬃcacy of alpha particle therapy.
7.2 Future work
Radiolabelling
As discussed in Section 2.6.2 and Chapter 6, radioisotopes such as 223Ra and 213Bi are
showing promising results in treating cancer metastases. This is mainly due to their high
LET alpha particle emission as well as the high dose-rate beta emission (for 213Bi). The
high LET particle emission can result in localised dose deposition within a small target
(i.e. micro metastases). 213Bi radioisotope emits both high LET alpha as well relatively
high LET beta particles at a high dose–rate (or decay–rate). These physical properties
make 213Bi and 223Ra unique therapeutic isotopes for RNT. Therefore, further radio-
labelling experiments are planned to radiolabel FH with these radioisotopes and other
relatively high LET emitter isotopes such as 64Cu and 67Cu.
Additional radiolabelling experiments will be performed to further investigate the opti-
misation of the the current radiolabelling technique. These experiments will include:
 Varying the reaction temperature from 150 C to 200 C to increase the reaction
time and minimise the HIR process time.
 Increasing the amount of initial activity for 90Y therapeutic isotope.
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 Comparing magnetic stirring with the developed heating vortex method to inves-
tigate the homogeneity of activity distribution and RCY achieved in each method.
Furthermore, Isotopes with shorter half–life decay to a daughter atom which has diﬀer-
ent chemical properties. Therefore, during the reaction time, in addition to activity, a
percentage of available radiometal ions for binding to the FH NPs will be lost as well.
Therefore, the amount of radiometal ions used in the reaction mixture should be consid-
ered relative to its activity. For example, based on the existing HIR, during the reaction
time (i.e. 2 hours), for a given initial activity of 64Cu (with half-life of  13 hours),
 15% of the available 64Cu ions will be decaying to stable 64Ni or 64Zn atoms. This
results in less available 64Cu ions to bind with FH NPs, thus resulting in poor RCY (e.g.
666%20). Therefore, decreasing the reaction time and using higher initial activity for
short half–life isotopes can improve the RCY. This needs to be investigated.
Pre-clinical animal studies
The purpose of these studies is to demonstrate the in vivo eﬃcacy of the developed
radio-SPIONs platform in diagnosing and treating lymph node metastases. In addition,
these studies will be carried out as the necessary pre-clinical animal studies in prepara-
tion for a first-in-human clinical study. These studies will be conducted in collaboration
with Massachusetts General hospital (MGH)/Harvard Medical School and the Kolling
Institute and Northern Sydney Local Health District (NSLHD) and the Sydney Vital
Translational Cancer Centre.
Simultaneous 89Zr-FH PET-MR imaging
As the first study, a hybrid PET-MR imaging of 89Zr-FH in a mouse model of metastatic
colorectal cancer (CRC) will be performed to not only detect the lymph nodes (with
PET), but also to obtain higher spatial resolution and diagnostic-quality images of the
lymph nodes (with contrast-enhanced MRI). Nanoparticle biodistribution/uptake imag-
ing will be performed with 89Zr-FH is expected to investigate monocyte traﬃcking and
demonstrate lymph node detection and diagnosis in both healthy and diseasedmice (with
CRC metastases in the lymph nodes). The developed approach and methodology in
Chapter 4 will be applied for image analysis.
90Y-FH RNT of CRC lymph node metastases
This study will include RNT of metastases in mice with 90Y-FH to monitor treatment
delivery with PET–CT and treatment response with MRI. The mice will be IV injected
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with 90Y-FH administering 30 MBq (relatively, LDR) and 50 MBq (relatively HDR)
90Y activity in subsets of mice to evaluate and compare therapeutic outcome. The sur-
vival time will be used as a primary outcome measure and the in vitro and theortical
studies carried out in Chapter 5 will be utilised in treatment planning as well as for
dose–response analysis.
Personalised 90Y-FH RNT dosimetry
This study will include nanodosimetry modelling to calculate 90Y radiation dose dis-
tribution delivered by FH to metastatic CRC tumour cells in lymph nodes. Nano-scale
dose distributions delivered to metastatic tumour cells in the lymph nodes by 90Y beta
particles (average range  2.5 mm) will be calculated using Monte Carlo particle trans-
port simulations with the open-source GATE/GEANT4 software toolkit. The geometry
of the lymph nodes will be mathematically modelled, based on the high-resolution MR
images acquired in the imaging studies, and imported into GATE/GEANT4. Dose dis-
tributions will be calculated as a function of administered 90Y activity and distribution
in the lymph nodes. This approach and methodology is similar to what we developed
for the study modelling patient specific dosimetry for the therapeutic radioisotope 32P
used to treat pancreatic cancer (see appendix, Chapter 8).
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Summary
A Monte Carlo particle
simulation platform was
developed to model the
dosimetry of 32P micropar-
ticle internal radionuclide
treatment for advanced
pancreatic cancer. Patient-
specific dosimetry simula-
tions based on data from
previous 32P microparticle
clinical studies demonstrated
the importance of consid-
ering non-uniform dose dis-
tributions as well as relative
dynamic changes in tumor
volume and dose rate during
treatment. These results will
be valuable in designing
future personalized treatment
strategies.
Purpose: To develop a Monte Carlo model for patient-specific dosimetry of 32P micro-
particle localized internal radionuclide therapy for advanced pancreatic cancer.
Methods and Materials: Spherical tumor geometries and a pancreatic phantom were
modeled, as well as different 3-dimensional non-uniform clinical pancreatic geome-
tries based on patient-specific ultrasound images. The dosimetry simulations modeled
the dose distribution due to the energy spectrum of emitted beta particles.
Results: The average dose for small (3-cm diameter) and large (6-cm diameter) spher-
ical tumors was 111 Gy (for 7.6 MBq administered activity) and 128 Gy (for 58 MBq),
respectively. For the clinical 3-dimensional geometries, on the basis of patient data, the
mean doses delivered to the tumor were calculated to be in the range 102 to 113 Gy,
with negligible dose to the pancreas for the smallest tumor volumes. The calculated
dose distributions are highly non-uniform. For the largest tumor studied, the pancreas
received approximately 6% of the tumor dose (5.7 Gy). Importantly, we found that
because the smallest tumor studied exhibited the most dynamic changes in volume
in response to the treatment, the dose to tumor and pancreas is significantly underes-
timated if a static tumor volume is assumed.
Conclusions: These results demonstrate the dosimetry of 32P microparticle localized
internal radionuclide therapy for pancreatic cancer and the possibility of developing
personalized treatment strategies. The results also highlight the importance of consid-
ering the effects of non-uniform dose distributions and dynamic change of tumor mass
during treatment on the dosimetry of the tumor and critical organs.  2017 Elsevier
Inc. All rights reserved.
Reprint requests to: Zdenka Kuncic, PhD, School of Physics, The
University of Sydney, A28, Sydney, New South Wales 2006, Australia. Tel:
(þ61) 2-9351-3162; E-mail: zdenka.kuncic@sydney.edu.au
Conflict of interest: Y.H.G. receives salary support from OncoSil
Medical. N.W. and D.J. are employed by OncoSil Medical.
Supplementary material for this article can be found at www
.redjournal.org.
AcknowledgmentdThe authors thank the reviewers, whose comments
and suggestions helped to improve this article.
Int J Radiation Oncol Biol Phys, Vol. 99, No. 4, pp. 1029e1038, 2017
0360-3016/$ - see front matter  2017 Elsevier Inc. All rights reserved.
http://dx.doi.org/10.1016/j.ijrobp.2017.07.031
Radiation Oncology
International Journal of
biology physics
www.redjournal.org
Introduction
Internal radionuclide therapy (IRT) is well established in
the field of nuclear medicine for treating different types of
cancer (1-3). Phosphorus-32 microparticle therapy is an
active implantable (radiologic) medical device intended for
use in IRT, whereby cancer is treated by the insertion of
radioactive implants directly into the cancerous tissue. It
consists of silicon microparticles containing the radioactive
phosphorous isotope 32P, which is a pure beta emitter.
Phosphorus-32 is one of the most promising radionuclides
for localized IRT (LIRT) owing to its ability to localize
energy deposition (short-range beta particles) and its long
exposure time (98% of the radiation is delivered within
81 days, or approximately 6 half-lives). Additionally, it has
been shown that 32P is the most effective therapeutic
radionuclide in heterogeneous radioactivity distribution
cases when the effective half-life is dominated by the
radionuclide physical half-life (4).
Internal radionuclide therapy/LIRT needs to be reliably
assessed with personalized (patient-specific) dosimetry cal-
culations to accurately evaluate the efficacy and safety of the
therapeutic radionuclide in both clinical and research set-
tings. Although existing standard dosimetry software (eg,
OLINDA/EXM) can perform dose calculations for an indi-
vidual patient’s critical organs, it has 2 major shortcomings.
First, the software assumes a uniform activity distribution in
the source organ for calculating the mean absorbed dose to a
target organ. Second, for tumor dosimetry, it does not
consider the effect of the dynamic change of the tumor mass
or volume and dose rate variation. A previous study (5)
showed that for tumors with a short shrinkage half-life
(shorter than the radionuclide half-life), the dose correction
factor could be as high as 10. These major shortcomings
might have led to inaccurate predictions of deterministic
biological effects, including tumor response and normal tis-
sue toxicity, attributable to the spatially non-uniform dose in
the target and temporally changing dose rates (4-6). Unfor-
tunately there is a lack of experimental and theoretical
dosimetry studies on dynamic tumormasses.More generally,
there are limited dosimetry studies of IRT/LIRT for pancre-
atic cancer. The dosimetry of internally distributed radioac-
tivity can, however, be calculated with high accuracy by
utilizing Monte Carlo particle simulations (6). Hence, this
study aims to develop a Monte Carlo model for patient-
specific dosimetry of 32P microparticle LIRT for pancreatic
cancer, including the effects of dynamic tumor mass on the
dosimetry of the tumor and surrounding pancreas.
Methods and Materials
Monte Carlo simulation
All simulations were performed using GATE7.1 software
(7), based on the Geant4 10.1 P01 Monte Carlo toolkit (8),
which includes databases for commonly used radionu-
clides. Phosphorus-32 is a pure beta-emitting radioisotope
with a physical half-life of 14.27 days. The mean and
maximum energy of the emitted betas is 0.695 MeV
and 1.711 MeV, respectively, corresponding to an average
and maximum range of 2.8 mm and 8.2 mm in water (7-9).
The Geant4 beta particle energy spectrum was imported
into GAT, and unless otherwise stated all the simulations
were performed using this spectrum.
The stochastic processes of beta emission, hit distribu-
tion, associated energy, and dose deposition were simulated
using Monte Carlo radiation transport within GATE. The
low-energy electromagnetic physics package (10) of
Geant4, which describes electron, photon, and light ion
interactions over an energy range of 250 eV to 1 GeV, was
used for all simulations.
Geometric model of tumor and pancreas
Tumors were initially modeled as spheres with a diameter of
either 3 cm (V Z 14.1 cm3) or 6 cm (V Z 113.1 cm3),
corresponding to the lower and upper limits of the range of
sizes encountered clinically. Each spherical tumor was uni-
formly filled with water and placed in a cubic water phantom
with a side length of 1 m. A source volume (VsZ 0.08tumor)
was placed at the center of each tumor. Additional simula-
tions were performed with 2 and 3 source volumes (to mimic
a multiple-injection scenario) for 3-cm and 6-cm diameter
tumors, respectively. The initial specific activity for the 2 and
3 volume sources was divided equally between each volume.
Additional simulations were performed for an ellipsoid
tumor inside a pancreas phantom (Figs. 1a and 1b). The
pancreas phantom was modeled as a half-ellipsoid with a
section removed, and an ellipsoid tumor shape with volume
of 14.1 cm3 was placed at the center of the pancreatic head.
This model is based on the mathematical human phantom
model developed by Cristy and Eckerman (11) for an
average adult pancreas size, defined by:

x x0
a
2
þ
y
b
2
þ

z z0
c
2
 1 ð1Þ
where a z 15 cm, b z 3 cm, c z 1 cm.
x> x0; and z z0
Two spherical sources were positioned along the y di-
rection inside the tumor (Fig. 1) for each simulation. Then
the average dose to the tumor and pancreas was calculated.
Clinical tumor geometries
Three different non-uniform tumor models with 9 different
volumes were modeled on the basis of 2-dimensional (2D)
ultrasound images and measured tumor volumes from
clinical study patients (Fig. 2). In this clinical study a total
of 17 patients with advanced pancreatic cancer were
treated with 32P microparticles. All the modeled tumor
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volumes were based on data from 3 patients with ultra-
sound images and 3 other patients whose measured tumor
volumes best represented the observed range of small,
medium, and large volumes. Because the ultrasound im-
ages were 2D, the 3-dimensional (3D) volume of each
tumor was modeled for a possible large, medium, and
small tumor size (Fig. 2). For each tumor volume size, a
number of square and rectangular voxels were used to
construct a 3D volume with geometric features similar to
the 2D ultrasound images. Voxels were scaled in 3D to
obtain initial tumor volumes that matched the clinically
measured values, 111, 29.2, and 8.9 cm3 (see movie pro-
vided in Supplementary Materials; available online at
www.redjournal.org).
Fig. 1. Geometry setup in the GATE simulation. (a) The pancreas phantom with an ellipsoid tumor at the center of the
pancreatic head; (b) ellipsoid tumor in the pancreatic head with boundary closer to the tumor. Two spherical sources (blue
spheres) are placed along the y direction. The source-target geometry is visualized from the z axis view. (A color version of
this figure is available at www.redjournal.org.)
Small tumorMedium tumorLarge Tumor
 V = 111 cc  V=29.2 cc  V= 8.9 cc
 V= 8.9 cc
 V= 8.9 cc
 V=29.2 cc
 V=29.2 cc
 V = 111 cc
 V = 111 cc
2D-Ultrasound
Fig. 2. Geometry of 9 irregularly shaped 3-dimensional tumor models based on clinical 2-dimensional ultrasound images
(a-c). White and red margins delineate the tumor and 32P activity distribution, respectively. (A color version of this figure is
available at www.redjournal.org.)
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Single or multiple ellipsoid sources were modeled in
each tumor volume to simulate the spatial activity distri-
bution in the 2D ultrasound images. For all the models the
ellipsoid source was positioned in a way that the boundary
would be close to or align with the tumor edge. These
source-target geometries are intended to represent the worst
case scenario that could occur in a clinical setting.
Total number of beta particles and average
absorbed dose
The total number of betas emitted in each tumor volume
was calculated from the total activity administered clini-
cally. For a typical treatment the prescribed activity con-
centration is 8% of the tumor volume multiplied by 6.6
MBq/mL. All simulations were performed assuming that
100% of activity remained within the initial volume. The
total number of nuclear disintegrations can be estimated
using the cumulated activity equation (12):
~A Z
ZN
0
A0e
ltdtZ
A0
l
Z1:44 A0 t1=2 ð2Þ
where lZ lnð2Þt1=2 .
For all the simulations a total of 1010 beta particles with
energies randomly sampled from the 32P spectrum were
emitted from the source volume in random directions
(Fig. 3a-e). For the spherical tumor models, simulations
were also performed using the average beta particle energy,
659 keV, for comparison against the full spectrum. Results
were normalized to the total number of beta particles
Fig. 3. Source-target geometry. (a, b) Single and double spherical sources at the center of a 3-cm tumor; (c, d) single and
triple spherical sources at the center of a 6-cm tumor; (e) pancreas phantom with ellipsoid tumor at the center of the
pancreatic head. Red and green tracks represent emitted beta particles and scattered photon trajectories, respectively. (A color
version of this figure is available at www.redjournal.org.)
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corresponding to each delivered activity. All the phantoms
(spherical, pancreatic, and clinical) were voxelized, and
parameters such as dose and deposited energy were stored
into this 3D matrix according to the spatial position of the
hit for each given volume. The average doses were calcu-
lated using Equation 3:
~DZ
1
N
Xn
iZ1
di ð3Þ
where N is the number of voxels and di is the computed
dose in each voxel. The total number of voxels (with side
length of z20 mm) for the 3-cm and 6-cm spherical
tumor volumes are z1.19  106 and z4.71  106,
respectively. Additionally, 2D histograms of the dose
distribution for different tumor volumes and the pancreas
were calculated.
Dynamic tumor volume variation
The dosimetry of a dynamically changing tumor volume
was investigated, and the corresponding variations in dose
rate and average dose to both tumor and the volume outside
the tumor were calculated as follows. The GATE dose re-
sults for the small, medium, and large non-uniform clinical
tumors (Fig. 2) and pancreas were imported into MATLAB
(MathWorks, Natick, MA). The dose in each voxel for both
tumor and pancreatic volumes was calculated as a function
of the total activity, ~A ðtÞ, to obtain the dose rate as a
function of treatment time (total 24 weeks). The total tumor
volume variation was modeled according to measurements
taken during the clinical study at time points of 0, 8, 16, and
24 weeks from the time of implant. The dose rate as well as
the average dose was then calculated for each tumor
volume and the pancreas using a polynomial fit to the
measured data points. The temporal evolution of the tumor
volume was automatically calculated by MATLAB for
1-minute time frames from this continuous polynomial
curve. Voxels were adjusted (scaled or removed) to update
the 3D dose calculations for each time frame. The activity
volume (voxels containing activity) was assumed to remain
static throughout, because the 32P microparticles are
delivered in a viscous suspension, with limited diffusion.
Results
Dose distribution in spherical and pancreatic
tumor models
Figure 4a-d shows 2D dose distributions within the spher-
ical tumor model calculated by integrating the corre-
sponding 3D dose distribution along the z axis. The mean
dose to the tumor volume ~DTV is indicated in each case.
These results demonstrate the high degree of dose locali-
zation confined to z8 mm from the source point and also
show that when approximating the beta energy spectrum
with the mean energy, ~DTV is underestimated, byz6% for
the 3-cm single-source case (Figs. 4a and 4b). The standard
deviation ðSDTVÞ values of the dose distributions for the
spherical tumor model also demonstrate the high degree of
non-uniformity in dose coverage. For the single-source case
shown in Figure 4b, for example, the maximum dose
is z748 Gy, which is z3.3 SD above the mean, whereas
the minimum dose is z0.1 Gy. These coldest voxels
represent z3% of the total spherical tumor volume. The
median dose isz10 Gy, which is considerably less than the
mean (z111 Gy) and thus demonstrates that the mean dose
is a poor indicator of the dose received by the majority of
voxels. The uniform dose coverage is further quantified
from the fraction of tumor volume that receives less than
10% and 25% of mean dose, which was calculated to be
V11 Gy z 49% and V27.8 Gy z 63%, respectively.
Figure 4e-g shows 2D dose distributions within the
pancreas phantom model containing an ellipsoid tumor
calculated from the corresponding 3D dose distributions in-
tegrated along the z axis. A double 32P source with the full
beta energy spectrum was used. Figs. 4h and 4i show the
corresponding cumulative dose-volume histograms
(CDVHs), compared with those assuming a uniform distri-
bution of dose to the tumor at the mean value,z109 Gy. The
median dose is 15 Gy and the coldest voxels receive 0.15 Gy,
which again demonstrates strong non-uniformity. Similarly,
the maximum dose to the tumor isz526 Gy (Fig. 4h), which
isz2.7 SD above themean.Moreover,z46%andz59%of
total tumor volume receive less than z11 Gy (10% of the
mean dose) and z27 Gy (25% of the mean dose), respec-
tively. These simulations predict that for a prescribed mean
dose of ~DTV Z 109 Gy delivered to the tumor, the pancreas
receives onlyz0.6% on average (ie,z0.6 Gy mean dose).
The peak dose received by the pancreas isz3.5 Gy (Fig. 4i),
and the minimum voxel dose is zero.
Dose distribution in clinical tumor geometries
Figure 5 shows the dose distributions of all 9 irregularly
shaped clinical tumorswith varying volumes, calculated from
2D ultrasound images from 3 individual patients. The red
regions indicate the highest dose deposition, whereas the
purple regions represent dose deposited by scattered elec-
trons, a small number of bremsstrahlung photons, and a small
percentage of emitted energetic beta particles.Corresponding
CDVHs for the tumor volumeare presented inSupplementary
Materials (available online at www.redjournal.org) and
demonstrate strong non-uniformity in dose distribution. The
tumor volumes receive inadequate dose coverage in some
regions, suggesting that multiple sources of 32P may be
necessary to achieve clinically significant outcomes. Dose to
the pancreas varies from negligible levels to up to 5.7 Gy.
Dosimetry of dynamic tumors
Figure 6 shows the changes in dose rate due to decreasing
activity and varying tumor volume for the large, medium,
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and small tumors over 24 weeks. The varying tumor
volumes were measured for each of the 3 patients, after
delivery of 32P microparticles, at 8, 16, and 24 weeks. In
all cases, the dose rate dropped to a negligible level in the
16- to 24-week period of the treatment. The large tumor
received 58 MBq of 32P microparticle activity. After the
first 8 weeks of treatment, the tumor volume decreased
from 111 cm3 to 93.6 cm3, and by 16 weeks it decreased
to 44.7 cm3. However, the tumor volume increased
slightly to 55.4 cm3 in the third 8-week period. The
medium tumor received 15 MBq of 32P microparticle
activity, and the volume decreased monotonically from
29.2 cm3 to 18.4 cm3 after the first 8 weeks and then to
16.6 cm3 and 12.8 cm3 after the second and third 8-week
periods, respectively. In the case of the small tumor 5
MBq of 32P microparticle activity was administered, and
the tumor volume exhibited a more dynamic response to
the treatment compared with the medium and large vol-
umes. The small tumor initially decreased in the first
8 weeks of treatment, from 8.9 cm3 to 6.3 cm3, but then
increased in size dramatically to 11.7 cm3 after the sec-
ond 8 weeks and then decreased again to 6.1 cm3 after
the third 8 weeks.
The results in Figure 6 clearly demonstrate the impor-
tance of considering the relative changes in dose rate and
tumor volume over treatment time. The dynamic changes in
Tu
m
or
 V
ol
um
e 
(%
)
Pa
nc
re
as
 V
ol
um
e 
(%
)
14
12
10
8
6
4
2
0 14121086420
14
12
10
8
6
4
2
0 14121086420
102
10-2
10-3
1
10
10-1
102
10-2
10-3
1
10
10-1
10-2
10-3
1
10-1
102
10-2
10-3
1
10
10-1
102
10-2
10-3
1
10
10-1
102
10-2
10-3
1
10
10-1
102
10-2
10-3
1
10
10-1
14
12
10
8
6
4
2
0 14121086420
3
2
1
0
-1
-2
-3 3210-1-2-3
1.5
-1.5
1
0.5
-0.5
-1
0
1.5-1.5 10.5-0.5-1 0
1.5
-1.5
1
0.5
-0.5
-1
0
1.5-1.5 10.5-0.5-1 0
1.5
-1.5
1
0.5
-0.5
-1
0
1.5-1.5 10.5-0.5-1 0
100 200150500 250 350 450 550300 400 500 600
0
10
20
30
40
50
60
100
70
80
90
0
10
20
30
40
50
60
100
70
80
90
1.5 2.5 3.53 4210.50
Tumor and Pancreas Tumor only, DTV = 109 Gy
∼ Pancreas only, DPV = 0.6 Gy
∼
SDPV = 1 GySDTV = 150 Gy
 DTV = 128 Gy
∼
SDTV = 149 Gy
 DTV = 110 Gy
∼
SDTV = 151 Gy
 DTV = 111 Gy
∼
SDTV = 191 Gy
 DTV = 104 Gy
∼
SDTV = 136 Gy
V≤ 11 Gy ≈ 46 %
V≤ 27 Gy ≈ 59 %
Dmin ≈ 0.15 Gy
Dmedian ≈ 15 Gy
V≤ 6 cGy ≈ 15 %
V≤ 15 cGy ≈ 27 %
Dmin ≈ 0 Gy
Dmedian ≈ 0.3 Gy
PVTV
UDD
Dose(Gy) Dose(Gy)
Z (cm) Z (cm) Z (cm)
X (cm)
Y 
(c
m
)
Y 
(c
m
)
Y 
(c
m
)
Y 
(c
m
)
Y 
(c
m
)
Y 
(c
m
)
Y 
(c
m
)
X (cm)X (cm)X (cm)
a b c d
e f g
h i
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tumor volume over the course of the treatment have an
impact on dose deposited both inside the tumor and outside
(ie, pancreas). For the small tumor the simulation of a static
volume predicts an average dose delivered in the first
8 weeks of treatment of 113 Gy, whereas the dynamic
volume simulation predicts 148 Gy. Indeed, in all 3 cases
(small, medium, and large tumors) our results indicate that
the assumption of a static tumor volume underpredicts the
actual delivered dose, with a larger discrepancy for smaller
initial tumor volumes.
The simulation results also reveal that the change in
tumor volume has the greatest impact on organ dose outside
the largest tumor. The average dose to the pancreas was
19 Gy, which is z16% of the tumor dose. This is mainly
due to the inadequate spatial coverage of the dose delivered
to the tumor. Note that if a static tumor volume is assumed,
then the average dose to the pancreas drops to 5.6 Gy,
which is only z5% of the tumor dose. Thus, assuming a
static tumor volume underestimates the absorbed dose to
the healthy parenchyma.
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Fig. 5. Calculated 2-dimensional dose distributions for the 9 modeled irregular tumors based on individual patient ultra-
sound images: a) large tumor; b) medium tumor; c) small tumor. Vi denotes the initial tumor volume. ~DTV and ~DPV are the
average dose to the tumor volume (TV) and to the pancreatic volume (PV), respectively, and SDTV is the standard deviation
in the dose to the tumor volume. Plots with a red asterisk ()) indicate tumor models were used for simulating the dosimetry of
dynamically changing tumors. (A color version of this figure is available at www.redjournal.org.)
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Fig. 6. Left: Dose rate ( _D) delivered to a large (a), medium (b), and small (c) tumor with initial volumes (Vi)z 8.9, 29.2,
and 111 cm3, and to the volume outside (healthy pancreas), as a function of treatment time. STV and DTV denote a static
tumor volume and the dynamic tumor volume, respectively. Right: Corresponding number of voxels in each tumor volume as
a function of treatment time (polynomial fit to measurements taken at 0, 8, 16, and 24 weeks) compared against changing
dose rate. ~DSTV, ~DDTV, ~DPVðSTVÞ, and ~DPVðDTVÞ are the average doses delivered to a static tumor volume, the dynamic tumor
volume, the pancreas volume for static, and dynamic tumor volume, respectively.
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Discussion
Dose distribution in spherical and pancreatic
tumors
For the spherical tumor models, our simulation results
(Fig. 4a-d) clearly show the non-uniform distribution of
dose that peaks at the injection site and declines rapidly,
spatially localizing tumor coverage to a radius limited by
the maximum range of the beta particles (8.2 mm in water).
Our results also show the strong non-uniformity in dose
within the coverage area. This demonstrates the limitations
of commonly used dosimetry software (eg, OLINDA) that
assume a uniform dose distribution throughout a tumor. Our
simulations indicate that multiple injections would be
required to achieve an approximately uniform dose distri-
bution in a 3-cm diameter tumor; 3 injections, for example,
would reduce the SD by z20% compared with a single
injection.
For the more realistic pancreatic tumor model, our
simulations (Fig. 4e-g) also suggest that more than a single
injection of 32P will give better tumor coverage and dose
uniformity in the pancreatic head, while minimizing
exposure to the surrounding pancreas. The CDVHs show
that z90% of the pancreas volume receives <1.5 Gy
(Fig. 4i). For the tumor volume CDVH, Figure 4h shows
that a uniform dose distribution at the mean dose value is a
poor approximation of the actual distribution. This is
important because it is the minimum dose to the tumor that
is mostly likely to affect the tumor response to treatment:
cancer cells receiving a dose below an effective dose may
proliferate and lead to tumor progression or recurrence,
whereas cells receiving a dose above an effective dose
should receive lethal damage.
Dose distribution in irregularly shaped tumors and
surrounding pancreas
For the tumor models based on clinical patient ultrasound
data (Fig. 5), our simulations indicate that more source sites
(injections of 32P) may be needed to achieve adequate dose
coverage of the tumor. The radiobiological effects of non-
uniformity in tumor coverage can be quantified with the
equivalent uniform dose calculation, based on the extended
linear-quadratic model for a nonconstant, exponentially
decreasing dose rate (4, 13, 14). This requires information
on the tissue radiosensitivity and DNA repair parameters
for patient-specific pancreatic tumor cell lines. Although
this information was not obtained for the patients whose
clinical data were used in this study, in principle it promises
a personalized approach to treating advanced pancreatic
cancer with 32P microparticles.
For tumors larger than 10 cm3, our results indicate that
more than 1 injection is needed. The dose to the pancreas
varies depending on tumor volume and the degree of ir-
regularity in tumor shape. The worst case scenario was for a
large tumor that received 105.5 Gy mean dose, but 5.7 Gy
(z5%) was delivered to the pancreas. This absorbed dose
is still lower than the dose that is delivered to the pancreas
from other IRT procedures. For example, a previous clinical
study (15) found that IRTwith an 131I radiolabeled antibody
for patients with peritoneal carcinomatoses could result in
an absorbed dose of 2.87 to 7.75 Gy to the pancreas. It was
suggested that this range of dose to the organ is unlikely to
result in acute symptoms or subacute disturbance in
pancreatic function. Nevertheless, the tail of the pancreas is
the most critical organ component because radiation
toxicity in the tail could result in diabetes. This is an
important issue for external beam radiation therapy because
the absorbed dose to the pancreas could be as high asz20
to 29 Gy (16). Our simulation results indicate that
comparatively little dose is delivered to the pancreatic tail
by 32P microparticle treatment.
Dosimetry of dynamic tumors
For the models in which shrinkage and growth of tumors
during treatment were considered, our results (Fig. 6) show
that the initial tumor volume is an important determinant of
the response to the time-varying dose delivered to the
tumor. Assuming the tumor volume remains static
throughout the treatment results in an under-prediction of
the actual delivered dose, and this has the most significant
impact on smaller tumors that can vary in size more
dynamically than larger tumors. Although all the tumors
(modeled as large, medium, or small) shrank in the first
8 weeks of treatment, in response to the peak in dose rate of
delivered 32P, the rapid increase in volume in the middle
8 weeks for the small tumor correlated with the rapid decay
in dose rate. This tumor swelling may be a sign of edema,
but no further clinical data are available to corroborate this.
Interestingly, in the final 8 weeks of treatment the small
tumor shrank rapidly, despite the negligible dose rate.
Although this swelling followed by shrinkage may simply
represent a lag in response to the radiation treatment,
another possible explanation is that the tumor, compro-
mised by the initial radiation treatment, becomes respon-
sive to the upregulated immune system. Indeed, previous
studies (17) have shown that localized irradiation of a
pancreatic tumor can change the tumor microenvironment,
causing inflammatory cytokines and thus increasing traf-
ficking and retention of T lymphocytes to the tumor. It is
possible that a synergistic effect may be in play: the initial
high rate and localization of dose deposition within the first
8 weeks of 32P treatment inflicts sufficient damage to the
tumor that it eventually succumbs to the immune system’s
response, which is then primarily responsible for the
observed treatment responseda marked decrease in tumor
volume during the third 8-week period after injection of
32P. The immuno-responsive mechanism could include an
increased activity of lymphocytes into the tumor microen-
vironment, thereby enhancing tumor cell recognition and
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killing through upregulation of tumor antigens and induc-
tion of positive immunomodulatory pathways (17-20).
A similar effect has been observed in the case of external
beam radiation therapy and selective internal radiation
therapy,whereby delivery of a high and localized dose has led
to systemic responses at distant sites, a phenomenon known
as the abscopal effect, which has been attributed to the in-
duction and enriching of the immune response (21-26).
However, because the patients were also treated with
gemcitabine, a chemotherapeutic with radiosensitizing
properties (27), the observed tumor shrinkage in the final
weeks of treatment, when activity was negligible, may be
attributable to the effects of this drug (28, 29). Further
clinical studies are needed to confirm this.
Conclusion
Our results have determined that for a clinically pre-
scribed activity in the range 5 to 60 MBq, 32P micro-
particles deliver a z100- to 120-Gy mean dose to a
pancreatic tumor volume. Our results also suggest that for
clinically relevant tumor shapes, multiple injections may
be required to overcome the non-uniform activity distri-
bution. We found that for 2 injections, the organ dose
remains limited to 5% to 6% of the tumor dose in the
worst case scenario studied. Our study also highlights the
limitation of assuming a uniform mean dose distribution.
We found significant deviations from the mean dose
value, including a nonnegligible number of cold voxels
that potentially present a risk of tumor recurrence or
proliferation. Additionally, this study demonstrates the
importance of considering the dynamic change in tumor
volume in internal radionuclide therapy dosimetry.
Dosimetry of both the tumor and adjacent critical organs
is affected by the dynamic change of the tumor mass
during treatment, and this effect is generally more pro-
nounced for small tumors that initially shrink at a rate
faster than the radioisotope decay rate. Our simulation
and modeling results, based on patient-specific data,
demonstrate the efficacy of 32P microparticles in treating
advanced pancreatic cancer and the possibility of
designing personalized treatment strategies.
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Objective: To develop an alpha dosimetry technique
for activity calibration of alpha-emitting radiopharma-
ceuticals using the Gafchromic® EBT3 (Gaf-EBT3)
radiochromic film (International Speciality product,
Wayne, NJ).
Methods: The Gaf-EBT3 has a tissue equivalent radiosen-
sitive layer (approximately 28mm) sandwiched between
two 100-mm thick polyester sheaths, thereby making it
insensitive to alpha particles. We have split a Gaf-EBT3
sheet using a surgical scalpel to remove one of the
polyester protective layers and covered the radiosensitive
layer with thin Mylar® foil (Goodfellow Cambridge Limited,
Huntingdon, UK) (2.5mm). Small pieces of modified film
were exposed at contact with a 560-Bq thin 241Am source
for 5, 10, 24 and 94h. The optical density of the films was
evaluated using an optical densitometer. The alpha energy
spectra of the 241Am source were recorded using a Si(Li)
surface barrier detector.
Results: Time-integrated specific alpha surface activity
(kBqcm22 h) was represented as a function of optical
density.
Conclusion: By removing one of the 100mm thick poly-
ester protective layers, the authors have modified the Gaf-
EBT3 film to a sensitive alpha dosemeter. The calibration
function relevant to a 241Am reference source was
evaluated from the optical densities of the dosemeter foils.
Furthermore, calibration functions for important alpha
emitters such as 223Ra, 225Ac or 210Bi were parameterized
from the 241Am reference data.
Advances in knowledge: The authors have developed
and tested the principle of a clinical alpha dosemeter
using Gaf-EBT3 radiochromic films originally developed
for photon dosimetry. This novel, user-friendly technique
could be implemented in quality assurance and calibration
procedures of important alpha-emitting radiopharmaceut-
icals prior to their clinical applications.
INTRODUCTION
The novel developments of radionuclide production and
advances in targeted internal therapy (TIT) have promoted
a particular interest in alpha-particle emitters for the treat-
ment of micrometastatic diseases.1 The usual external beam
radiation therapy is a mainstay of cancer treatment. However,
a major drawback is the lack of speciﬁcity, which can result in
normal tissue toxicity. TIT is an alternative approach, which
can seek molecular targets within a tumour site and allows
a sensitive identiﬁcation between the normal and tumour
cells. There are different alpha-emitting isotopes available for
human clinical use such as 211At, 212Bi, 225Ac, 223Ra and 149Tb.
These isotopes emit alpha particles within the energy range of
4–8MeV.2 Currently, 223Ra is the most promising radionu-
clide that can be used for treating bone metastases associated
with prostate cancer.1,3 Large quantities of 223Ra with half-life
of 11.4 days can be acquired from uranium mill trailing. It
could also be obtained as a generator based on the 227Ac
parent with half-life of 21.8 years.4 Alpharadin (223Ra chlo-
ride) is an alpha-emitting radioisotope recently approved by
the Food and Drug Administration to treat bone metastases
associated with prostate cancer. 223Ra has a half-life of
11.4 days, and it basically emits four alpha particles per decay,
which is 95% of the total energy emitted and about ,2% of
the energy originates from photons which could be used for
qualitative imaging.3,5 There have been suggestions to cus-
tomize these alpha-emitting radionuclides for treating differ-
ent types of cancers by enclosing them in a nanoparticle cage
and linking the antibodies on their surface.6
Evidently, suitable calibration and quality assurance (QA)
procedures are prerequisite for clinical trials and routine
applications of the above radiopharmaceuticals. Most of the alpha
radionuclides co-emit low-intensity characteristic g-rays. Gamma
spectrometers are used to assess those g-rays for the purpose of
calibration. However, modern high-resolution gamma spec-
trometers are bulky and expensive. This motivated the authors to
develop a user-friendly calibration method based on alpha do-
simetry utilizing widely used radiochromic ﬁlms.
Radiochromic ﬁlms belong to the category of chemical dose-
meters. The principle is based on the phenomenon of perma-
nent colouration of a thin radiosensitive layer (wrapped with
transparent polyester foils) caused by ionizing radiations.7 Un-
like photographic ﬁlms, radiochromic ﬁlms require no chemical
processing and are now widely used in medical radiation do-
simetry.8 Alpha particles possess very short range in materials
and, hence, are completely stopped by the protective polyester
sheaths before reaching the radiosensitive layer. This makes
common radiochromic ﬁlms insensitive to alpha particles.
The authors have overcome this drawback by splitting the
radiochromic ﬁlm, removing one of the 100mm (thick) pro-
tective polyester layers and replacing it with 2.5-mm (thin)
Mylar® foil (scientiﬁc name: polyethylene terephthalate; spec-
iﬁcation: ES301025; supplier: Goodfellow Cambridge Ltd,
Huntingdon, UK). This facilitates alpha particles to reach the
sensitive layer without signiﬁcant energy loss. Based on this
principle, we have developed an alpha dosemeter suitable for
versatile applications including calibration of alpha-emitting
radiopharmaceuticals.
METHODS AND MATERIALS
Film sample preparation
The most recent brand of radiochromic ﬁlm (Gafchromic®
EBT3; International Speciality Products, Wayne, NJ) was used in
this study. The EBT3 sheet (20.33 25.4 cm) is made of an ap-
proximately 28-mm tissue equivalent radiosensitive active dye
layer sandwiched between two 100-mm polyester protective foils.
Radiochromic ﬁlms are principally sensitive to photons and are
widely used by medical and radiological physics communities.7,8
The radiosensitive dye layer and protective foils were not ﬁrmly
glued to each other. Therefore, one of the protective foils could
be conveniently separated using a splitting blade (surgical scal-
pel) as depicted in Figure 1. This allows alpha particles to in-
teract directly with the dye layer. Two square (53 5 cm) sections
were cut out from a single EBT3 ﬁlm sheet, with one protective
layer removed. The dimensions of the sections were evaluated
using a digital calliper (Oehmen Labortechnik, Cologne,
Figure 1. Schematic diagram showing the cross-section of the
EBT3 radiochromic film widely used in photon dosimetry
applications. The splitting of the sensitive dye layer from
protective polyester sheath using a surgical scalpel is
highlighted.
Figure 2. Showing the normalized spectrum of the 560-Bq
241Am alpha source recorded with a high-resolution Si(Li)
surface barrier detector. The unattenuated spectrum and the
spectrum attenuated using a 2.5mm Mylar foils are shown by
“filled circles” and “hollow circles”, respectively. One observes
the main energy peak shifted from 5.48 to 5.21MeV owing to
energy loss in the Mylar foil. Consequently, the width (full width
at half maximum) of main peak increased from 26 to 45keV.
Figure 3. Photograph of the modified EBT3 film pieces
irradiated with alpha particles from a 560-Bq 241Am source
for: (a) 5h, (b) 10h, (c) 24h and (d) 94h. The rectangular film
sections are the unexposed samples cut out from the same lot
used for alpha irradiation. These specimens were used as
references (control) for optical density calculation.
Figure 4. Schematic diagram of the modified Gafchromicâ
EBT3 film cross-section used in alpha depth–dose calculations.
E0 represents the unattenuated alpha energy from the source
(d50.7cm). E1 and E2 represent the energy of the alpha
particles entering the dye layer (TD523mm) after passing
through the Mylar foil (TM52.5mm) and exit energy, respec-
tively. DE stands for the alpha energy loss in the radiosensitive
dye layer.
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Germany) with an accuracy of 60.01mm. The ﬁrst section
(area525 cm2) was covered with 2.5-mm Mylar foil (contributing
a minimal attenuation to impinging alpha particles) and stored in
a light-tight box for alpha dosimetry purpose. Evidently, the 2.5-mm
(thin) Mylar foil becomes extremely fragile during handling. Hence,
utmost precautions should be taken while cutting the foil using
a sharp scalpel. The second section (area525 cm2) was used for
thickness estimation of the dye layer. This ﬁlm section was weighed
using a chemical microbalance (PS-H200; Voltcraft, Taiwan, China)
with an accuracy of 60.1mg. The dye layer was removed using
warm (approximately 40 °C) distilled water, and the remaining
polyester substrate was dried thoroughly in a hot air cabinet and
weighed again. The dye layer thickness (tD) was estimated as follows:
tD5½ðmF2mPÞ=F=rD (1)
where, mF, mP, F and rD are the mass of the ﬁlm section
(0.517 g), polyester substrate only (0.459 g), ﬁlm area (25 cm2)
and density of the tissue equivalent dye material (1 g cm23),
respectively. By substituting the numerical values in Equation (1),
the thickness of the dye layer (tD) was calculated to be 23.2mm,
17% lower than the manufacturer’s quoted value 28mm. For dye
layer thickness estimation, the same radiochromic ﬁlm section
(area5 25 cm2) was weighed twice, with the dye layer and layer
removed. Therefore, the uncertainty in the weight estimation will
be the major contributor in error calculation of dye layer thick-
ness than the uncertainty in area measurement.
Alpha spectrometry of the 241Am source
We have used a thin, electrodeposited9 alpha reference source
(activity: 560Bq; spot diameter: 7mm, serial number: 64–98 RA;
Amersham International, Amersham, UK) for irradiation pur-
pose. The alpha spectra of the bare source and covered with
2.5-mm Mylar foil were recorded using a high-resolution Si(Li)
surface barrier detector (LEC 200-2000, active thickness: 200mm
mounting diameter 28.50mm; Canberra Industries, Inc., Mer-
iden, CT) interfaced to a 1459 channel computerized analyser.
The high-voltage supply, signal gain and detection time (live)
were 80V, 2048 and 605.9 s, respectively. The measurements were
carried out in a dedicated alpha spectroscopy vacuum chamber.
The alpha spectra are depicted in Figure 2.
Alpha exposure and evaluation of radiochromic films
For the alpha exposure, the authors have prepared four pieces of
23 3-cm samples cut from the modiﬁed EBT3 ﬁlm sheet
(area5 25 cm2), whereas the sensitive (dye) surface was covered
with 2.5-mm Mylar foil. The alpha was source placed at contact
with the ﬁlm and sequentially exposed for 5, 10, 24 and 94 h.
After completion of alpha exposure, each ﬁlm sample was cut in
two pieces, the upper exposed part and the lower unexposed
part (control) as depicted in Figure 3.
As the result of alpha exposure, the ﬁlms turned “bluish dark”;
furthermore, this colouration effect is estimated in terms of net
optical density (NOD) deﬁned10 as the difference between the
optical densities of exposed ﬁlm (ODexp) and that of the control
ﬁlm (ODcont):
NOD5ODexp2ODcont (2a)
or
NOD5log10

I0=Iexp

2 log10ðI0=IcontÞ (2b)
where, I0, Iexp and Icont stand for intensities of incident light and
transmitted light through exposed and control (unexposed)
ﬁlms, respectively. The authors have used a simple handheld
spot densitometer (DensiX; PTW Freiburg, Freiburg, Germany)
Figure 5. Depicting the range of alpha particles as functions of
energy (a) and subsequently alpha energy as functions range
(b) in Mylar and EBT3 dye (tissue equivalent) layer. Data points
were adopted from the literature11 and fitted with polyno-
mials (Table 1).
Table 1. Showing the fitting polynomials relevant to functions: alpha range and energy in the Mylar and EBT3 dye material (tissue
equivalent) as depicted in Figure 5
Function
Stopping material
Mylar EBT3 dye (tissue equivalent)
Range5 f(Energy)
(1) y5 6.113 10201x21 2.643 10100x1 5.903 10201,
R25 1.003 10100
(3) y5 7.433 10201x21 3.183 10100x1 3.713 10201,
R25 1.003 10100
Energy5 f(Range)
(2) y54.55310205x324.92310203x212.79310201
x25.50310202, R251.00310100
(4) y53.05310205x323.71310203x212.35310201
x21.23310203, R251.00310100
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for the explicit estimation of the optical densities of the exposed
(ODexp) and control (ODcont) ﬁlms.
The time-integrated speciﬁc surface activity (A) was calculated as:
A 

kBq cm2 2 h

5Qt

pr2 (3)
where Q (0.56 kBq), r (0.35 cm) and t (h) are the alpha source
activity, source radius and exposure time, respectively. By
substituting the numerical values in Equation (3), the value of A
was calculated to be 1.45t (kBq cm22 h).
Alpha energy loss and depth–dose calculation
The optical densities of the exposed ﬁlms are evidently directly
proportional to energy loss (i.e. energy dose) of the impinging
alpha particles11 reaching the ﬁlm layer after passing through the
2.5-mm Mylar foil and speciﬁc surface activity of the alpha
source (Figure 4). The alpha energy and range calculations in the
Mylar and tissue equivalent dye layer7 of the ﬁlm material were
performed using the range/energy and energy/range functions
(Figure 5) constructed using the reference data.12 The ﬁtting
polynomials relevant to these functions are presented in Table 1.
The rest energy of the alpha particles (initial energy: E0) tra-
versing 2.5-mm Mylar foil (E1), energy loss within 23-mm thick
dye layer (DE) and the exit energy (E2) were calculated using the
ﬁtting polynomials (Table 1) as presented below:
Step 1: Set initial alpha energy E0 and calculate the range in
Mylar (RM) using polynomial (1), RM5 f (E0).
Step 2: Calculate the range difference (RM –TM) and exit alpha
energy (E1) using polynomial (2), E15 f (RM –TM).
Step 3: Calculate the range (RD) of alpha particle of energy E1 in
the dye layer using polynomial (3), RD5 f (E1).
Step 4: Calculate the range difference (RD –TD) and the
corresponding energy difference (DE) in the dye layer
using polynomial (4), DE5 f (RD –TD).
Step 5: Calculate the exit energy (E2) from dye layer as
ﬂows: E25 E1 –DE.
Step 6: The remaining energy E2 is completely lost in the
sufﬁciently thick polyester layer (TP5 100mm) as
shown in Figure 4.
Alpha dose delivered in the energy loss (DE) volume (v) in
radiosensitive dye is given as:
Da ðGyÞ5DEAS=DM 

J kg2 11

(4)
where alpha energy loss DE (in mega electronvolts) expressed as
(DE/6.2431012) (in joules) 5 1.60310213 DE J; time-integrated
speciﬁc alpha surface activity A (in kBq cm22 h) expressed as
(360031000) (in Bqcm22 s) 5 3.63106ABq cm22 s; the surface
area S (Figure 4) was calculated to be p3 (0.7/2)2 cm250.385 cm2;
alpha energy loss volume (v) considered to be a 23-mm long
0.7-cm diameter right cylinder (Figure 4), v52331024p3
(0.7/2)2 cm358.8531024 cm3; consequently, the mass (DM) of
stopping (dye) material (r5 1 g cm23) within the energy loss
volume calculated as: 8.853 1024 cm33 1 (g cm23)
5 8.853 1024 g5 8.853 1027 kg.
By substituting the numerical values in Equation (4), we get:
Da ðGyÞ5

1:603 102 133 3:63 1063 0:3853 1:133 106

DEA
or
Da ðGyÞ50:251DEA (5)
Gamma background estimation
Alpha radionuclides, including 241Am also emits g-rays.13 The
authors have placed a Geiger-Mueller (GM) counter-based
Table 2. Presenting the alpha exposure time, time-integrated specific surface activity (A), net optical density (NOD) of the film
samples (Figure 3) and the corresponding alpha (Da) and background gamma
13 (Dg) doses
Sample ID Exposure time (h) A (kBq cm22 h) NOD Da (Gy) Dg (Gy)
– 0 0 0 0 0
(a) 5 7.3 0.04 4.9 1.153 1026
(b) 10 14.6 0.07 9.8 2.303 1026
(c) 24 35.0 0.15 23.4 5.523 1026
(d) 94 137.2 0.75 91.6 2.163 1025
Table 3. Showing important alpha emitters14 with corresponding half-lives and energies (E0), calculated entrance (E1) and exit (E2)
energies and energy loss (DE) in the sensitive layer (Figure 5) and the dose normalization factor (ka) relative to
241Am
Alpha emitter Half-life E0 (MeV) E1 (MeV) E2 (MeV) DE (MeV) ka
210Bi 5.01 days 4.67 4.40 3.17 1.24 2.15
241Am 450 years 5.48 5.21 2.55 2.66 1.0
223Ra 11.4 days 5.70 5.43 2.42 3.01 0.88
225Ac 10 days 5.94 5.67 2.29 3.37 0.79
BJR Mukherjee et al
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Gamma-probe (FHZ 632; Thermo Electron GmbH, Erlangen,
Germany) interfaced to a Gamma-monitor (FH 40G-L10;
Thermo Electron GmbH) at contact with the 241Am reference
source. The 0.2-mm-thick hard-aluminium entrance wall of the
GM probe eliminates the alpha particles totally, thereby enabling
the assessment of unperturbed gamma dose rate.
RESULTS
The values of NOD, time-integrated speciﬁc alpha surface ac-
tivity (A) of 241Am reference source and corresponding alpha
dose (Da) were calculated using Equations 2a, 3 and 5, re-
spectively, and are presented in Table 2.
The energies of alpha emitters of interest,14 210Bi, 241Am, 223Ra
and 225Ac at the entrance (E1) and exit (E2) points of the radio-
sensitive EBT3 dye layer (Figure 4) and related energy loss (DE)
were evaluated using calculation Steps 1–6 as described in “Alpha
energy loss and depth-dose calculation” section. Furthermore, the
alpha energy losses were normalized against that of 241Am refer-
ence, and the normalization factors (ka) are presented in Table 3.
Time-integrated speciﬁc alpha surface activity (A) of the 241Am
reference source was plotted as a linear function (inset) of NOD,
thereby yielding the calibration graph (Figure 6a). Evidently, the
NOD is directly proportional to alpha dose (Da). On the other
hand, Da depends on both alpha energy loss (DE) and time-
integrated speciﬁc surface activity (A) as described in Equation
(5). Hence, NOD could be expressed as an explicit function of DE
and A. Hence, we have used the alpha energy loss normalization
factors (ka) to parameterize the calibration graph for
241Am
reference source in order to construct the calibration graphs for
other alpha emitters of interest (Figure 6b).
The unperturbed gamma dose rate at contact with the 241Am
reference source was estimated to be 2.3mGy h21. The calculated
gamma background doses are presented in Table 2.
DISCUSSION
The authors have developed a novel alpha dosimetry technique
based on radiochromic ﬁlms widely used in photon dosimetry
and a low activity, thin 241Am reference source. Most of the
alpha radionuclides also emit low-intensity g-rays, and the
conventional QA protocols validate those g-rays using sophis-
ticated gamma spectrometers. The present method is based on
cost-effective radiochromic ﬁlms and a user-friendly handheld
optical densitometer. Furthermore, the use of 2.5-mm (thin)
Mylar foil wrapping the radiosensitive layer of the ﬁlm enabled
the detection of low-energy alpha particles down to approxi-
mately 4MeV.
This technique, however, suffers from three major shortcomings.
(a) Owing to longer exposure time (Table 2), it is suitable for
assessment alpha emitters of relatively longer half-lives, i.e. in the
order of several days (Table 3). (b) During routine applications,
thick alpha sources i.e. alpha radiopharmaceuticals of interest
absorbed in small pieces of ﬁlter paper will be deployed. This will
cause a substantial “self-absorption”, resulting in reduction of
speciﬁc surface activity (Equation (3)) and energy loss of the
alpha particles. To overcome this limitation, an alpha self-
absorption correction factor15 will be taken into account. (c) Loss
of dye material (sensitive layer) while removing the protecting
polyester sheath (Figure 1). Hence, the sensitive layer thickness of
the modiﬁed EBT3 radiochromic ﬁlm sheet should be estimated
using the method described in this article prior to dosimetric
applications.
Majority of alpha-emitting radionuclides also emit g-rays and b
particles, however, of very low intensities.13 In this work, the
gamma (background) dose contribution was estimated to be
negligible in comparison with alpha dose (Table 2).
The authors already have developed a radiochromic ﬁlm-based
alpha dosemeter, considering all radiological safety aspects,13 in
particular, contamination hazard. Application of this user-friendly
method for activity calibration and QA procedures of radio-
pharmaceuticals incorporating alpha emitter is envisaged. Those
drugs are the principal candidates of highly efﬁcient TIT for the
treatment of micrometastatic ailments.1 Scientiﬁc collaboration
with a leading teaching hospital in Sydney, Australia, involved in
clinical trials of 223Ra-dichloride (Alphadrin) for the treatment of
bone metastasis of prostate cancer patients is in progress.
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Figure 6. (a) The calibration graph representing the time-
integrated specific surface activity (A) of alpha particles from
the 560-Bq 241Am reference source as a function (inset) of net
optical density (NOD) of the modified EBT3 radiochromic film.
(b) Calibration graphs of alpha emitters 210Bi (1), 223Ra (3) and
225Ac (4) evaluated using the experimentally estimated energy
loss normalization factor ka (Table 2) and calibration function
of 241Am reference (2).
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Abstract
The addition of gold nanoparticles within target tissue (i.e. a tumour) to 
enhance the delivered radiation dose is a well studied radiotherapy treatment 
strategy, despite not yet having been translated into standard clinical practice. 
While several studies have used Monte Carlo simulations to investigate 
radiation dose enhancement by Auger electrons emitted from irradiated 
gold nanoparticles, none have yet considered the effects due to escaping 
fluorescence photons.
Geant4 was used to simulate a water phantom containing 10 mg ml−1 
uniformly dispersed gold (1% by mass) at 5 cm depth. Incident monoenergetic 
photons with energies either side of the gold K-edge at 73 keV and 139.5 keV 
were chosen to give the same attenuation contrast against water, where water 
is used as a surrogate for biological tissue.
For 73 keV incident photons, adding 1% gold into the water phantom 
enhances the energy deposited in the phantom by a factor of  ≈1.9 while 
139.5 keV incident photons give a lower enhancement ratio of  ≈1.5. This 
difference in enhancement ratio, despite the equivalent attenuation ratios, can 
be attributed to energy carried from the target into the surrounding volume 
by fluorescence photons for the higher incident photon energy. The energy 
de-localisation is maximal just above the K-edge with 36% of the initial 
energy deposit in the phantom lost to escaping fluorescence photons.
Conversely we find that the absorption of more photons by gold in the 
phantom reduces the number of scattered photons and hence energy deposited 
in the surrounding volume by up to 6% for incident photons below the 
K-edge. For incident photons above the K-edge this is somewhat offset by 
fluorescence.
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Our results give new insight into the previously unstudied centimetre 
scale energy deposition outside a target, which will be valuable for the future 
development of treatment plans using gold nanoparticles. From these results, 
we can conclude that gold nanoparticles delivered to a target tumour are 
capable of increasing dose to the tumour whilst simultaneously decreasing 
scatter dose to surrounding healthy tissue.
Keywords: nanoparticles, gold, Monte Carlo, fluorescence, Auger
(Some figures may appear in colour only in the online journal)
1. Introduction
The enhancement of radiation damage effects by gold nanoparticles (GNPs) has been demon-
strated experimentally by a number of studies, both in vitro and in vivo, with various kilovolt-
age (keV) x-ray sources (Hainfeld et al 2004, 2013, Kong et al 2008, Liu et al 2008, Rahman 
et al 2009, Butterworth et al 2012, Jain et al 2012, Zhang et al 2012, Bobyk et al 2013, Miladi 
et al 2014, McQuade et al 2015, Her et al 2016). Although GNP radiation dose enhance-
ment can be attributed largely to the strong contrast in photoelectric attenuation of gold com-
pared to water (or soft tissue) at keV energies, Auger electron emission can also contribute 
to radio-enhancement effects on nanoscales and a number of simulation studies have focused 
on quanti fying the high nanoscale dose gradients caused by Auger electrons emitted from the 
surface of GNPs (Jones et al 2010, Leung et al 2011, McMahon et al 2011, Douglass et al 
2013, Li et al 2014, Xie et al 2015).
Simulation studies to date, however, have paid relatively little attention to the role of 
 fluorescence photon emission in energy deposition following GNP irradiation. Atomic 
 de-excitation by Auger emission is negligible compared to fluorescence emission following 
K-shell ionisation and Kα1 fluorescence photons in particular can typically reach centime-
tre scales e.g. the Kα1 energy in gold is 68.8 keV, corresponding to an attenuation length 
of  ≈5.15 cm in water (Berger et al 2010, NIST XCOM). This implies that fluorescence pho-
tons, in contrast to photoelectrons and Auger electrons, can potentially delocalise dose depo-
sition to regions outside the intended target (i.e. a tumour). Figure 1 schematically shows the 
zones of influence of these secondary radiations around a gold atom. Monte Carlo simulations 
carried out by Lechtman et al (2011) determined the proportion of incoming photon energy 
transferred to fluorescence photons by a single GNP, but only considered energy deposited 
by secondary electrons up to 1 cm from the nanoparticle, thus missing the scale impacted by 
fluorescence photons.
In this Monte Carlo simulation study, we investigate the multi-scale redistribution of energy 
by atomic gold in a target irradiated by keV x-rays, specifically quantifying the delocalisa-
tion of energy by fluorescence emission. Simulation results are compared for the following 
scenarios: (1) neglect all atomic de-excitation processes; (2) include only fluorescence emis-
sion; and (3) include full de-excitation (fluorescence and Auger). Importantly, we consider the 
contribution to energy deposition by fluorescence photons both within and outside a target 
phantom containing gold, to determine whether dose enhancement in the target is offset by 
out-of-field dose due to fluorescence delocalisation.
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2. Method
Simulations were carried out using the Geant4 Monte Carlo toolkit, version 10.02 patch 01 
(Agostinelli et al 2003, Allison et al 2006). The simulation geometry depicted in figure 2 
consisted of a 50 cm  ×  50 cm  ×  20 cm box of water, used as a surrogate for biological tissue, 
with a 3 cm  ×  3 cm  ×  3 cm phantom at 5 cm depth containing either water alone or water with 
Au at a uniform concentration of 10 mg ml−1 (1% by mass). A homogeneous gold atom/water 
mixture was used because the quantities of interest considered in this study are not dependent 
on the nano-scale structure of gold nanoparticles or electron tracks and energy deposition. The 
whole geometry was surrounded by air. This concentration of Au has been reported in in vivo 
radio-enhancement experiments with GNPs (Hainfeld et al 2013). A total of 107 photons were 
initiated from the face of the water box using a square beam profile of 3 cm  ×  3 cm directed 
parallel to the z-axis (see figure 2). Mono-energetic photons were used to examine the physics 
processes involved and their energy dependence, but are also directly relevant to stereotactic 
synchrotron radiation treatment with nanoparticles (Adam et al 2008, Bobyk et al 2013).
Incident photon energies of 73 keV or 139.5 keV were chosen as they have the same ratio 
of mass attenuation coefficient in gold to that in water (see figure 3(a)) and because they have 
the same energy above the gold L-edge (14.4 keV) and K-edge (80.7 keV) respectively and 
thus produce equally energetic photoelectrons. This allows comparison of the effects of tuning 
above and below the gold K-edge.
The interdependence of the photoelectric effect and subsequent atomic relaxation above 
and below the K-edge is of key importance in relation to fluorescence. Which of the competing 
de-excitation routes of fluorescence or Auger electron emission occurs following ionisation 
of an atom depends upon the shell containing the initial vacancy. Photoelectric interactions 
predominantly eject an electron from the innermost available shell of the target atom, the 
K-shell only becoming available for incident photon energies above the K-edge. In a high-Z 
material, atomic relaxation following a K-shell vacancy proceeds almost exclusively via fluo-
rescence while relaxation following an L-shell vacancy proceeds predominantly via Auger 
Figure 1. Schematic illustration of the zones of influence of Auger and fluorescence 
emissions following photoelectric interaction with a gold atom (not to scale).
H L Byrne et alPhys. Med. Biol. 62 (2017) 3097
3100
electron emission (see figure 4). The enhanced mass attenuation coefficient of gold compared 
to water in the keV energy range (see figure 3(a)) can give rise to significant fluorescence 
capable of delocalising energy deposition for incident photon energies above the gold K-edge 
(80.7 keV). This results in a decrease in mass energy absorption coefficient above the K-edge 
(cf. figure 3(b)).
Geant4 Low Energy Livermore physics models were used with the low-energy cut set 
to 100 eV. Photon interaction models included photoelectric absorption as well as Compton 
and Rayleigh scattering. For charged particle transport, the main process is electron impact 
ionis ation. Although bremsstrahlung radiation is negligible at keV electron energies, it was 
Figure 2. Simulation geometry showing 50 cm  ×  50 cm  ×  20 cm box of water (blue) 
with a central 3 cm  ×  3 cm  ×  3 cm phantom (orange) and surrounding slice (grey 
dashed) in which energy deposit and ionisation count were recorded. Photon tracks are 
shown in green.
(a) (b)
Figure 3. (a) Mass attenuation coefficient of 10 mg ml−1 gold/water mixture compared 
to pure water as given by Geant4 Low Energy Livermore models. (b) Mass energy 
absorption coefficient of 10 mg ml−1 gold/water mixture compared to pure water from 
NIST XCOM data.
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included in the simulations for completeness. Range cuts for electrons and photons were set 
to 1 nm. Internally Geant4 converts this to a cut in energy for each material, only producing 
a secondary particle to track separately if it is both above this energy and above the 100 eV 
low energy cut-off for the physics models, otherwise it simply records a local energy deposit. 
This low energy cut-off due to uncertainty in the cross-sections at very low energies dictates 
that care must be taken interpreting the absolute numbers of ionisations, but trends in the 
count of ionisations can be informative. To simulate the production and transport of Auger 
electrons which have energies below this default cut-off, the command ‘/process/em/deexcita-
tionIgnoreCut’ was set to true. Energy deposit and the count of all ionising interactions were 
recorded both within the 3 cm  ×  3 cm  ×  3 cm phantom and for a rectangular slice extending 
5 cm beyond the phantom in the x and y directions (see figure 2).
Atomic de-excitation processes were implemented in Geant4 as follows. Fluorescence acti-
vated with /process/em/fluo allows only fluorescence photons to be produced and tracked, 
while Auger electron emission is treated as local energy deposit. For this case a simplified de-
excitation cascade is used. When an atom de-excites by Auger electron emission, two vacan-
cies are left. However in the simplified Geant4 cascade only one of these vacancies is used 
to propagate the cascade, the other being discarded. This corresponds to some outer shell 
de-excitations being neglected, but these neglected vacancies have a very low probability of 
producing fluorescence (see figure 4). Full de-excitation produces and tracks all fluorescence 
and Auger products including the full Auger cascade and was activated with the commands: 
/process/em/fluo, /process/em/auger, /process/em/augerCascade. For more discussion of the 
difference between the simplified and full cascades, see Incerti et al (2016).
3. Results and discussion
3.1. Within the target
Table 1 presents the energy deposit and ionisation count within the target phantom both with 
and without Au. With Au present, results are shown for three scenarios: no de-excitation 
(all de-excitation energy is deposited locally); only fluorescence activated (no Auger elec-
trons produced, their energy instead deposited locally); and full de-excitation (all Auger and 
Figure 4. Probability of de-excitation via fluorescence photon and Auger electron 
emission, given as an average over the shell of the initial vacancy. Data from the 
Lawrence Livermore National Laboratory Evaluated Atomic Data Library (Perkins 
et al 1991).
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fluorescence products produced and tracked). The enhancement ratio (ER) is defined for each 
incident energy as:
=ER
Energy deposit (or ionisation count) with Au
Energy deposit (or ionisation count) without Au
For the case of water only in the phantom, for either incident photon energy, no change in 
energy deposit was observed when activating only fluorescence or full de-excitation within 
the statistical uncertainty of 0.1%; the number of ionisations was unchanged when activating 
fluorescence but increased by  ≈5% upon activating full de-excitation due to a small amount 
of Auger electron production (data not shown).
With Au in the phantom the enhancement in energy deposit is 1.86 for 73 keV incident 
photons and 1.49 for 139.5 keV incident photons. This is comparable to previous studies: 
Lechtman et al (2011) found that 11 mg g−1 of gold nanoparticles doubles the dose to a 1 cm 
volume at 5 cm depth for a 300 kVp beam (127 keV average beam energy); Amato et al (2013) 
simulated a target at 5 cm depth with 10 mg ml−1 gold, and found an ER of  ≈2.5 with a 150 
kVp beam; and McMahon et al (2008) found an ER of 1.8 with a 150 kVp beam.
For 139.5 keV incident photons the ER in energy deposit with full de-excitation is signifi-
cantly less than that for 73 keV photons despite their equivalent mass attenuation coefficients 
relative to water (figure 3(a)). This is attributed to the significant (≈18%) escape of energy 
from the phantom carried by fluorescence photons, as evidenced by comparison of the energy 
deposit and ER in table 1 for the case where there is no de-excitation (ER  =1.82) to the case 
where fluorescence only is activated ( =ER 1.49). Lechtman et  al (2011) found a similar 
result using a 300kVp beam (127 keV average beam energy at 5 cm depth) showing 42% of 
the energy emitted from a single gold nanoparticle is due to characteristic x-rays. This change 
in the energy deposit in the phantom with activation of fluorescence is not evident for 73 keV 
incident photons.
To explain these results further, at both incident photon energies enhancement of the pho-
toelectric cross section in gold relative to that in water leads to a greater number of photo-
ionisations in the target volume when gold is present. The photoelectrons produced in both 
cases have a range of  ≈60 μm in water and therefore do not escape the phantom. For 73 keV 
incident photons, the K-shell is not available for ionisation. Photo-ionisation therefore pro-
duces L-shell vacancies, with  ≈25% probability of de-exciting via fluorescence (figure 4) and 
producing fluorescence photons with an attenuation length  ≈0.2 cm. Above the K-edge, for 
Table 1. Energy deposit and ionisation count in the phantom with and without 1% 
Au, targeted by 107 incident photons. Enhancement ratio (ER) is relative to the 
corresponding de-excitation case in water.
Energy 
(keV) Material De-excitation
Energy 
deposit (GeV) ER
Total 
ionisations 
(×107) ER
73 Water Auger & fluo. ±27.69 0.03   1.00 ±7.50 0.01   1.00
73 1% Au None ±51.76 0.04   1.87 ±12.20 0.01 1.71
73 1% Au Fluo. only ±51.68 0.04   1.87 ±12.37 0.01 1.73
73 1% Au Auger & fluo. ±51.61 0.05   1.86 ±14.20 0.01 1.89
139.5 Water Auger & fluo. ±57.19 0.03   1.00 ±15.42 0.01 1.00
139.5 1% Au None ±103.92 0.07 1.82 ±20.13 0.01 1.37
139.5 1% Au Fluo. only ±85.31 0.05   1.49 ±20.78 0.01 1.41
139.5 1% Au Auger & fluo. ±85.26 0.05   1.49 ±23.23 0.01 1.51
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139.5 keV incident photons, atomic de-excitation following K-shell ionisation results in emis-
sion of a fluorescence photon with an attenuation length  ≈5 cm, leading to escape from the 
phantom and de-localisation of the energy deposit.
The mass energy absorption coefficient (µen) can be used to predict the energy absorbed 
within the phantom (see figure  3(b)), but assumes that all energy carried by fluorescence 
photons is lost from the volume. In our simulation the small amount of fluorescence pro-
duced by 73 keV photons is absorbed within the phantom, and for incident photons above the 
K-edge the fluorescence photons may undergo photo-absorption or scattering before leaving 
the volume. The 68.8 keV K-alpha fluorescence photons do not have sufficient energy to ion-
ise the gold K-shell, but may be absorbed in the L-shell resulting in a 54.4 keV photoelectron 
with range  ≈50 um and short range Auger electrons depositing energy locally. So µen slightly 
underestimates the energy deposition, predicting ER of 1.80 for 73 keV incident photons and 
1.43 for 139.5 keV incident photons. The proportion of energy lost from the phantom depends 
on its size, but will be large in any target volume with dimensions smaller than the 5 cm 
 attenuation length of the Au Kα1 fluorescence photons.
At both incident photon energies, the contribution to the number of ionisations within 
the phantom from each de-excitation process is similar. Note that for all cases the number 
of low energy secondary electrons (excluding Auger electrons) and hence their ionisations 
are underestimated in the simulation due to the 100 eV low energy cut-off. As noted above, 
in pure water Auger electrons account for approximately 5% of ionisations, fluorescence has 
no effect and the remaining 95% of ionisations are electron impact events following primary 
photon interactions. With gold in the phantom, at both incident photon energies, the primary 
photon interactions (the case with no de-excitation processes activated) account for  ≈86% of 
the total number of ionisations. Fluorescence accounts for only  ≈2% of ionisations, similar at 
both energies despite the expectation of producing fluorescence photons with 139.5 keV inci-
dent photons. Auger electron emission accounts for  ≈12% of the ionisations in the phantom 
with 1% gold present. However, this extra contribution from Auger electrons is constrained to 
a zone  ≈200 nm from the gold atom or nanoparticle surface (McMahon et al 2011), implying 
that to take advantage of the extra Auger electron emission to enhance radiation damage, gold 
nanoparticles are required to efficiently target tumour cell nuclei or other sensitive organelles 
such as mitochondria (McNamara et al 2016).
3.2. Outside the target
Figures 5 and 6 show the change in energy deposited in successive volumes outside the target 
phantom when 10 mg ml−1 Au is added. Each layer is 1 cm thick in the x and y directions 
extending laterally out from the phantom and summed over 3 cm in the z direction, which is 
the depth of the phantom (see figure 2).
Figure 5 shows the percentage change in energy deposit per unit volume outside the phan-
tom with 1% Au compared to water only. For 73 keV incident photons energy per unit volume 
deposited outside the phantom is reduced by up to 6% when Au is added to the phantom com-
pared to the water only case. For 139.5 keV photons there is  ≈0.5% increase in energy deposit 
per unit volume in the first 1 cm outside the phantom, then a similar small decrease in subse-
quent layers. For higher concentrations of Au, the net effect is a decrease in out-of-field dose, 
despite energy de-localisation by fluorescence (data not shown). This suggests an additional 
benefit to enhancement by GNPs; not only is energy deposition in the target volume greater 
when gold is present, but also the energy deposited in the surrounding volume is reduced, 
further improving the ratio of energy deposited inside the target to that outside.
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Figure 6 shows the contribution from fluorescence photon and Auger electron emission to the 
energy deposited per unit volume outside the phantom. The histograms show the ratio of dose 
deposited when 1% Au is added to the phantom compared to the water only phantom. For inci-
dent 73 keV photons the energy deposit per unit volume outside the phantom is reduced by  ≈5% 
(figure 6(a)). This is attributed to the more efficient absorption of primary photons by gold in 
the phantom, reducing energy deposited by scattered photons in the surrounding volume. There 
is a small increase in energy deposit upon activating Geant4 de-excitation processes in the first 
1 cm due to a few low energy fluorescence photons escaping the phantom; outside the first 1 cm 
energy deposited is unchanged by activating de-excitation processes. For 139.5 keV incident 
photons, with no de-excitation processes activated there is a similar up to 5% reduction in energy 
deposit per unit volume. However, the dose deposition ratio in each outside layer significantly 
increases with activation of fluorescence (figure 6(b)). Clearly fluorescence is responsible for 
transporting energy from the phantom to the surrounding layers out to several centimetres, but 
this is offset by the reduction in energy desposition from fewer scattered primary photons. This 
Figure 5. Percentage change in energy deposit per unit volume in 1 cm layers outside 
the phantom lateral to the incident photon beam when 1% Au is added to the phantom. 
Auger and fluorescence processes are activated.
Figure 6. Ratio of energy deposit per unit volume in 1 cm layers outside the phantom 
lateral to the incident photon beam when 1% Au is added to the phantom compared to 
a water only phantom. The de-excitation processes activated are indicated. (a) 73 keV 
incident photons and (b) 139.5 keV incident photons.
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is important because radiation treatment is often limited by the acceptable cumulative dose to 
normal tissue surrounding the target volume (Hainfeld et al 2008, Thariat et al 2013).
This is further demonstrated by figure 7 which presents the energy deposited per unit vol-
ume in the 1 cm layers surrounding the phantom normalised by the energy deposited per unit 
volume in the phantom (E Eout phantom/ ). For the water only phantom the first 1 cm surrounding 
the phantom receives  ≈18.5% of the energy deposit per unit volume delivered to the phantom 
for 73 keV incident photons, while this is only  ≈12.5% for 139.5 keV photons. As can be 
seen from table 1, when using a fixed number of incident photons more energy is deposited 
in the target by the higher energy incident photons. To deliver the same energy deposit to the 
target for both photon energies, more lower energy incident photons are required and so more 
primary photons scatter into the surrounding volume. With the addition of gold, however, 
the increased number of photoelectric events increases absorption of primary photons in the 
phantom and thus reduces the proportion scattered into the surrounding volume. The higher 
photoelectric attenuation at 73 keV compared to 139.5 keV reduces scattering more for the 
lower energy incident photons. Energy deposited per unit volume in the peripheral layers is 
reduced by half for 73 keV incident photons and by one third for 139.5 keV incident photons 
when Au is present in the phantom and the out-of-target dose in the first 1 cm layer is  ≈9% for 
both incident photon energies, making the two energies comparable for therapeutic purposes.
Figures 8(a) and (b) show the 2D energy deposit distributions lateral to an 73 keV incident 
beam, with and without gold in the phantom. When gold is added to the phantom there is a 
slight reduction in the spread of energy to the region surrounding the phantom. Figure 8(c) 
presents a line profile along x across the centre of the phantom averaged over y showing the 
ER of 1.86 in energy deposition within the phantom and the  ≈5% reduction in the surround-
ing region when gold is present in the phantom.
3.3. Effects near the K-edge
The 139.5 keV incident photon energy lies well above the gold K-edge of 80.7 keV and was 
chosen because it gives a comparable attenuation coefficient to 73 keV incident photons. 
However the photoelectric attenuation has a local maximum just above the K-edge (figure 3), 
Figure 7. Proportion of energy deposited per unit volume in 1 cm layers outside the 
phantom lateral to the beam to that deposited within the phantom, with and without 
Au. Auger and fluorescence processes are activated. (a) 73 keV incident photons; 
(b) 139.5 keV incident photons.
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Figure 8. Energy deposit outside the 3 cm  ×  3 cm phantom integrated along z for 
73 keV incident photons. (a) Water only phantom, (b) 1% gold in the phantom, (c) line 
profile along x, averaged over y.
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and could potentially lead to greater enhancement of energy deposit. Figure 9 shows the energy 
deposit within the phantom at several different incident photon energies with and without 
Geant4 de-excitation processes activated. The pattern of energy delocalisation demonstrated 
above in the case of 139.5 keV photons is evident to an even greater degree as the K-edge is 
approached. For 81 keV incident photons the enhancement with no de-excitation activated is 
3.13, but when de-excitation is taken into account this drops to 1.94, comparable to the case 
for 73 keV incident photons. It is worth reiterating that this reduction in enhancement due to 
the fluorescence photons carrying energy away from the phantom is to some extent dependent 
on the geometry of the phantom chosen. A large enough phantom volume would absorb fluo-
rescence photons within the phantom and so only those fluorescence photons within  ≈5 cm of 
the phantom boundaries would de-localise energy deposit to regions outside.
As shown in figure 3(b), although the photoelectric cross-section increases significantly at 
the K-edge, the mass energy absorption coefficient in 1% gold compared to water has only a 
minimal increase at 80.7 keV. The increases at the L-edges have a much greater effect on the 
energy absorption coefficient, and the maximum contrast against water occurs at  ≈40 keV.
Higher incident photon energies up to a few hundred keV were investigated with refer-
ence to the importance of fluorescence (data not shown). At higher energies the photoelectric 
interaction becomes progressively less important than Compton scatter, for which the mass 
attenuation coefficient is no different in gold and water. The ER in energy deposit within the 
phantom drops to 1.08 for 300 keV incident photons. Compton interactions favour outer rather 
than inner shell ionisations so there is no de-excitation by fluorescence or associated energy 
relocalisation. At these energies the photo- and Compton electrons produced are not capable 
of significant de-localisation of dose on the centimetre scale, needing an energy of over 2 MeV 
before they have a range of 1 cm (Berger et al 2005, NIST ESTAR).
Gold in this study was included as a homogeneous mixture of gold atoms with water to 
decouple from the effects of nanoparticle size and density. It has been noted in several studies 
that the finite size of nanoparticles and the way they cluster influences the spectrum of sec-
ondary particles that can escape from the nanoparticle and the dose distributions immediately 
surrounding it (Lechtman et al 2011, McMahon et al 2011, Zygmanski et al 2013, Casta et al 
2015, Incerti et al 2016, Koger and Kirkby 2016), though nanoparticle size has a greater effect 
on the secondary electron spectrum than the fluorescence photon spectrum.
Figure 9. Ratio of energy deposit in the phantom with gold compared to water only for 
varying incident photon energy. De-excitation processes activated are indicated.
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4. Conclusion
In this simulation study, we have shown that the enhancement in energy deposited in a water 
phantom when 1% gold is added is different for two incident photon energies which have the 
same attenuation contrast against water. We found enhancement ratios of  ≈1.9 and  ≈1.5 for 
73 keV and 139.5 keV incident photons, respectively. We showed that the reduced enhance-
ment at energies above the gold K-edge is due to delocalisation of energy from the phantom 
by fluorescence photons. We also showed that Auger de-excitation enhances the number of 
ionisations, but not the energy deposition in the phantom.
Our study also highlights the importance of considering not just the enhancement in energy 
deposition and ionisations in a target containing gold atoms, but also the effects outside the 
target. We showed that the delocalisation of energy by fluorescence photons escaping from 
the target phantom containing 1% gold is comparable to the delocalisation of energy due 
to primary photon scatter out of a water-only phantom. For incident photon energies below 
the gold K-edge, energy delocalisation by fluorescence photons is negligible and enhanced 
photo-absorption results in a decrease in out-of-target dose deposition compared to a water 
only phantom. Indeed, we determined that for 73 keV incident photons, the margin dose 
could be reduced by up to 50% when the phantom contains 1% gold atoms. From these 
results, we can conclude that gold nanoparticles delivered to a target tumour are capable of 
not just increasing dose to the tumour but also decreasing scatter dose to surrounding healthy 
tissue.
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